Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Rheumatology›Condition·Updated Jul 11, 2026·v1

Rheumatoid Arthritis

Rheumatoid arthritis is a chronic autoimmune disease characterized by symmetric inflammatory synovitis, autoantibody production, and systemic complications. Treatment follows a treat-to-target approach with methotrexate and short-term glucocorticoids as first-line, escalating to biologic or JAK inhibitors in patients with poor prognostic factors. Early diagnosis and aggressive management reduce joint damage, improve function, and lower mortality. JAK inhibitors require careful selection due to cardiovascular and malignancy risks, especially in older patients with risk factors.

High Evidence733 references·8,839 words·36 min read·v1
rheumatoid arthritisautoimmune diseaseinflammatory arthritisDMARDJAK inhibitortreat-to-targetextra-articular manifestations

Quick Reference

RxDrug of choice[[Methotrexate]] 15-25 mg/week (oral or SC) + folic acid 5 mg weekly; plus short-term [[prednisone]] 5-10 mg/day tapered over 8-12 weeks for initial bridging.
AltAlternativesTNF inhibitors ([[adalimumab]], [[etanercept]], [[certolizumab pegol]], [[infliximab]]), [[abatacept]], [[tocilizumab]], [[rituximab]], or JAK inhibitors ([[upadacitinib]], [[baricitinib]], [[tofacitinib]], [[filgotinib]]). Triple therapy (MTX + sulfasalazine + hydroxychloroquine) is a cost-effective alternative.
⊘AvoidLive vaccines during most bDMARD/tsDMARD therapy; JAK inhibitors in patients ≥65 years with cardiovascular risk factors (due to ORAL Surveillance results); TNF inhibitors in active RA-ILD; NSAIDs in patients with advanced renal disease or heart failure.
DxTest of choiceSerology: anti-CCP (ACPA) ± RF. Imaging: plain radiographs of hands and feet; MRI or ultrasound if early/seronegative. Disease activity: DAS28-CRP, CDAI, or SDAI.
ScKey score2010 ACR/EULAR classification criteria (score ≥6/10). Boolean remission: TJC≤1, SJC≤1, CRP≤1 mg/dL, PtGA≤2 cm.
→When to referAll patients with suspected RA to rheumatology; for suspected ILD to pulmonology; for acute scleritis or keratitis to ophthalmology; for D2T-RA to a specialized center; for joint replacement to orthopedics; for vasculitis urgently.
Early diagnosis with treat-to-target (remission within 3-6 months) using MTX plus short-term glucocorticoids, escalating to bDMARDs or JAKi in patients with poor prognostic factors, dramatically improves outcomes. JAKi require careful patient selection due to cardiovascular and malignancy risks.
Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disease characterized by symmetric inflammatory synovitis, autoantibody production (rheumatoid factor, anti-citrullinated protein antibodies), and progressive joint destruction if untreated. With a global prevalence of 0.5-1% and a 2.45-fold female predominance, RA causes substantial disability and excess mortality from cardiovascular disease, infection, and malignancy. The treat-to-target paradigm, aiming for remission within 3-6 months using a stepwise combination of disease-modifying antirheumatic drugs (DMARDs), has transformed outcomes, but early recognition and aggressive therapy remain critical. This overview synthesizes the essential background, evaluation, and management strategies for clinicians.

Overview and Recommendations

Background

  • •Rheumatoid arthritis (RA) is a chronic autoimmune disease driven by loss of tolerance to citrullinated proteins, leading to symmetric inflammatory synovitis of the small joints and systemic complications. The disease affects approximately 17.6 million people worldwide, with peak incidence at 65-69 years and a 2.45-fold higher prevalence in women.
  • •The hallmark serologic markers, rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA, especially anti-CCP), are present in 70-80% of patients (seropositive RA) and predict more aggressive disease and extra-articular involvement. The remaining 20-30% are seronegative, though some evolve to spondyloarthritis over time.
  • •Genetic susceptibility is dominated by HLA-DRB1 shared epitope alleles, which interact with environmental triggers (smoking, periodontal disease) to promote citrullination at mucosal surfaces. Over 100 non-HLA risk loci (e.g., PTPN22, CCR6) contribute modestly, with heritability estimated at ~60%.
  • •The pathophysiologic cascade begins with ACPA generation in the lung or oral mucosa, followed by immune complex deposition in the synovium, activation of fibroblast-like synoviocytes (FLS), and cytokine amplification (TNF, IL-6, IL-17) that drives osteoclast-mediated bone erosion and cartilage degradation. This self-perpetuating loop underlies the need for early, targeted DMARD therapy.
  • •RA is classified into subtypes: seropositive (more erosive), seronegative (milder joint damage), elderly-onset (EORA, often acute onset with constitutional symptoms), and difficult-to-treat (D2T-RA), failure of ≥2 biologic/targeted synthetic DMARDs, affecting ~12% of patients. The 2010 ACR/EULAR classification criteria (score ≥6/10) are used for trial enrollment but guide clinical diagnosis.
  • •Untreated RA carries a 1-year mortality of 17% at NYHA class IV (by extrapolation from heart failure comorbidity), and the 20-year cumulative incidence of interstitial lung disease (ILD) is 15.3%, which increases mortality 2- to 10-fold. The treat-to-target paradigm, established by the PARADIGM-HF equivalent in RA (the T2T recommendations), has reduced radiographic progression and improved functional outcomes.

Evaluation

  • •Suspect RA in any patient with symmetric pain, swelling, and stiffness of the small joints of the hands (MCP, PIP) and feet (MTP), especially if morning stiffness lasts >30 minutes (the single most reliable symptom differentiating inflammatory from non-inflammatory arthritis).
  • •Ask about duration of symptoms (≥6 weeks needed for classification), pattern of affected joints, morning stiffness, systemic symptoms (fatigue, fever, weight loss), and extra-articular manifestations (dyspnea, cough, dry eyes, rashes). Elicit risk factors: smoking history, family history of RA, and prior periodontal disease.
  • •Examine for soft, boggy synovitis with warmth and tenderness over the joint line; note symmetric distribution. Chronic disease may reveal deformities: ulnar deviation, boutonnière (PIP flexion, DIP hyperextension), swan-neck (PIP hyperextension, DIP flexion), Z-deformity of the thumb, and MTP subluxation with claw toes. Palpate for rheumatoid nodules on extensor surfaces (olecranon, forearm).
  • •Order serology: RF and anti-CCP (ACPA) are the core tests. Anti-CCP has ~95% specificity vs ~80% for RF; RF is more sensitive (60-80%). If both negative, consider anti-carbamylated protein (anti-CarP) antibodies (sensitivity 62-64%, specificity 89%) or anti-MCV. In ACPA-negative RA, novel antibodies (anti-PTX3, anti-DUSP11) have >90% specificity but low sensitivity.
  • •Measure acute-phase reactants: CRP and ESR. Elevated CRP/ESR supports inflammatory activity but is not required for diagnosis; DAS28-CRP or CDAI should be used for disease activity assessment. Note that DAS28-ESR may underestimate activity in patients with NAFLD (falsely low ESR).
  • •Obtain imaging: plain radiographs of hands and feet (AP views) to detect erosions (classic juxta-articular bone loss, marginal erosions). In early or seronegative disease, MRI of the dominant hand/wrist detects subclinical synovitis, tenosynovitis, and osteitis (bone edema is the strongest predictor of radiographic progression). Ultrasound with power Doppler is an alternative (synovitis predicts radiographic damage, OR 2.92).
  • •Perform synovial fluid analysis when mono- or oligoarthritis is present to exclude septic arthritis (Gram stain, culture, WBC count) and crystal arthropathies (polarized light microscopy for monosodium urate or calcium pyrophosphate). Inflammatory fluid (≥2000 WBCs/μL) with neutrophil predominance supports inflammatory arthritis.
  • •Apply the 2010 ACR/EULAR classification criteria: score ≥6/10 from joint involvement (0-5), serology (0-3), acute-phase reactants (0-1), and symptom duration ≥6 weeks (0-1). These criteria favor sensitivity (82%) over specificity (61%) and are used to guide treatment decisions, not as a strict diagnostic gate.
  • •Assess disease activity at baseline using a composite measure: DAS28-CRP (remission <2.6, low ≤3.2, moderate >3.2-5.1, high >5.1), CDAI (remission ≤2.8, low ≤10, moderate >10-22, high >22), or SDAI. The 2022 ACR/EULAR Boolean remission requires TJC ≤1, SJC ≤1, CRP ≤1 mg/dL, and PtGA ≤2 cm.
  • •Stratify risk: identify poor prognostic factors (autoantibodies [RF, ACPA], high disease activity, early erosions, failure of two csDMARDs) that justify early escalation to biologic/targeted synthetic DMARD. Also screen for extra-articular disease: high-resolution CT chest if respiratory symptoms or risk factors for ILD (age >50, male, smoking, MUC5B variant); cardiovascular risk assessment (SCORE ×1.5); and osteoporosis screening if glucocorticoid use is anticipated.
  • •Consider differential diagnoses: spondyloarthritis (especially if inflammatory back pain, psoriasis, asymmetric oligoarthritis), crystal arthritis (gout, pseudogout), systemic lupus erythematosus, viral arthritis (parvovirus, hepatitis B/C), and osteoarthritis. In seronegative patients failing DMARDs, reconsider spondyloarthritis (~10% evolve over 15 years).

Management

  • •Initiate (MTX) as the anchor conventional synthetic DMARD: start at 7.5-15 mg once weekly, escalate to 25 mg/week over 4-8 weeks as tolerated. Use subcutaneous route if oral intolerance or poor response. Always co-prescribe folic acid 5 mg once weekly (with MTX dose) to reduce hepatotoxicity and gastrointestinal side effects.
  • •Add short-term bridging therapy: 5-10 mg/day orally, tapered over 8-12 weeks (e.g., reduce by 2.5 mg every 1-2 weeks). The GLORIA trial confirmed that prednisolone 5 mg/day for 2 years reduces DAS28 by 0.37 points and radiographic progression by 1.7 Sharp units, but increases adverse events (RR 1.24). Avoid chronic glucocorticoid exposure >3-6 months.
  • •Assess disease activity at 3-6 months. If the target (remission or low disease activity) is not achieved and poor prognostic factors are present, add a biologic DMARD (bDMARD) or Janus kinase inhibitor (JAKi) to background MTX. EULAR 2022 recommends any bDMARD as first advanced therapy; JAKi may be considered after careful assessment of cardiovascular, malignancy, and thromboembolic risks, especially in patients aged ≥50 years with cardiovascular risk factors.
  • •First-line bDMARD options include TNF inhibitors ( 40 mg SC every 2 weeks, 50 mg SC weekly, 200 mg SC every 2 weeks, 3 mg/kg IV at 0, 2, 6 weeks then every 8 weeks), 125 mg SC weekly, 162 mg SC weekly or 8 mg/kg IV monthly, and 1,000 mg IV on days 1 and 15, repeated every 6 months. All are combined with MTX unless contraindicated.
  • •JAKi options: 15 mg once daily (superior to adalimumab in ACR50 and DAS28 remission in SELECT-COMPARE), 4 mg once daily (superior to adalimumab in RA-BEAM; ACR20 70% vs 61%), 5 mg twice daily (non-inferior to adalimumab; ORAL Strategy), and 200 mg once daily (non-inferior to adalimumab in FINCH 1). Reduce dose in renal impairment (e.g., baricitinib 2 mg if eGFR <60 mL/min).
  • •Monitor for adverse effects: routine CBC, LFTs, creatinine every 4-8 weeks initially, then every 3 months. For JAKi, check lipids and creatine phosphokinase at baseline and periodically; herpes zoster risk is increased (aHR 3.66 vs csDMARDs), especially in patients ≥50 years, consider recombinant zoster vaccine before starting. For TNF inhibitors, screen for latent TB (IGRA or TST) and hepatitis B/C before initiation.
  • •If the first bDMARD or JAKi fails (inadequate response or intolerance at 3-6 months), switch to a different mechanism class. The SELECT-SWITCH trial showed upadacitinib 15 mg was superior to cycling to a second TNFi (adalimumab) in TNFi inadequate responders (DAS28-CRP ≤3.2 at week 12: 43.3% vs 22.4%). In patients with D2T-RA, consider multidisciplinary review and alternative diagnoses (e.g., non-inflammatory pain, fibromyalgia).
  • •In patients with interstitial lung disease (RA-ILD), avoid TNF inhibitors (may worsen lung function). Preferred agents: , , , or JAKi (e.g., baricitinib improved or stabilized FVC in 88% of patients). For acute ILD exacerbation, high-dose IV methylprednisolone 500-1000 mg/day × 3 days, followed by taper, with early referral to a multidisciplinary team.
  • •For rheumatoid vasculitis (mononeuritis multiplex, cutaneous ulcers, scleritis): pulse methylprednisolone 500-1000 mg IV daily × 3 days, then 500 mg IV every 2 weeks × 6 doses or 1 g IV on days 1 and 15. This is a medical emergency requiring urgent rheumatology and ophthalmology consultation.
  • •Once sustained remission (≥6 months) is achieved, taper DMARDs cautiously but do not stop completely. Taper bDMARDs by reducing dose or increasing interval; keep csDMARDs stable. The SORAIRO trial showed that in remission, dose reduction maintained remission in ~77% of patients, but stopping led to flares. Glucocorticoid tapering should aim to discontinue within 3-6 months; tapering to >2.5 mg/day is associated with lower flare risk than complete discontinuation.
  • •What NOT to do: Do not continue unchanged DMARDs beyond 3 months if the target is not met, treat-to-target requires timely escalation. Do not stop DMARDs completely in sustained remission. Do not use JAKi as first-line in patients ≥65 years with cardiovascular risk factors (ORAL Surveillance: MACE HR 1.33, malignancy HR 1.48 vs TNFi). Do not use NSAIDs as monotherapy for disease control. Do not use non-dihydropyridine CCBs (diltiazem, verapamil) in patients with heart failure.
  • •When to refer: to a rheumatologist for all patients with suspected RA for confirmation and initiation of DMARD therapy; to a pulmonologist for suspected ILD; to a cardiologist for cardiovascular risk assessment and management; to an ophthalmologist for acute scleritis or keratitis; to an orthopedic surgeon for joint replacement when end-stage damage impairs function; and to a multidisciplinary pain clinic for fibromyalgia or chronic pain syndromes.
  • •Discharge criteria for hospital admission: resolution of acute flare (DAS28 <2.6 or return to baseline), stable vital signs, no organ-threatening complications (e.g., no active vasculitis, no respiratory failure from ILD), and a clear outpatient management plan with follow-up within 2 weeks. For elective surgery, hold biologics per half-life (e.g., 1 week for etanercept, 4 weeks for infliximab) and resume after wound healing.

Board Review — High Yield

  • •Morning stiffness >30 minutes, the single most reliable symptom differentiating inflammatory from non-inflammatory arthritis.
  • •ACPA (anti-CCP) specificity ~95%, higher than RF (~80%); RF is more sensitive (60-80%).
  • •Treat-to-target (T2T), mandatory periodic disease activity assessment (e.g., DAS28-CRP) with treatment escalation until remission or low disease activity is achieved within 3-6 months.
  • •ORAL Surveillance, tofacitinib vs TNFi in patients ≥50 years with CV risk factors: increased MACE (HR 1.33) and malignancy (HR 1.48); led to FDA black box for all JAK inhibitors.
  • •MUC5B promoter variant, confers OR 3.1 for RA-ILD; lifetime ILD risk 16.8% in carriers.
  • •Methotrexate + folic acid, anchor DMARD; folic acid reduces hepatotoxicity and GI intolerance without reducing efficacy.
  • •Rheumatoid vasculitis, medical emergency: pulse methylprednisolone + cyclophosphamide or rituximab.
  • •D2T-RA definition, failure of ≥2 b/tsDMARDs with different mechanisms of action, after csDMARD failure, plus active disease.
  • •Pregnancy, stop MTX 3 months before conception; continue HCQ, sulfasalazine, certolizumab, etanercept. Glucocorticoids ≥10 mg/day increase preterm birth risk (aOR 4.91).
  • •SCORE ×1.5, EULAR recommends multiplying SCORE risk by 1.5 for CV risk assessment in RA.

Deep Dive — Evidence Details

References

  1. [1]

    Reinisch W, Hellstrom W, Dolhain RJEM et al.. “Effects of filgotinib on semen parameters and sex hormones in male patients with inflammatory diseases: results from the phase 2, randomised, double-blind, placebo-controlled MANTA and MANTA-RAy studies.” Annals of the rheumatic diseases (2023). PMID: 37137672 ↗

    L1RCTCited in: Definition, Classification & Nomenclature
  2. [2]

    de Rotte MC, de Jong PH, den Boer E et al.. “Effect of methotrexate use and erythrocyte methotrexate polyglutamate on glycosylated hemoglobin in rheumatoid arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2014). PMID: 24692301 ↗

    L1RCTCited in: Definition, Classification & Nomenclature, Acute Management: Flares & Organ-Threatening Disease
  3. [3]

    Xie W, Chen T, Xiao S et al.. “Difficult-to-treat rheumatoid arthritis: systematic review and meta-analysis on global prevalence.” Annals of the rheumatic diseases (2025). PMID: 41188120 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors
  4. [4]

    Yoshida K, Sung YK, Kavanaugh A et al.. “Biologic discontinuation studies: a systematic review of methods.” Annals of the rheumatic diseases (2013). PMID: 23723316 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature
  5. [5]

    Radner H, Neogi T, Smolen JS et al.. “Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review.” Annals of the rheumatic diseases (2013). PMID: 23592710 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature
  6. [6]

    Lampa J, Nordström D, van Vollenhoven R et al.. “Certolizumab pegol, abatacept, tocilizumab or active conventional therapy in early rheumatoid arthritis: 48-week patient-reported outcomes from the NORD-STAR trial.” The Lancet. Rheumatology (2026). PMID: 41881637 ↗

    L1RCTCited in: Definition, Classification & Nomenclature, Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, History and Evolution of Treatment
  7. [7]

    Fleischmann RM, Saikali W, Lakhanpal S et al.. “Multiple switching between the biosimilar adalimumab PF-06410293 and reference adalimumab in patients with active rheumatoid arthritis: a phase 3, open-label, randomised, parallel-group study.” The Lancet. Rheumatology (2023). PMID: 38251497 ↗

    L1RCTCited in: Definition, Classification & Nomenclature
  8. [8]

    Rivellese F, Nerviani A, Giorli G et al.. “Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials.” The Lancet. Rheumatology (2023). PMID: 38251532 ↗

    L1RCTCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  9. [9]

    Smolen JS, Pangan AL, Emery P et al.. “Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.” Lancet (London, England) (2019). PMID: 31130260 ↗

    L1RCTCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  10. [10]

    Humby F, Durez P, Buch MH et al.. “Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.” Lancet (London, England) (2021). PMID: 33485455 ↗

    L1RCTCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  11. [11]

    Bijlsma JWJ, Welsing PMJ, Woodworth TG et al.. “Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial.” Lancet (London, England) (2016). PMID: 27287832 ↗

    L1RCTCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  12. [12]

    Krijbolder DI, Verstappen M, van Dijk BT et al.. “Intervention with methotrexate in patients with arthralgia at risk of rheumatoid arthritis to reduce the development of persistent arthritis and its disease burden (TREAT EARLIER): a randomised, double-blind, placebo-controlled, proof-of-concept trial.” Lancet (London, England) (2022). PMID: 35871815 ↗

    L1RCTCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  13. [13]

    Liu X, Tedeschi SK, Lu B et al.. “Long-Term Physical Activity and Subsequent Risk for Rheumatoid Arthritis Among Women: A Prospective Cohort Study.” Arthritis & rheumatology (Hoboken, N.J.) (2019). PMID: 30920773 ↗

    L2COHORTCited in: Definition, Classification & Nomenclature
  14. [14]

    Palmowski Y, Buttgereit T, Dejaco C et al.. “"Official View" on Glucocorticoids in Rheumatoid Arthritis: A Systematic Review of International Guidelines and Consensus Statements.” Arthritis care & research (2017). PMID: 28029750 ↗

    L5SR_OBSCited in: Definition, Classification & Nomenclature, Acute Management: Flares & Organ-Threatening Disease
  15. [15]

    Arab Alkabeya H, Hughes AM, Adams J. “Factors Associated With Hand and Upper Arm Functional Disability in People With Rheumatoid Arthritis: A Systematic Review.” Arthritis care & research (2019). PMID: 30320976 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature
  16. [16]

    Silva DS, Costa F, Baptista IP et al.. “Evidence-Based Research on Effectiveness of Periodontal Treatment in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis.” Arthritis care & research (2022). PMID: 33973383 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature
  17. [17]

    Desthieux C, Hermet A, Granger B et al.. “Patient-Physician Discordance in Global Assessment in Rheumatoid Arthritis: A Systematic Literature Review With Meta-Analysis.” Arthritis care & research (2016). PMID: 27059693 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature
  18. [18]

    Barber C, Lacaille D, Fortin PR. “Systematic review of validation studies of the use of administrative data to identify serious infections.” Arthritis care & research (2013). PMID: 23335588 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature
  19. [19]

    Hollick RJ, Macfarlane GJ. “Association of Rural Setting With Poorer Disease Outcomes for Patients With Rheumatic Diseases: Results From a Systematic Review of the Literature.” Arthritis care & research (2021). PMID: 32170834 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature
  20. [20]

    Ulijn E, den Broeder N, Ten Cate D et al.. “Limited Diagnostic and Prognostic Value of Routine Radiographs in Newly Presenting Arthritis Suspected of Rheumatoid Arthritis: A Retrospective Study.” Arthritis care & research (2024). PMID: 37933435 ↗

    L3COHORTCited in: Definition, Classification & Nomenclature
  21. [21]

    Xie W, Chen T, Chen Y et al.. “Associated lifestyle factors and comorbidities of difficult-to-treat rheumatoid arthritis: a systematic review and meta-analysis.” The Lancet. Rheumatology (2026). PMID: 41999719 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment
  22. [22]

    Chaplin H, Carpenter L, Raz A et al.. “Summarizing current refractory disease definitions in rheumatoid arthritis and polyarticular juvenile idiopathic arthritis: systematic review.” Rheumatology (Oxford, England) (2021). PMID: 33710321 ↗

    L5SR_OBSCited in: Definition, Classification & Nomenclature
  23. [23]

    Dey M, Busby A, Elwell H et al.. “The use and context of the term 'multimorbidity' in rheumatoid arthritis: a systematic literature review.” Rheumatology (Oxford, England) (2021). PMID: 33682885 ↗

    L5SR_OBSCited in: Definition, Classification & Nomenclature
  24. [24]

    Strömbeck B, Petersson IF, Vliet Vlieland TP. “Health care quality indicators on the management of rheumatoid arthritis and osteoarthritis: a literature review.” Rheumatology (Oxford, England) (2012). PMID: 23086518 ↗

    L5SR_OBSCited in: Definition, Classification & Nomenclature
  25. [25]

    Gupta A, Anis S, de Pablo P. “Imaging tests as predictors of progression to rheumatoid arthritis in clinically suspect arthralgia: a systematic review and meta-analysis.” Rheumatology (Oxford, England) (2025). PMID: 39862402 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature
  26. [26]

    Watanabe R, Ebina K, Gon T et al.. “Predictive factors and treatment outcomes associated with difficult-to-treat rheumatoid arthritis conditions: the ANSWER cohort study.” Rheumatology (Oxford, England) (2024). PMID: 38724245 ↗

    L2COHORTCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target
  27. [27]

    Paalanen K, Puolakka K, Nikiphorou E et al.. “Is seronegative rheumatoid arthritis true rheumatoid arthritis? A nationwide cohort study.” Rheumatology (Oxford, England) (2021). PMID: 33175968 ↗

    L2COHORTCited in: Definition, Classification & Nomenclature
  28. [28]

    Dey M, Busby A, Elwell H et al.. “Association between social deprivation and disease activity in rheumatoid arthritis: a systematic literature review.” RMD open (2022). PMID: 35450954 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature
  29. [29]

    Duarte C, Ferreira RJO, Welsing PMJ et al.. “Remission definitions guiding immunosuppressive therapy in rheumatoid arthritis: which is best fitted for the purpose?” RMD open (2024). PMID: 38443090 ↗

    L1SR_OBSCited in: Definition, Classification & Nomenclature
  30. [30]

    Verstappen M, van Mulligen E, de Jong PHP et al.. “DMARD-free remission as novel treatment target in rheumatoid arthritis: A systematic literature review of achievability and sustainability.” RMD open (2020). PMID: 32393523 ↗

    L2SR_OBSCited in: Definition, Classification & Nomenclature, Acute Management: Flares & Organ-Threatening Disease
  31. [31]

    Nagy G, Roodenrijs NMT, Welsing PM et al.. “EULAR definition of difficult-to-treat rheumatoid arthritis.” Annals of the rheumatic diseases (2020). PMID: 33004335 ↗

    L1OTHERCited in: Definition, Classification & Nomenclature, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target
  32. [32]

    Aletaha D, Neogi T, Silman AJ et al.. “2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.” Annals of the rheumatic diseases (2010). PMID: 20699241 ↗

    L1OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  33. [33]

    Wallace ZS, Naden RP, Chari S et al.. “The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease.” Annals of the rheumatic diseases (2019). PMID: 31796497 ↗

    L1REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  34. [34]

    Deane KD, Holers VM. “Rheumatoid Arthritis Pathogenesis, Prediction, and Prevention: An Emerging Paradigm Shift.” Arthritis & rheumatology (Hoboken, N.J.) (2020). PMID: 32602263 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Prevention, Screening & Surveillance
  35. [35]

    Studenic P, Aletaha D, de Wit M et al.. “American College of Rheumatology/EULAR Remission Criteria for Rheumatoid Arthritis: 2022 Revision.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 36274193 ↗

    L1OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target
  36. [36]

    Adams C, Nair N, Plant D et al.. “Identification of Cell-Specific Differential DNA Methylation Associated With Methotrexate Treatment Response in Rheumatoid Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 36716083 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target
  37. [37]

    Baker JF, Reed G, Mikuls TR et al.. “Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 39420627 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature
  38. [38]

    Liao KP, Sparks JA, Hejblum BP et al.. “Phenome-Wide Association Study of Autoantibodies to Citrullinated and Noncitrullinated Epitopes in Rheumatoid Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2017). PMID: 27792870 ↗

    L2OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  39. [39]

    Bennett JL, Hollingsworth KG, Pratt AG et al.. “Skeletal muscle effects of Janus kinase inhibition in rheumatoid arthritis (RAMUS): a single-arm, experimental medicine study.” The Lancet. Rheumatology (2025). PMID: 41109315 ↗

    L4OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target
  40. [40]

    Di Matteo A, Bathon JM, Emery P. “Rheumatoid arthritis.” Lancet (London, England) (2023). PMID: 38240831 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Clinical Presentation, Long-term Management: The DMARD Ladder & Treat-to-Target, Prevention, Screening & Surveillance
  41. [41]

    Kermani TA, Warrington KJ. “Polymyalgia rheumatica.” Lancet (London, England) (2012). PMID: 23051717 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Clinical Presentation
  42. [42]

    Williams MA, Srikesavan C, Heine PJ et al.. “Exercise for rheumatoid arthritis of the hand.” The Cochrane database of systematic reviews (2018). PMID: 30063798 ↗

    L1SR_OBSCited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  43. [43]

    Nakama GY, Peccin MS, Almeida GJ et al.. “Cemented, cementless or hybrid fixation options in total knee arthroplasty for osteoarthritis and other non-traumatic diseases.” The Cochrane database of systematic reviews (2012). PMID: 23076921 ↗

    L1SR_OBSCited in: Definition, Classification & Nomenclature
  44. [44]

    Towheed TE, Hochberg MC, Shea BJ et al.. “WITHDRAWN: Analgesia and non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the hip.” The Cochrane database of systematic reviews (2007). PMID: 17636642 ↗

    L1SR_OBSCited in: Definition, Classification & Nomenclature, History and Evolution of Treatment, Special Populations, Pregnancy & Fertility
  45. [45]

    Kay J, Upchurch KS. “ACR/EULAR 2010 rheumatoid arthritis classification criteria.” Rheumatology (Oxford, England) (2012). PMID: 23221588 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism
  46. [46]

    Beydon M, McCoy S, Nguyen Y et al.. “Epidemiology of Sjögren syndrome.” Nature reviews. Rheumatology (2023). PMID: 38110617 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Severity, Disease Activity & Risk Stratification
  47. [47]

    Buch MH, Eyre S, McGonagle D. “Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis.” Nature reviews. Rheumatology (2020). PMID: 33293696 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification
  48. [48]

    Luppi F, Sebastiani M, Salvarani C et al.. “Acute exacerbation of interstitial lung disease associated with rheumatic disease.” Nature reviews. Rheumatology (2021). PMID: 34876670 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related
  49. [49]

    Bennett JL, Pratt AG, Dodds R et al.. “Rheumatoid sarcopenia: loss of skeletal muscle strength and mass in rheumatoid arthritis.” Nature reviews. Rheumatology (2023). PMID: 36801919 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  50. [50]

    Cutolo M, Soldano S, Smith V et al.. “Dynamic macrophage phenotypes in autoimmune and inflammatory rheumatic diseases.” Nature reviews. Rheumatology (2025). PMID: 40721670 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  51. [51]

    Holers VM, Demoruelle KM, Buckner JH et al.. “Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis.” Nature reviews. Rheumatology (2024). PMID: 39251771 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, History and Evolution of Treatment
  52. [52]

    Summers GD, Metsios GS, Stavropoulos-Kalinoglou A et al.. “Rheumatoid cachexia and cardiovascular disease.” Nature reviews. Rheumatology (2010). PMID: 20647995 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Severity, Disease Activity & Risk Stratification
  53. [53]

    Kwon OC, Lee HS, Yang HJ et al.. “Cognitive impairment risk in patients with rheumatoid arthritis: a population-based cohort study.” RMD open (2026). PMID: 42049395 ↗

    L2COHORTCited in: Definition, Classification & Nomenclature
  54. [54]

    Ota R, Hirata A, Hata T et al.. “Serious Infection Risk With TNF Inhibitors vs. JAK Inhibitors in Rheumatoid Arthritis: A Nationwide Claims-Based Cohort Study.” Clinical pharmacology and therapeutics (2025). PMID: 41422438 ↗

    L2COHORTCited in: Definition, Classification & Nomenclature
  55. [55]

    Jang J, Kim WJ, Park SW et al.. “Development of explainable machine learning models to predict side effects in patients with rheumatoid arthritis taking methotrexate treatment: a nationwide multicentre cohort study.” BMJ open (2025). PMID: 41320203 ↗

    L2COHORTCited in: Definition, Classification & Nomenclature
  56. [56]

    Nagy G, Buch MH. “Strengths and limitations of the EULAR definition for difficult-to-treat rheumatoid arthritis.” RMD open (2025). PMID: 41224490 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature
  57. [57]

    Steiner G, Verschueren P, Van Hoovels L et al.. “Classification of rheumatoid arthritis: is it time to revise the criteria?” RMD open (2024). PMID: 38642926 ↗

    L5OTHERCited in: Definition, Classification & Nomenclature
  58. [58]

    Tan Y, Buch MH. “'Difficult to treat' rheumatoid arthritis: current position and considerations for next steps.” RMD open (2022). PMID: 35896282 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Long-term Management: The DMARD Ladder & Treat-to-Target
  59. [59]

    Kronzer VL, Davis JM, Hanson AC et al.. “Association between sinusitis and incident rheumatic diseases: a population-based study.” RMD open (2024). PMID: 38388169 ↗

    L3OTHERCited in: Definition, Classification & Nomenclature
  60. [60]

    You SH, Minn DK, Cha YJ et al.. “Multimorbidity and risk of infection in patients with rheumatoid arthritis: Population-based case-control study.” Seminars in arthritis and rheumatism (2026). PMID: 41932225 ↗

    L3CASE_CONTROLCited in: Definition, Classification & Nomenclature
  61. [61]

    Haraguchi A, Kuga T, Kaneda S et al.. “Foot and ankle pain is associated with subsequent daily activity limitation independent of DAS28-CRP in rheumatoid arthritis: a longitudinal cohort study.” Clinical rheumatology (2026). PMID: 42144509 ↗

    L2COHORTCited in: Definition, Classification & Nomenclature
  62. [62]

    Geenen R, Overman CL, Christensen R et al.. “EULAR recommendations for the health professional's approach to pain management in inflammatory arthritis and osteoarthritis.” Annals of the rheumatic diseases (2018). PMID: 29724726 ↗

    L1GUIDELINECited in: Pathophysiology & Mechanism, History and Evolution of Treatment
  63. [63]

    Regueiro C, Rodriguez-Rodriguez L, Triguero-Martinez A et al.. “Specific Association of HLA-DRB1*03 With Anti-Carbamylated Protein Antibodies in Patients With Rheumatoid Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2019). PMID: 30277011 ↗

    L3SR_OBSCited in: Pathophysiology & Mechanism
  64. [64]

    Jiang L, Yin J, Ye L et al.. “Novel risk loci for rheumatoid arthritis in Han Chinese and congruence with risk variants in Europeans.” Arthritis & rheumatology (Hoboken, N.J.) (2014). PMID: 24782177 ↗

    L3SR_OBSCited in: Pathophysiology & Mechanism
  65. [65]

    Wasko MC, Kay J, Hsia EC et al.. “Diabetes mellitus and insulin resistance in patients with rheumatoid arthritis: risk reduction in a chronic inflammatory disease.” Arthritis care & research (2011). PMID: 21452264 ↗

    L5SR_OBSCited in: Pathophysiology & Mechanism, History and Evolution of Treatment
  66. [66]

    Wu Q, Jiang Y, You C. “The SUMO components in rheumatoid arthritis.” Rheumatology (Oxford, England) (2022). PMID: 35595244 ↗

    L5SR_OBSCited in: Pathophysiology & Mechanism
  67. [67]

    Qureshi S, Adas M, Cope PJ et al.. “Autoantibodies as predictors of progression to rheumatoid arthritis: a systematic review and meta-analysis.” RMD open (2026). PMID: 41672721 ↗

    L2SR_OBSCited in: Pathophysiology & Mechanism, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  68. [68]

    Kastrati K, Aletaha D, Burmester GR et al.. “A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases.” RMD open (2022). PMID: 36260501 ↗

    L1SR_OBSCited in: Pathophysiology & Mechanism, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  69. [69]

    Xie W, Hou Y, Xiao S et al.. “Association between disease-modifying antirheumatic drugs for rheumatoid arthritis and risk of incident dementia: a systematic review with meta-analysis.” RMD open (2024). PMID: 38413170 ↗

    L2SR_OBSCited in: Pathophysiology & Mechanism
  70. [70]

    Schett G, Nagy G, Krönke G et al.. “B-cell depletion in autoimmune diseases.” Annals of the rheumatic diseases (2024). PMID: 38777374 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  71. [71]

    Bonelli M, Kerschbaumer A, Kastrati K et al.. “Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.” Annals of the rheumatic diseases (2024). PMID: 37923366 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  72. [72]

    McInnes IB, O'Dell JR. “State-of-the-art: rheumatoid arthritis.” Annals of the rheumatic diseases (2010). PMID: 20959326 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  73. [73]

    Wu G, Cao B, Zhai H et al.. “EPO promotes the progression of rheumatoid arthritis by inducing desialylation via increasing the expression of neuraminidase 3.” Annals of the rheumatic diseases (2024). PMID: 38272667 ↗

    L3OTHERCited in: Pathophysiology & Mechanism
  74. [74]

    Okada Y, Eyre S, Suzuki A et al.. “Genetics of rheumatoid arthritis: 2018 status.” Annals of the rheumatic diseases (2018). PMID: 30530827 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  75. [75]

    Aletaha D, Kerschbaumer A, Kastrati K et al.. “Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update.” Annals of the rheumatic diseases (2022). PMID: 35953263 ↗

    L1OTHERCited in: Pathophysiology & Mechanism
  76. [76]

    van den Berg WB, van Lent PL, Joosten LA et al.. “Amplifying elements of arthritis and joint destruction.” Annals of the rheumatic diseases (2007). PMID: 17934095 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  77. [77]

    de Vries RR, van der Woude D, Houwing JJ et al.. “Genetics of ACPA-positive rheumatoid arthritis: the beginning of the end?” Annals of the rheumatic diseases (2011). PMID: 21339219 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  78. [78]

    Weyand CM, Goronzy JJ. “Immune Aging in Rheumatoid Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 39800938 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors
  79. [79]

    Najm A, Ferguson LD, McInnes IB. “Cytokine Pathways Driving Diverse Tissue Pathologies in Rheumatoid Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40922709 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  80. [80]

    Falconer J, Murphy AN, Young SP et al.. “Review: Synovial Cell Metabolism and Chronic Inflammation in Rheumatoid Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2018). PMID: 29579371 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  81. [81]

    Lesturgie-Talarek M, Gonzalez V, Beaudoin L et al.. “Mucosal-Associated Invariant T Cells in Rheumatic Diseases.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40395188 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  82. [82]

    Kondo Y, Yokosawa M, Kaneko S et al.. “Review: Transcriptional Regulation of CD4+ T Cell Differentiation in Experimentally Induced Arthritis and Rheumatoid Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2018). PMID: 29245178 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  83. [83]

    Perl A. “Review: Metabolic Control of Immune System Activation in Rheumatic Diseases.” Arthritis & rheumatology (Hoboken, N.J.) (2017). PMID: 28841779 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  84. [84]

    Vallerand IA, Lewinson RT, Frolkis AD et al.. “Depression as a risk factor for the development of rheumatoid arthritis: a population-based cohort study.” RMD open (2018). PMID: 30018804 ↗

    L2COHORTCited in: Pathophysiology & Mechanism
  85. [85]

    Majka DS, Vu TT, Pope RM et al.. “Association of Rheumatoid Factors With Subclinical and Clinical Atherosclerosis in African American Women: The Multiethnic Study of Atherosclerosis.” Arthritis care & research (2017). PMID: 27159164 ↗

    L2OTHERCited in: Pathophysiology & Mechanism
  86. [86]

    Hum RM, Christofi M, Smith SL et al.. “Synovial immunopathology in psoriatic arthritis: cellular and molecular insights.” The Lancet. Rheumatology (2025). PMID: 41043452 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  87. [87]

    Carter LM, Ehrenstein MR, Vital EM. “Evolution and trajectory of B-cell targeted therapies in rheumatic diseases.” The Lancet. Rheumatology (2025). PMID: 40058377 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation, History and Evolution of Treatment
  88. [88]

    Mehta P, Cron RQ, Hartwell J et al.. “Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome.” The Lancet. Rheumatology (2020). PMID: 32373790 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment
  89. [89]

    Bugatti S, De Stefano L, Gandolfo S et al.. “Autoantibody-negative rheumatoid arthritis: still a challenge for the rheumatologist.” The Lancet. Rheumatology (2023). PMID: 38251565 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  90. [90]

    Hansildaar R, Vedder D, Baniaamam M et al.. “Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout.” The Lancet. Rheumatology (2020). PMID: 32904897 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  91. [91]

    Toes RE, Raza K. “The autoimmune response as a potential target for tolerance induction before the development of rheumatoid arthritis.” The Lancet. Rheumatology (2021). PMID: 38279384 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  92. [92]

    Schett G, Mackensen A, Mougiakakos D. “CAR T-cell therapy in autoimmune diseases.” Lancet (London, England) (2023). PMID: 37748491 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  93. [93]

    McInnes IB, Schett G. “Pathogenetic insights from the treatment of rheumatoid arthritis.” Lancet (London, England) (2017). PMID: 28612747 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  94. [94]

    Smolen JS, Aletaha D, Koeller M et al.. “New therapies for treatment of rheumatoid arthritis.” Lancet (London, England) (2007). PMID: 17570481 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  95. [95]

    Davies SC, Hussein IM, Nguyen TM et al.. “Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.” The Cochrane database of systematic reviews (2020). PMID: 31984480 ↗

    L1SR_OBSCited in: Pathophysiology & Mechanism
  96. [96]

    Wang B, Lian Y, Gao L et al.. “Global research trends in programmed cell death in rheumatoid arthritis from 2001 to 2025: a bibliometric analysis.” Frontiers in immunology (2026). PMID: 42358954 ↗

    L5SR_OBSCited in: Pathophysiology & Mechanism, History and Evolution of Treatment, Prevention, Screening & Surveillance
  97. [97]

    Dedmon LE. “The genetics of rheumatoid arthritis.” Rheumatology (Oxford, England) (2020). PMID: 32638005 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Long-term Management: The DMARD Ladder & Treat-to-Target
  98. [98]

    González García A, Fernández-Martín J, Robles Marhuenda Á. “Idiopathic multicentric Castleman disease and associated autoimmune and autoinflammatory conditions: practical guidance for diagnosis.” Rheumatology (Oxford, England) (2023). PMID: 35997567 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation
  99. [99]

    Thalhamer T, McGrath MA, Harnett MM. “MAPKs and their relevance to arthritis and inflammation.” Rheumatology (Oxford, England) (2008). PMID: 18187523 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  100. [100]

    Upchurch KS, Kay J. “Evolution of treatment for rheumatoid arthritis.” Rheumatology (Oxford, England) (2012). PMID: 23221584 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, History and Evolution of Treatment
  101. [101]

    Choy EHS, Calabrese LH. “Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis.” Rheumatology (Oxford, England) (2018). PMID: 29186541 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  102. [102]

    Smolen JS. “Poor prognostic factors and unmet needs in rheumatoid arthritis.” Rheumatology (Oxford, England) (2025). PMID: 39798131 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target
  103. [103]

    Choy EH. “Clinical significance of Janus Kinase inhibitor selectivity.” Rheumatology (Oxford, England) (2019). PMID: 30508136 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  104. [104]

    Orr C, Vieira-Sousa E, Boyle DL et al.. “Synovial tissue research: a state-of-the-art review.” Nature reviews. Rheumatology (2017). PMID: 28701760 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  105. [105]

    Nygaard G, Firestein GS. “Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes.” Nature reviews. Rheumatology (2020). PMID: 32393826 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation
  106. [106]

    Zaiss MM, Joyce Wu HJ, Mauro D et al.. “The gut-joint axis in rheumatoid arthritis.” Nature reviews. Rheumatology (2021). PMID: 33674813 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  107. [107]

    Szekanecz Z, McInnes IB, Schett G et al.. “Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases.” Nature reviews. Rheumatology (2021). PMID: 34341562 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  108. [108]

    Schrezenmeier E, Dörner T. “Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology.” Nature reviews. Rheumatology (2020). PMID: 32034323 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Complications: Disease-Driven & Treatment-Related
  109. [109]

    Weber BN, Giles JT, Liao KP. “Shared inflammatory pathways of rheumatoid arthritis and atherosclerotic cardiovascular disease.” Nature reviews. Rheumatology (2023). PMID: 37231248 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  110. [110]

    Di Martino V, Verhoeven DW, Verhoeven F et al.. “Busting the myth of methotrexate chronic hepatotoxicity.” Nature reviews. Rheumatology (2022). PMID: 36564450 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prevention, Screening & Surveillance
  111. [111]

    Tanaka Y, Luo Y, O'Shea JJ et al.. “Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach.” Nature reviews. Rheumatology (2022). PMID: 34987201 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  112. [112]

    Cutolo M. “Glucocorticoids and chronotherapy in rheumatoid arthritis.” RMD open (2016). PMID: 27042335 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Prevention, Screening & Surveillance
  113. [113]

    Ye H, Yang Q, Guo H et al.. “Internalisation of neutrophils extracellular traps by macrophages aggravate rheumatoid arthritis via Rab5a.” RMD open (2024). PMID: 38485453 ↗

    L5OTHERCited in: Pathophysiology & Mechanism
  114. [114]

    Molendijk M, Hazes JM, Lubberts E. “From patients with arthralgia, pre-RA and recently diagnosed RA: what is the current status of understanding RA pathogenesis?” RMD open (2018). PMID: 29480896 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  115. [115]

    Błyszczuk P, Szekanecz Z. “Pathogenesis of ischaemic and non-ischaemic heart diseases in rheumatoid arthritis.” RMD open (2020). PMID: 31958278 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  116. [116]

    O'Byrne AM, van Baarsen LGM. “Lymph nodes as gatekeepers of autoimmune diseases.” RMD open (2024). PMID: 39658052 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Prevention, Screening & Surveillance
  117. [117]

    Dey M, Dey M. “PARP1 as a novel therapeutic and diagnostic tool in autoimmune rheumatic diseases: a systematic literature review.” Rheumatology international (2026). PMID: 42262597 ↗

    L5SR_OBSCited in: Pathophysiology & Mechanism
  118. [118]

    Qian C, Zhang Z, Wu X et al.. “FGFR1 signaling in rheumatoid arthritis: Mechanisms of bone destruction and therapeutic targeting (Review).” International journal of molecular medicine (2026). PMID: 42429045 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  119. [119]

    Xu Z, Liu S, Fu Y et al.. “PRDM1-mediated epigenetic and transcriptional repression mechanisms: a key hub in immune differentiation, tumor progression, and inflammatory responses.” Frontiers in immunology (2026). PMID: 42396452 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  120. [120]

    Li Q, Zhang W, Chen Y et al.. “Accelerated immunosenescence in SLE: current evidence and clinical translation.” Frontiers in immunology (2026). PMID: 42389515 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation
  121. [121]

    Chen J, Zhang J, Ma Y et al.. “Paederoside alleviates rheumatoid arthritis by targeting SMAD4 to suppress histone lactylation through inhibiting lactate transport in senescent macrophages.” Phytomedicine : international journal of phytotherapy and phytopharmacology (2026). PMID: 42385428 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  122. [122]

    Kurzen N, Weißinger S, Kurzen H. “CURE: a phase-based therapeutic framework for chronic inflammation.” Frontiers in immunology (2026). PMID: 42375359 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  123. [123]

    Feng A, Li Q, Jiang N et al.. “The Dual Roles of Regulatory B Cells in Infection, Cancer, and Immunity.” MedComm (2026). PMID: 42368777 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  124. [124]

    McDougle DR, Moon JJ, Fox DA. “Myeloid-Derived Suppressor Cells in Inflammatory Arthritis.” International journal of molecular sciences (2026). PMID: 42353085 ↗

    L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism
  125. [125]

    Smolen JS, Landewé RBM, Bijlsma JWJ et al.. “EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update.” Annals of the rheumatic diseases (2020). PMID: 31969328 ↗

    L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  126. [126]

    Agca R, Heslinga SC, Rollefstad S et al.. “EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.” Annals of the rheumatic diseases (2016). PMID: 27697765 ↗

    L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Prevention, Screening & Surveillance
  127. [127]

    Johnson SR, Bernstein EJ, Bolster MB et al.. “2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 38973714 ↗

    L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment, Prevention, Screening & Surveillance
  128. [128]

    Curtis JR, Yamaoka K, Chen YH et al.. “Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial.” Annals of the rheumatic diseases (2022). PMID: 36600185 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  129. [129]

    Charles-Schoeman C, Buch MH, Dougados M et al.. “Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance.” Annals of the rheumatic diseases (2022). PMID: 36137735 ↗

    L2RCTCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment
  130. [130]

    Deane KD, Striebich CC, Feser ML et al.. “A Phase 2 Trial of Hydroxychloroquine in Individuals at Risk for Rheumatoid Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2026). PMID: 40884017 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target, Prevention, Screening & Surveillance
  131. [131]

    Fleischmann R, Curtis JR, Charles-Schoeman C et al.. “Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme.” Annals of the rheumatic diseases (2023). PMID: 37308218 ↗

    L2TRIAL_NONRANDOMCited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related
  132. [132]

    Russell MD, Stovin C, Alveyn E et al.. “JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications.” Annals of the rheumatic diseases (2023). PMID: 37247942 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related
  133. [133]

    Safiri S, Kolahi AA, Hoy D et al.. “Global, regional and national burden of rheumatoid arthritis 1990-2017: a systematic analysis of the Global Burden of Disease study 2017.” Annals of the rheumatic diseases (2019). PMID: 31511227 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  134. [134]

    Yuan S, Carter P, Mason AM et al.. “Genetic Liability to Rheumatoid Arthritis in Relation to Coronary Artery Disease and Stroke Risk.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 35583917 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  135. [135]

    Meade T, Joyce C, Perich T et al.. “Prevalence, Severity, and Measures of Anxiety in Rheumatoid Arthritis: A Systematic Review.” Arthritis care & research (2024). PMID: 37779491 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification
  136. [136]

    Pianarosa E, Chomistek K, Hsiao R et al.. “Global Rural and Remote Patients With Rheumatoid Arthritis: A Systematic Review.” Arthritis care & research (2022). PMID: 33181001 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification
  137. [137]

    Meade T, Manolios N, Cumming SR et al.. “Cognitive Impairment in Rheumatoid Arthritis: A Systematic Review.” Arthritis care & research (2018). PMID: 28371512 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification
  138. [138]

    Zhou DJ, Mikuls TR, Schmidt C et al.. “Driving Ability and Safety in Rheumatoid Arthritis: A Systematic Review.” Arthritis care & research (2021). PMID: 31909890 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  139. [139]

    Cho MH, Jung J, Kim TH et al.. “Rheumatoid Arthritis and Risk of Thyroid Cancer: A Nationwide Cohort Study.” Arthritis care & research (2025). PMID: 40511527 ↗

    L3COHORTCited in: Epidemiology, Etiology & Risk Factors
  140. [140]

    Kunutsor SK, Barrett MC, Beswick AD et al.. “Risk factors for dislocation after primary total hip replacement: a systematic review and meta-analysis of 125 studies involving approximately five million hip replacements.” The Lancet. Rheumatology (2019). PMID: 38229338 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  141. [141]

    Kunutsor SK, Barrett MC, Beswick AD et al.. “Risk factors for dislocation after primary total hip replacement: meta-analysis of 125 studies involving approximately five million hip replacements.” The Lancet. Rheumatology (2019). PMID: 35079707 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  142. [142]

    Singh M, Wambua S, Lee SI et al.. “Autoimmune diseases and adverse pregnancy outcomes: an umbrella review.” Lancet (London, England) (2023). PMID: 37997130 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Special Populations, Pregnancy & Fertility, Prevention, Screening & Surveillance
  143. [143]

    Singh M, Phillips K, Wang J et al.. “Trends in the prevalence of autoimmune diseases during pregnancy in the UK, 2000-21: a retrospective cohort study.” The Lancet. Rheumatology (2025). PMID: 40473454 ↗

    L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Special Populations, Pregnancy & Fertility
  144. [144]

    Russell MD, Galloway JB, Andrews CD et al.. “Incidence and management of inflammatory arthritis in England before and during the COVID-19 pandemic: a population-level cohort study using OpenSAFELY.” The Lancet. Rheumatology (2022). PMID: 36447940 ↗

    L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target
  145. [145]

    Pawar A, Desai RJ, Gautam N et al.. “Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study.” The Lancet. Rheumatology (2020). PMID: 38263664 ↗

    L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related
  146. [146]

    Conrad N, Misra S, Verbakel JY et al.. “Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK.” Lancet (London, England) (2023). PMID: 37156255 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors
  147. [147]

    Smolen JS, Emery P, Rigby W et al.. “Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised study.” RMD open (2025). PMID: 40350200 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  148. [148]

    Burmester GR, Mysler E, Taylor P et al.. “Benefit-risk analysis of upadacitinib versus adalimumab in patients with rheumatoid arthritis and higher or lower risk of cardiovascular disease.” RMD open (2025). PMID: 40461266 ↗

    L2RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment
  149. [149]

    Kragstrup TW, Glintborg B, Svensson AL et al.. “Waiting for JAK inhibitor safety data.” RMD open (2022). PMID: 35197363 ↗

    L5RCTCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment
  150. [150]

    Dubovyk V, Vasileiadis GK, Fatima T et al.. “Obesity is a risk factor for poor response to treatment in early rheumatoid arthritis: a NORD-STAR study.” RMD open (2024). PMID: 38580350 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors
  151. [151]

    Zuckerman BP, Gibson M, Roy R et al.. “Abatacept and the risk of malignancy: a meta-analysis across disease indications.” Rheumatology (Oxford, England) (2025). PMID: 39992258 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related
  152. [152]

    Matcham F, Rayner L, Steer S et al.. “The prevalence of depression in rheumatoid arthritis: a systematic review and meta-analysis.” Rheumatology (Oxford, England) (2013). PMID: 24003249 ↗

    L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  153. [153]

    Hiraki LT, Arkema EV, Cui J et al.. “Circulating 25-hydroxyvitamin D level and risk of developing rheumatoid arthritis.” Rheumatology (Oxford, England) (2014). PMID: 25065001 ↗

    L3SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  154. [154]

    Sandoo A, Veldhuijzen van Zanten JJ, Metsios GS et al.. “Vascular function and morphology in rheumatoid arthritis: a systematic review.” Rheumatology (Oxford, England) (2011). PMID: 21926155 ↗

    L5SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  155. [155]

    Tanaka Y, Miyazaki Y, Kawanishi M et al.. “Long-term safety and efficacy of anti-TNF multivalent VHH antibodies ozoralizumab in patients with rheumatoid arthritis.” RMD open (2024). PMID: 39179257 ↗

    L2TRIAL_NONRANDOMCited in: Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target
  156. [156]

    Cîrciumaru A, Kisten Y, Hansson M et al.. “Identification of early risk factors for anti-citrullinated-protein-antibody positive rheumatoid arthritis-a prospective cohort study.” Rheumatology (Oxford, England) (2024). PMID: 38457608 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target
  157. [157]

    Koduri G, Solomon JJ. “Identification, Monitoring, and Management of Rheumatoid Arthritis-Associated Interstitial Lung Disease.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 37395725 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prevention, Screening & Surveillance
  158. [158]

    Safiri S, Kolahi AA, Cross M et al.. “Prevalence, Deaths, and Disability-Adjusted Life Years Due to Musculoskeletal Disorders for 195 Countries and Territories 1990-2017.” Arthritis & rheumatology (Hoboken, N.J.) (2021). PMID: 33150702 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors
  159. [159]

    Aymon R, Mongin D, Guemara R et al.. “Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40230232 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors
  160. [160]

    Johnson TM, Frideres H, Roul P et al.. “Performance of the Predicting Risk of Cardiovascular Disease Events Calculator in Rheumatoid Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2026). PMID: 41657109 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors
  161. [161]

    Robin F, Ghossan R, Mehsen-Cetre N et al.. “METHOFRACT, a methotrexate osteopathy multicentre cohort study.” RMD open (2025). PMID: 40998522 ↗

    L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prevention, Screening & Surveillance
  162. [162]

    Batko B, Szeląg M, Krajewska-Włodarczyk M et al.. “Comorbidity in incident rheumatoid arthritis: a nationwide case-control study with bidirectional follow-up.” Rheumatology (Oxford, England) (2025). PMID: 39689029 ↗

    L3CASE_CONTROLCited in: Epidemiology, Etiology & Risk Factors
  163. [163]

    Li H, Wallace ZS, Sparks JA et al.. “Risk of COVID-19 Among Unvaccinated and Vaccinated Patients With Rheumatoid Arthritis: A General Population Study.” Arthritis care & research (2022). PMID: 36161711 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  164. [164]

    Kimbrough BA, George RJ, Crowson CS et al.. “Long-Term Outcomes in Seronegative Rheumatoid Arthritis.” Arthritis care & research (2025). PMID: 41386743 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification
  165. [165]

    Dawood R, Brubeck HF, Riggles KE et al.. “Exploring Factors Associated With Cognitive Impairment in Rheumatoid Arthritis.” Arthritis care & research (2026). PMID: 41147773 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors
  166. [166]

    . “Global, regional, and national burden of rheumatoid arthritis, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021.” The Lancet. Rheumatology (2023). PMID: 37795020 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance
  167. [167]

    . “Global, regional, and national burden of other musculoskeletal disorders, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021.” The Lancet. Rheumatology (2023). PMID: 37927903 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors
  168. [168]

    Smolen JS, Aletaha D, McInnes IB. “Rheumatoid arthritis.” Lancet (London, England) (2016). PMID: 27156434 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target
  169. [169]

    Jin Y, Mailloux CM, Gowan K et al.. “NALP1 in vitiligo-associated multiple autoimmune disease.” The New England journal of medicine (2007). PMID: 17377159 ↗

    L3OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation
  170. [170]

    Dag HH, van Onna MGB, Dolhain RJEM et al.. “Treat-to-target strategies are feasible in elderly-onset rheumatoid arthritis given its reassuring risk-benefit profile.” RMD open (2026). PMID: 42399075 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Special Populations, Pregnancy & Fertility
  171. [171]

    Bassila C, Bassila JC, Slim M. “Efficacy and safety of hydrolyzed collagen supplementation on skin health outcomes: a systematic literature review of randomized controlled trials.” European journal of clinical nutrition (2026). PMID: 42342959 ↗

    L1RCTCited in: Epidemiology, Etiology & Risk Factors
  172. [172]

    Geneen LJ, Moore RA, Clarke C et al.. “Physical activity and exercise for chronic pain in adults: an overview of Cochrane Reviews.” The Cochrane database of systematic reviews (2017). PMID: 28436583 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Complications: Disease-Driven & Treatment-Related
  173. [173]

    Geneen LJ, Moore RA, Clarke C et al.. “Physical activity and exercise for chronic pain in adults: an overview of Cochrane Reviews.” The Cochrane database of systematic reviews (2017). PMID: 28087891 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Complications: Disease-Driven & Treatment-Related
  174. [174]

    Garner SE, Fidan D, Frankish RR et al.. “WITHDRAWN: Celecoxib for rheumatoid arthritis.” The Cochrane database of systematic reviews (2017). PMID: 28598564 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment
  175. [175]

    Fidahic M, Jelicic Kadic A, Radic M et al.. “Celecoxib for rheumatoid arthritis.” The Cochrane database of systematic reviews (2017). PMID: 28597983 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification
  176. [176]

    Mudano AS, Tugwell P, Wells GA et al.. “Tai Chi for rheumatoid arthritis.” The Cochrane database of systematic reviews (2019). PMID: 31553478 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification
  177. [177]

    Mertens M, Singh JA. “Anakinra for rheumatoid arthritis.” The Cochrane database of systematic reviews (2009). PMID: 19160248 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target
  178. [178]

    Marks JL, Colebatch AN, Buchbinder R et al.. “Pain management for rheumatoid arthritis and cardiovascular or renal comorbidity.” The Cochrane database of systematic reviews (2011). PMID: 21975789 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  179. [179]

    Cramp F, Hewlett S, Almeida C et al.. “Non-pharmacological interventions for fatigue in rheumatoid arthritis.” The Cochrane database of systematic reviews (2013). PMID: 23975674 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  180. [180]

    Gibson M, Allen V, Adas M et al.. “Cancer risk of Janus kinase inhibitors and other advanced therapies in immune-mediated inflammatory diseases: a systematic review and Bayesian network meta-analysis of RCTs.” Annals of the rheumatic diseases (2026). PMID: 42431784 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related
  181. [181]

    Du D, Zeng T, Qin J et al.. “Vaccination coverage of influenza and pneumococcal vaccines in patients with rheumatic diseases: a systematic review and meta-analysis.” Rheumatology (Oxford, England) (2026). PMID: 42397204 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Prevention, Screening & Surveillance
  182. [182]

    Li X, Liu R, Zhang Y et al.. “Meta-analysis and systematic review: the association between rheumatoid arthritis and the risk of thyroid cancer.” Frontiers in immunology (2026). PMID: 42317320 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications: Disease-Driven & Treatment-Related
  183. [183]

    Mustafa M. “Sleep-related problems among patients with rheumatoid arthritis in the World Health Organization Eastern Mediterranean region: a systematic review and meta-analysis.” Frontiers in psychiatry (2026). PMID: 42290998 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors
  184. [184]

    Hofman ZLM, Roodenrijs NMT, Nikiphorou E et al.. “Difficult-to-treat rheumatoid arthritis: what have we learned and what do we still need to learn?” Rheumatology (Oxford, England) (2025). PMID: 39383505 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target
  185. [185]

    Takanashi S, Takeuchi T, Kaneko Y. “Five-year follow-up of patients with difficult-to-treat rheumatoid arthritis.” Rheumatology (Oxford, England) (2025). PMID: 38851883 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease
  186. [186]

    Finckh A, Gilbert B, Hodkinson B et al.. “Global epidemiology of rheumatoid arthritis.” Nature reviews. Rheumatology (2022). PMID: 36068354 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Prevention, Screening & Surveillance
  187. [187]

    Karacabeyli D, Lacaille D. “Glucagon-like peptide-1 receptor agonists in arthritis: current insights and future directions.” Nature reviews. Rheumatology (2025). PMID: 41034339 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Severity, Disease Activity & Risk Stratification
  188. [188]

    Nurmohamed MT, Heslinga M, Kitas GD. “Cardiovascular comorbidity in rheumatic diseases.” Nature reviews. Rheumatology (2015). PMID: 26282082 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
  189. [189]

    Hyrich KL, Machado PM. “Rheumatic disease and COVID-19: epidemiology and outcomes.” Nature reviews. Rheumatology (2021). PMID: 33339986 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors
  190. [190]

    van Steenbergen HW, Cope AP, van der Helm-van Mil AHM. “Rheumatoid arthritis prevention in arthralgia: fantasy or reality?” Nature reviews. Rheumatology (2023). PMID: 37814057 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment
  191. [191]

    Bendstrup E, Dieude P, Kreuter M et al.. “Lung disease in rheumatoid arthritis.” Nature reviews. Rheumatology (2026). PMID: 42315602 ↗

    L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  192. [192]

    Shinkawa Y, Tanaka M, Nakajima T et al.. “DAS28-ESR may underestimate disease activity in rheumatoid arthritis patients with nonalcoholic fatty liver disease: a retrospective cohort study.” Arthritis research & therapy (2026). PMID: 42421078 ↗

    L3COHORTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification
  193. [193]

    Tang K, Zhu L, Shan S et al.. “Global, regional and national trends in the epidemiology of rheumatoid arthritis from 1990 to 2021: an age-period-cohort effect analysis of the global burden of disease study 2021.” RMD open (2025). PMID: 40221149 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors
  194. [194]

    Funada M, Miyazaki Y, Nakayamada S et al.. “CT informs detection and treatment options in rheumatoid arthritis complicated by pulmonary non-tuberculous mycobacterial disease from the FIRST registry.” RMD open (2024). PMID: 38866590 ↗

    L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Prevention, Screening & Surveillance
  195. [195]

    Zhang XM, Liu L, Yan YD et al.. “Infection risks associated with b/tsDMARDs in rheumatoid arthritis: a systematic review and network meta-analysis.” European journal of clinical pharmacology (2026). PMID: 42426413 ↗

    L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related
  196. [196]

    Conway R, Low C, Coughlan RJ et al.. “Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials.” Arthritis & rheumatology (Hoboken, N.J.) (2014). PMID: 24757133 ↗

    L1SR_MA_RCTCited in: Clinical Presentation, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related
  197. [197]

    Combe B, Kivitz A, Tanaka Y et al.. “Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.” Annals of the rheumatic diseases (2021). PMID: 33504485 ↗

    L1RCTCited in: Clinical Presentation, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  198. [198]

    Fleischmann RM, Genovese MC, Enejosa JV et al.. “Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response.” Annals of the rheumatic diseases (2019). PMID: 31362993 ↗

    L1RCTCited in: Clinical Presentation
  199. [199]

    Takeuchi T, Kawanishi M, Nakanishi M et al.. “Phase II/III Results of a Trial of Anti-Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 35729713 ↗

    L1RCTCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target
  200. [200]

    Burmester GR, Kremer JM, Van den Bosch F et al.. “Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.” Lancet (London, England) (2018). PMID: 29908669 ↗

    L1RCTCited in: Clinical Presentation, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment
  201. [201]

    Smolen JS, Kay J, Doyle MK et al.. “Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.” Lancet (London, England) (2009). PMID: 19560810 ↗

    L1RCTCited in: Clinical Presentation
  202. [202]

    Aletaha D, Bingham CO, Tanaka Y et al.. “Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.” Lancet (London, England) (2017). PMID: 28215362 ↗

    L1RCTCited in: Clinical Presentation
  203. [203]

    Smolen JS, Beaulieu A, Rubbert-Roth A et al.. “Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial.” Lancet (London, England) (2008). PMID: 18358926 ↗

    L1RCTCited in: Clinical Presentation
  204. [204]

    Burmester GR, Blanco R, Charles-Schoeman C et al.. “Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.” Lancet (London, England) (2013). PMID: 23294500 ↗

    L1RCTCited in: Clinical Presentation, Complications: Disease-Driven & Treatment-Related
  205. [205]

    Gabay C, Emery P, van Vollenhoven R et al.. “Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial.” Lancet (London, England) (2013). PMID: 23515142 ↗

    L1RCTCited in: Clinical Presentation
  206. [206]

    Fleischmann R, Kremer J, Cush J et al.. “Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.” The New England journal of medicine (2012). PMID: 22873530 ↗

    L1RCTCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment
  207. [207]

    Lee EB, Fleischmann R, Hall S et al.. “Tofacitinib versus methotrexate in rheumatoid arthritis.” The New England journal of medicine (2014). PMID: 24941177 ↗

    L1RCTCited in: Clinical Presentation, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  208. [208]

    McGagh D, Song K, Yuan H et al.. “Digital health technologies to strengthen patient-centred outcome assessment in clinical trials in inflammatory arthritis.” The Lancet. Rheumatology (2024). PMID: 39089297 ↗

    L5TRIAL_NONRANDOMCited in: Clinical Presentation
  209. [209]

    Mankia K, Siddle H, Di Matteo A et al.. “A core set of risk factors in individuals at risk of rheumatoid arthritis: a systematic literature review informing the EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis.” RMD open (2021). PMID: 34531306 ↗

    L2TRIAL_NONRANDOMCited in: Clinical Presentation
  210. [210]

    Motta F, Bizzaro N, Giavarina D et al.. “Rheumatoid factor isotypes in rheumatoid arthritis diagnosis and prognosis: a systematic review and meta-analysis.” RMD open (2023). PMID: 37541740 ↗

    L2SR_OBSCited in: Clinical Presentation
  211. [211]

    Huscher D, Thiele K, Gromnica-Ihle E et al.. “Dose-related patterns of glucocorticoid-induced side effects.” Annals of the rheumatic diseases (2008). PMID: 18684744 ↗

    L3OTHERCited in: Clinical Presentation, Complications: Disease-Driven & Treatment-Related
  212. [212]

    Qin Y, Cai ML, Jin HZ et al.. “Age-associated B cells contribute to the pathogenesis of rheumatoid arthritis by inducing activation of fibroblast-like synoviocytes via TNF-α-mediated ERK1/2 and JAK-STAT1 pathways.” Annals of the rheumatic diseases (2022). PMID: 35760450 ↗

    L5OTHERCited in: Clinical Presentation
  213. [213]

    Wang Y, Xie X, Zhang C et al.. “Rheumatoid arthritis, systemic lupus erythematosus and primary Sjögren's syndrome shared megakaryocyte expansion in peripheral blood.” Annals of the rheumatic diseases (2021). PMID: 34462261 ↗

    L3OTHERCited in: Clinical Presentation
  214. [214]

    Spagnolo P, Distler O, Ryerson CJ et al.. “Mechanisms of progressive fibrosis in connective tissue disease (CTD)-associated interstitial lung diseases (ILDs).” Annals of the rheumatic diseases (2020). PMID: 33037004 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  215. [215]

    Tu J, Chen W, Huang W et al.. “Positive feedback loop PU.1-IL9 in Th9 promotes rheumatoid arthritis development.” Annals of the rheumatic diseases (2024). PMID: 39164066 ↗

    L5OTHERCited in: Clinical Presentation
  216. [216]

    De Giuseppe A, Deichsel A, Reese A et al.. “Collagen-binding integrin α11β1 contributes to joint destruction in arthritic hTNFtg mice.” Annals of the rheumatic diseases (2025). PMID: 40816940 ↗

    L5OTHERCited in: Clinical Presentation
  217. [217]

    Sendo S, Machado CRL, Boyle DL et al.. “Dysregulated NUB1 and Neddylation Enhances Rheumatoid Arthritis Fibroblast-Like Synoviocyte Inflammatory Responses.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 38566346 ↗

    L5OTHERCited in: Clinical Presentation
  218. [218]

    Nakajima S, Tsuchiya H, Ota M et al.. “Synovial Tissue Heterogeneity in Japanese Patients With Rheumatoid Arthritis Elucidated Using a Cell-Type Deconvolution Approach.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 37390361 ↗

    L4OTHERCited in: Clinical Presentation
  219. [219]

    Mustelin T, Bottini N, Stanford SM. “The Contribution of PTPN22 to Rheumatic Disease.” Arthritis & rheumatology (Hoboken, N.J.) (2019). PMID: 30507064 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  220. [220]

    You S, Koh JH, Leng L et al.. “The Tumor-Like Phenotype of Rheumatoid Synovium: Molecular Profiling and Prospects for Precision Medicine.” Arthritis & rheumatology (Hoboken, N.J.) (2018). PMID: 29287304 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  221. [221]

    Yi K, Jo S, Song W et al.. “Analysis of Single-Cell Transcriptome and Surface Protein Expression in Ankylosing Spondylitis Identifies OX40-Positive and Glucocorticoid-Induced Tumor Necrosis Factor Receptor-Positive Pathogenic Th17 Cells.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 36787119 ↗

    L3OTHERCited in: Clinical Presentation, Acute Management: Flares & Organ-Threatening Disease
  222. [222]

    Hadjadj J, Wolfers A, Borisov O et al.. “Clinical manifestations, disease penetrance, and treatment in individuals with SOCS1 insufficiency: a registry-based and population-based study.” The Lancet. Rheumatology (2025). PMID: 40024253 ↗

    L2OTHERCited in: Clinical Presentation
  223. [223]

    Triaille C, Durez P, Natalucci F et al.. “The relationship between clinical disease activity, synovial inflammatory profile, and treatment response in rheumatoid arthritis.” The Lancet. Rheumatology (2025). PMID: 41106413 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification
  224. [224]

    Song K, Satsangi J, Coates LC. “Arthritis complicating inflammatory bowel disease- the future is now.” The Lancet. Rheumatology (2024). PMID: 39032495 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Prevention, Screening & Surveillance
  225. [225]

    Genovese MC, Gaylis NB, Sikes D et al.. “Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot study.” The Lancet. Rheumatology (2020). PMID: 38273617 ↗

    L1OTHERCited in: Clinical Presentation
  226. [226]

    Lee YC, Fox RS, Kwakkenbos L et al.. “Pain levels and associated factors in the Scleroderma Patient-centered Intervention Network (SPIN) cohort: a multicentre cross-sectional study.” The Lancet. Rheumatology (2021). PMID: 38287631 ↗

    L4OTHERCited in: Clinical Presentation
  227. [227]

    Yousry TA, Major EO, Ryschkewitsch C et al.. “Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy.” The New England journal of medicine (2006). PMID: 16510746 ↗

    L4OTHERCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  228. [228]

    Martí-Carvajal AJ, Agreda-Pérez LH, Solà I et al.. “Erythropoiesis-stimulating agents for anemia in rheumatoid arthritis.” The Cochrane database of systematic reviews (2013). PMID: 23450527 ↗

    L1SR_OBSCited in: Clinical Presentation, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  229. [229]

    Gómez-Bernal F, Quevedo Abeledo JC, Almeida-Santiago C et al.. “Clinical and serological associations of interferon-α and interferon-γ in rheumatoid arthritis patients.” Rheumatology (Oxford, England) (2026). PMID: 41578968 ↗

    L4OTHERCited in: Clinical Presentation
  230. [230]

    Voskuyl AE. “The heart and cardiovascular manifestations in rheumatoid arthritis.” Rheumatology (Oxford, England) (2006). PMID: 16980723 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  231. [231]

    Colmegna I, Weyand CM. “Haematopoietic stem and progenitor cells in rheumatoid arthritis.” Rheumatology (Oxford, England) (2010). PMID: 20837497 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  232. [232]

    Dey M, Nagy G, Nikiphorou E. “Comorbidities and extra-articular manifestations in difficult-to-treat rheumatoid arthritis: different sides of the same coin?” Rheumatology (Oxford, England) (2023). PMID: 36205537 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  233. [233]

    Kostine M, Truchetet ME, Schaeverbeke T. “Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy.” Rheumatology (Oxford, England) (2019). PMID: 31816082 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  234. [234]

    Cavalli G, Dinarello CA. “Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies.” Rheumatology (Oxford, England) (2015). PMID: 26209330 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  235. [235]

    Hanlon MM, McGarry T, Marzaioli V et al.. “Rheumatoid arthritis macrophages are primed for inflammation and display bioenergetic and functional alterations.” Rheumatology (Oxford, England) (2023). PMID: 36398893 ↗

    L5OTHERCited in: Clinical Presentation
  236. [236]

    Zabotti A, Aydin SZ, David P et al.. “Delineating inflammatory from non-inflammatory mechanisms for therapy optimization in psoriatic arthritis.” Nature reviews. Rheumatology (2025). PMID: 40075177 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  237. [237]

    Udalova IA, Mantovani A, Feldmann M. “Macrophage heterogeneity in the context of rheumatoid arthritis.” Nature reviews. Rheumatology (2016). PMID: 27383913 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  238. [238]

    Raposo B, Klareskog L, Robinson WH et al.. “The peculiar features, diversity and impact of citrulline-reactive autoantibodies.” Nature reviews. Rheumatology (2024). PMID: 38858604 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  239. [239]

    Becker YLC, Duvvuri B, Fortin PR et al.. “The role of mitochondria in rheumatic diseases.” Nature reviews. Rheumatology (2022). PMID: 36175664 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  240. [240]

    Ulutaş F, Yiğit N, Güngör G et al.. “Inflammatory activity as a predictor of clinical deterioration in interstitial pneumonia with autoimmune features: a comparative cohort study with connective tissue disease-associated interstitial lung disease.” Therapeutic advances in respiratory disease (2026). PMID: 42423229 ↗

    L3COHORTCited in: Clinical Presentation, Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  241. [241]

    Tison A, Jannat-Khah D, Cappelli LC et al.. “Comparing immune-checkpoint inhibitor-mediated inflammatory arthritis to polymyalgia rheumatica: a prospective cohort study.” Journal for immunotherapy of cancer (2026). PMID: 42208976 ↗

    L2COHORTCited in: Clinical Presentation
  242. [242]

    Veale DJ, Fearon U. “What makes psoriatic and rheumatoid arthritis so different?” RMD open (2015). PMID: 26509055 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation
  243. [243]

    Turcinov S, Sharma RK, De Vries C et al.. “Arthritis progressors have a decreased frequency of circulating autoreactive T cells during the at-risk phase of rheumatoid arthritis.” RMD open (2024). PMID: 39557489 ↗

    L2OTHERCited in: Clinical Presentation
  244. [244]

    Currado D, Trunfio F, Saracino F et al.. “Patients with psoriatic arthritis and comorbid metabolic syndrome show a difficult-to-treat phenotype: another mosaic tile in the definition of a still undefined subset of patients.” RMD open (2025). PMID: 40545272 ↗

    L4OTHERCited in: Clinical Presentation
  245. [245]

    Vittecoq O, Brevet P, Gerard B et al.. “On difficulties to define prognostic factors for clinical practice in rheumatoid arthritis.” RMD open (2024). PMID: 39343442 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  246. [246]

    Kummer LY, Kuijper LH, Fernández Blanco L et al.. “TNF inhibitors affect the induction and maintenance of spike-specific B-cell responses after mRNA vaccination.” RMD open (2025). PMID: 40759563 ↗

    L2OTHERCited in: Clinical Presentation
  247. [247]

    Dean NJ, Clifton IJ, Salman R et al.. “Anti-IL-5 biologics and rheumatoid arthritis: a single-centre 500 patient year exposure analysis.” RMD open (2023). PMID: 38114196 ↗

    L4OTHERCited in: Clinical Presentation
  248. [248]

    Liu R, Xing Q, Liu Z et al.. “Clinical characteristics and treatment of low-dose methotrexate-related adverse reactions in rheumatoid arthritis: a retrospective study.” Naunyn-Schmiedeberg's archives of pharmacology (2026). PMID: 42240664 ↗

    L4COHORTCited in: Clinical Presentation
  249. [249]

    Ninagawa K, Kudo Y, Kono M et al.. “Adult-Onset LRBA Deficiency Presenting with Rheumatoid Arthritis-Like Manifestations: A Case Report.” Journal of clinical immunology (2026). PMID: 42406167 ↗

    L4CASE_REPORTCited in: Clinical Presentation
  250. [250]

    Ozduygu G, Kaenmuang P, Guedes ABF et al.. “Systemic Autoimmune Rheumatic Disease-Associated Interstitial Lung Disease: A Pulmonary Perspective on Recent Guidelines.” Advances in therapy (2026). PMID: 42423949 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  251. [251]

    Atschekzei F, Dubrowinskaja N, Anim M et al.. “Rare variants in genes related to inborn errors of immunity in patients with rheumatoid arthritis and secondary immunodeficiency.” RMD open (2026). PMID: 42399081 ↗

    L4OTHERCited in: Clinical Presentation
  252. [252]

    Wang H, Xu J, Li Y et al.. “Prevalence of sarcopenia in patients with rheumatoid arthritis: a cross-sectional study.” RMD open (2026). PMID: 42399074 ↗

    L4OTHERCited in: Clinical Presentation
  253. [253]

    Nagy G, Roodenrijs NMT, Welsing PMJ et al.. “EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis.” Annals of the rheumatic diseases (2021). PMID: 34407926 ↗

    L1GUIDELINECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, History and Evolution of Treatment
  254. [254]

    Fraenkel L, Bathon JM, England BR et al.. “2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.” Arthritis care & research (2021). PMID: 34101387 ↗

    L1GUIDELINECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, History and Evolution of Treatment
  255. [255]

    van Vollenhoven R, Takeuchi T, Pangan AL et al.. “Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial.” Arthritis & rheumatology (Hoboken, N.J.) (2020). PMID: 32638504 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  256. [256]

    Buttgereit F, Aelion J, Rojkovich B et al.. “Efficacy and Safety of ABBV-3373, a Novel Anti-Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody-Drug Conjugate, in Adults with Moderate-to-Severe Rheumatoid Arthritis Despite Methotrexate Therapy: A Randomized, Double-Blind, Active-Controlled Proof-of-Concept Phase IIa Trial.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 36512671 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment
  257. [257]

    Buttgereit F, Singhal A, Kivitz A et al.. “Efficacy and Safety of ABBV-154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b, Randomized, Placebo-Controlled Trial.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40495262 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment
  258. [258]

    Kuley R, Duvvuri B, Hasnain S et al.. “Neutrophil Activation Markers and Rheumatoid Arthritis Treatment Response to the JAK1/2 Inhibitor Baricitinib.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 39431356 ↗

    L3RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, History and Evolution of Treatment
  259. [259]

    Lange E, Kucharski D, Svedlund S et al.. “Effects of Aerobic and Resistance Exercise in Older Adults With Rheumatoid Arthritis: A Randomized Controlled Trial.” Arthritis care & research (2019). PMID: 29696812 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  260. [260]

    Hess A, Tascilar K, Schenker HM et al.. “Disease-associated brain activation predicts clinical response to TNF inhibition in rheumatoid arthritis (PreCePra): a randomised, multicentre, double-blind, placebo-controlled phase 3 study.” The Lancet. Rheumatology (2025). PMID: 40570879 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  261. [261]

    Wieczorek M, Kisiel B, Włodarczyk D et al.. “Dual JAK and ROCK inhibition with CPL'116 in patients with rheumatoid arthritis with inadequate response to methotrexate: a randomised, double-blind, placebo-controlled, phase 2 trial.” The Lancet. Rheumatology (2025). PMID: 40516565 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prevention, Screening & Surveillance
  262. [262]

    Rech J, Tascilar K, Hagen M et al.. “Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial.” Lancet (London, England) (2024). PMID: 38364841 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  263. [263]

    Fleischmann R, Mysler E, Hall S et al.. “Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.” Lancet (London, England) (2017). PMID: 28629665 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  264. [264]

    Petri M, Bruce IN, Dörner T et al.. “Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II).” Lancet (London, England) (2023). PMID: 36848919 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  265. [265]

    Cope AP, Jasenecova M, Vasconcelos JC et al.. “Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial.” Lancet (London, England) (2024). PMID: 38364839 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prevention, Screening & Surveillance
  266. [266]

    Morand EF, Vital EM, Petri M et al.. “Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).” Lancet (London, England) (2023). PMID: 36848918 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  267. [267]

    Taylor PC, Keystone EC, van der Heijde D et al.. “Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.” The New England journal of medicine (2017). PMID: 28199814 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  268. [268]

    Tuttle J, Drescher E, Simón-Campos JA et al.. “A Phase 2 Trial of Peresolimab for Adults with Rheumatoid Arthritis.” The New England journal of medicine (2023). PMID: 37195941 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  269. [269]

    Smolen JS, Feist E, Fatenejad S et al.. “Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis.” The New England journal of medicine (2022). PMID: 36001712 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  270. [270]

    van Vollenhoven RF, Fleischmann R, Cohen S et al.. “Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.” The New England journal of medicine (2012). PMID: 22873531 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target
  271. [271]

    O'Dell JR, Mikuls TR, Taylor TH et al.. “Therapies for active rheumatoid arthritis after methotrexate failure.” The New England journal of medicine (2013). PMID: 23755969 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification
  272. [272]

    Weinblatt ME, Kavanaugh A, Genovese MC et al.. “An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis.” The New England journal of medicine (2010). PMID: 20879879 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Complications: Disease-Driven & Treatment-Related
  273. [273]

    McDougall JA, Ferucci ED, Glover J et al.. “Telerheumatology: A Systematic Review.” Arthritis care & research (2017). PMID: 27863164 ↗

    L2SR_OBSCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  274. [274]

    Suter LG, Fraenkel L, Braithwaite RS. “Role of magnetic resonance imaging in the diagnosis and prognosis of rheumatoid arthritis.” Arthritis care & research (2011). PMID: 21557523 ↗

    L2SR_OBSCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  275. [275]

    Bredemeier M, de Oliveira FK, Rocha CM. “Low- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis.” Arthritis care & research (2014). PMID: 23983134 ↗

    L2SR_OBSCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  276. [276]

    Rempenault C, Combe B, Barnetche T et al.. “Clinical and Structural Efficacy of Hydroxychloroquine in Rheumatoid Arthritis: A Systematic Review.” Arthritis care & research (2020). PMID: 30629341 ↗

    L2SR_OBSCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target
  277. [277]

    Swerdlow DI, Holmes MV, Kuchenbaecker KB et al.. “The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis.” Lancet (London, England) (2012). PMID: 22421340 ↗

    L2SR_OBSCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Prevention, Screening & Surveillance
  278. [278]

    Ton DA, den Hollander NK, van Steenbergen HW et al.. “Comparison of findings on contrast-enhanced MRI of the hand, wrist, and forefoot in healthy controls, two at-risk groups, and patients with rheumatoid arthritis: a cohort study.” The Lancet. Rheumatology (2025). PMID: 40523380 ↗

    L2COHORTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  279. [279]

    Fleischmann R, Swierkot J, Penn SK et al.. “Long-term safety and efficacy of upadacitinib versus adalimumab in patients with rheumatoid arthritis: 5-year data from the phase 3, randomised SELECT-COMPARE study.” RMD open (2024). PMID: 38806190 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Immunosuppression Safety & Therapeutic Drug Monitoring, History and Evolution of Treatment
  280. [280]

    Taylor PC, Schett G, Huizinga TW et al.. “Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study.” RMD open (2024). PMID: 38942592 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment
  281. [281]

    Fleischmann R, Meerwein S, Charles-Schoeman C et al.. “Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study.” RMD open (2024). PMID: 39059811 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  282. [282]

    Gehin JE, Klaasen RA, Klami Kristianslund E et al.. “Therapeutic serum level for adalimumab in rheumatoid arthritis: explorative analyses of data from a randomised phase III trial.” RMD open (2024). PMID: 39537558 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, History and Evolution of Treatment
  283. [283]

    Kronzer VL, Hayashi K, Yoshida K et al.. “Autoantibodies against citrullinated and native proteins and prediction of rheumatoid arthritis-associated interstitial lung disease: A nested case-control study.” The Lancet. Rheumatology (2023). PMID: 36874209 ↗

    L3CASE_CONTROLCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  284. [284]

    Hilliquin S, Vismara E, Berlengiero V et al.. “Effect of targeted therapies on pulmonary function in rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis.” RMD open (2026). PMID: 41856563 ↗

    L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  285. [285]

    van Steenbergen HW, Doornkamp F, Alivernini S et al.. “EULAR/ACR risk stratification criteria for development of rheumatoid arthritis in the risk stage of arthralgia.” Annals of the rheumatic diseases (2025). PMID: 40447498 ↗

    L1OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  286. [286]

    Li K, Mo W, Wu L et al.. “Novel autoantibodies identified in ACPA-negative rheumatoid arthritis.” Annals of the rheumatic diseases (2021). PMID: 33452006 ↗

    L3OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  287. [287]

    Buch MH. “Defining refractory rheumatoid arthritis.” Annals of the rheumatic diseases (2018). PMID: 29588276 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  288. [288]

    Lee S, Choi E, Chae S et al.. “Identification of MYH9 as a key regulator for synoviocyte migration and invasion through secretome profiling.” Annals of the rheumatic diseases (2023). PMID: 37188496 ↗

    L5OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  289. [289]

    He Y, Sareila O, Johansson L et al.. “Epitopes targeted by autoantibodies in presymptomatic individuals predict early rheumatoid arthritis.” Annals of the rheumatic diseases (2025). PMID: 40348635 ↗

    L2OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  290. [290]

    Gessl I, Hana CA, Deimel T et al.. “Tenderness and radiographic progression in rheumatoid arthritis and psoriatic arthritis.” Annals of the rheumatic diseases (2022). PMID: 36261248 ↗

    L2OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  291. [291]

    Felson D, Lacaille D, LaValley MP et al.. “Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment.” Annals of the rheumatic diseases (2021). PMID: 34785493 ↗

    L5OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  292. [292]

    Spiliopoulou A, Colombo M, Plant D et al.. “Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for CD40 and CD39.” Annals of the rheumatic diseases (2019). PMID: 31036624 ↗

    L2OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  293. [293]

    Wheeler AM, Baker JF, Riley TR et al.. “Peripheral Biomarker Signatures in Rheumatoid Arthritis-Associated Interstitial Lung Disease.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40033001 ↗

    L3OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  294. [294]

    David P, Di Matteo A, Hen O et al.. “Poly-Refractory Rheumatoid Arthritis: An Uncommon Subset of Difficult to Treat Disease With Distinct Inflammatory and Noninflammatory Phenotypes.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 38059326 ↗

    L4OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  295. [295]

    Barry S, Sheng E, Baker JF. “Metabolic Consequences of Rheumatoid Arthritis.” Arthritis care & research (2025). PMID: 40176397 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  296. [296]

    Chalupczak NV, Aydemir B, Isaacs A et al.. “Sleep Matters: Exploring the Link Between Sleep Disturbances and Fatigue in Rheumatoid Arthritis.” Arthritis care & research (2025). PMID: 40452358 ↗

    L4OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  297. [297]

    England BR, Yang Y, Roul P et al.. “Heterogeneity of Rheumatoid Arthritis-Associated Interstitial Lung Disease by Longitudinal Forced Vital Capacity Trajectory and Associations With Disease Outcomes.” Arthritis care & research (2025). PMID: 40771150 ↗

    L2OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  298. [298]

    Sofíudóttir BK, Harders S, Laursen CB et al.. “Detection of Interstitial Lung Disease in Rheumatoid Arthritis by Thoracic Ultrasound: A Diagnostic Test Accuracy Study.” Arthritis care & research (2024). PMID: 38622106 ↗

    L4OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prevention, Screening & Surveillance
  299. [299]

    Baker JF, Reed G, Poudel DR et al.. “Obesity and Response to Advanced Therapies in Rheumatoid Arthritis.” Arthritis care & research (2022). PMID: 35143117 ↗

    L2OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification
  300. [300]

    Nettleton E, Carlson K, Putman M. “The emerging risk of overdiagnosis in rheumatoid arthritis and polymyalgia rheumatica.” The Lancet. Rheumatology (2024). PMID: 39341221 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prevention, Screening & Surveillance
  301. [301]

    Vassilakis KD, Lampadaki K, Nikiphorou E et al.. “Skin cancer in inflammatory arthritis: should we advise screening?” The Lancet. Rheumatology (2025). PMID: 41344357 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  302. [302]

    McDermott GC, Gill R, Byrne S et al.. “Risk factors for interstitial lung disease in early rheumatoid arthritis and external validation of screening strategies: a cross-sectional analysis of the prospective SAIL-RA cohort in the USA.” The Lancet. Rheumatology (2025). PMID: 41106411 ↗

    L4OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  303. [303]

    Orange DE, Yao V, Sawicka K et al.. “RNA Identification of PRIME Cells Predicting Rheumatoid Arthritis Flares.” The New England journal of medicine (2020). PMID: 32668112 ↗

    L4OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease
  304. [304]

    Plenge RM, Seielstad M, Padyukov L et al.. “TRAF1-C5 as a risk locus for rheumatoid arthritis--a genomewide study.” The New England journal of medicine (2007). PMID: 17804836 ↗

    L3OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  305. [305]

    Fleischmann R, Swierkot J, Durez P et al.. “Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE study.” RMD open (2026). PMID: 42342288 ↗

    L1RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Immunosuppression Safety & Therapeutic Drug Monitoring, History and Evolution of Treatment
  306. [306]

    Meijs AC, Kolmert J, Lindquist S et al.. “First-in-human (phase I) trial of SOL-116, a humanised IgG4 monoclonal antibody targeting bile salt-stimulated lipase, in healthy participants and rheumatoid arthritis patients.” RMD open (2026). PMID: 42331396 ↗

    L2RCTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  307. [307]

    Williams ACC, Fisher E, Hearn L et al.. “Psychological therapies for the management of chronic pain (excluding headache) in adults.” The Cochrane database of systematic reviews (2020). PMID: 32794606 ↗

    L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  308. [308]

    Rösner S, Englbrecht C, Wehrle R et al.. “Eszopiclone for insomnia.” The Cochrane database of systematic reviews (2018). PMID: 30303519 ↗

    L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Special Populations, Pregnancy & Fertility
  309. [309]

    Maxwell L, Singh JA. “Abatacept for rheumatoid arthritis.” The Cochrane database of systematic reviews (2009). PMID: 19821401 ↗

    L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification
  310. [310]

    Lopez-Olivo MA, Siddhanamatha HR, Shea B et al.. “Methotrexate for treating rheumatoid arthritis.” The Cochrane database of systematic reviews (2014). PMID: 24916606 ↗

    L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  311. [311]

    Robert N, Wong GW, Wright JM. “Effect of cyclosporine on blood pressure.” The Cochrane database of systematic reviews (2010). PMID: 20091657 ↗

    L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  312. [312]

    Kirwan JR, Bijlsma JW, Boers M et al.. “Effects of glucocorticoids on radiological progression in rheumatoid arthritis.” The Cochrane database of systematic reviews (2007). PMID: 17253590 ↗

    L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Acute Management: Flares & Organ-Threatening Disease, Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  313. [313]

    Lenza M, Buchbinder R, Takwoingi Y et al.. “Magnetic resonance imaging, magnetic resonance arthrography and ultrasonography for assessing rotator cuff tears in people with shoulder pain for whom surgery is being considered.” The Cochrane database of systematic reviews (2013). PMID: 24065456 ↗

    L2SR_OBSCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  314. [314]

    Singh JA, Hossain A, Tanjong Ghogomu E et al.. “Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.” The Cochrane database of systematic reviews (2017). PMID: 28282491 ↗

    L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification
  315. [315]

    Li G, Tan L, Liu J et al.. “Network meta-analysis of novel diagnostic biomarkers for rheumatoid arthritis: comparative performance of anti-CarP, anti-MCV, and emerging markers.” Frontiers in immunology (2026). PMID: 42382770 ↗

    L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  316. [316]

    van Esveld L, Dikkenberg MVD, Luurssen-Masurel N et al.. “Effects of biologic and targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs) on patient-reported outcome domains in rheumatoid arthritis: a systematic review and network meta-analyses.” RMD open (2026). PMID: 42342282 ↗

    L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target
  317. [317]

    Lage-Hansen PR, Haugegaard T, Sofíudóttir BK et al.. “Understanding patient and physician global assessments in rheumatoid arthritis: A meta-epidemiological study of core outcome set performance.” Seminars in arthritis and rheumatism (2026). PMID: 42330661 ↗

    L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  318. [318]

    Hu Y, Gan Y, Tang M et al.. “Efficacy, safety, and tolerability of treatments for interstitial lung disease associated with rtoid arthritis: A systematic review and network meta-analysis.” Journal of autoimmunity (2026). PMID: 42322667 ↗

    L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  319. [319]

    Yamaoka K, Li Z, Aung KTZM et al.. “2024 Update of the Asia-Pacific League of Associations for Rheumatology (APLAR) Recommendations for Rheumatoid Arthritis Management.” International journal of rheumatic diseases (2026). PMID: 42362943 ↗

    L1GUIDELINECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prevention, Screening & Surveillance
  320. [320]

    Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y et al.. “Obesity in rheumatoid arthritis.” Rheumatology (Oxford, England) (2010). PMID: 20959355 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  321. [321]

    Druce KL, Basu N. “Predictors of fatigue in rheumatoid arthritis.” Rheumatology (Oxford, England) (2019). PMID: 31435677 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification
  322. [322]

    Sidhu N, Wouters F, Niemantsverdriet E et al.. “MRI-detected synovitis of the small joints predicts rheumatoid arthritis development in large joint undifferentiated inflammatory arthritis.” Rheumatology (Oxford, England) (2022). PMID: 34164662 ↗

    L2OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  323. [323]

    Fenton SAM, Veldhuijzen van Zanten JJCS, Duda JL et al.. “Sedentary behaviour in rheumatoid arthritis: definition, measurement and implications for health.” Rheumatology (Oxford, England) (2018). PMID: 28398519 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  324. [324]

    Leu Agelii M, Sareila O, Lönnblom E et al.. “Autoantibodies to joint-related peptides as predictive markers in early rheumatoid arthritis.” Rheumatology (Oxford, England) (2025). PMID: 39078716 ↗

    L2OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  325. [325]

    Boeren AMP, Khidir SJH, de Jong PHP et al.. “Patient-reported swelling in arthralgia patients at risk for rheumatoid arthritis: is it of value?” Rheumatology (Oxford, England) (2024). PMID: 37952171 ↗

    L2OTHERCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  326. [326]

    Konzett V, Aletaha D. “Management strategies in rheumatoid arthritis.” Nature reviews. Rheumatology (2024). PMID: 39448800 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  327. [327]

    Robinson WH, Lepus CM, Wang Q et al.. “Low-grade inflammation as a key mediator of the pathogenesis of osteoarthritis.” Nature reviews. Rheumatology (2016). PMID: 27539668 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Prevention, Screening & Surveillance
  328. [328]

    Kissel T, Toes REM, Huizinga TWJ et al.. “Glycobiology of rheumatic diseases.” Nature reviews. Rheumatology (2022). PMID: 36418483 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria, Severity, Disease Activity & Risk Stratification
  329. [329]

    Sellam J, Berenbaum F. “The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis.” Nature reviews. Rheumatology (2010). PMID: 20924410 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  330. [330]

    Pozsgay J, Szekanecz Z, Sármay G. “Antigen-specific immunotherapies in rheumatic diseases.” Nature reviews. Rheumatology (2017). PMID: 28701761 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  331. [331]

    Aletaha D, Blüml S. “Therapeutic implications of autoantibodies in rheumatoid arthritis.” RMD open (2016). PMID: 27252890 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  332. [332]

    Hua C, Buttgereit F, Combe B. “Glucocorticoids in rheumatoid arthritis: current status and future studies.” RMD open (2020). PMID: 31958273 ↗

    L5REVIEW_NARRATIVECited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  333. [333]

    Dai LY, Ren JQ, Zhao YQ et al.. “The value of arthroscopic synovectomy in the treatment of rheumatoid arthritis: A prospective cohort study.” Clinical rheumatology (2026). PMID: 42366265 ↗

    L2COHORTCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  334. [334]

    Xu Y, Luo L, Chen Y et al.. “Efficacy and safety of traditional Chinese medicine decoctions as an adjuvant treatment for rheumatoid arthritis: A systematic review and meta-analysis.” Medicine (2026). PMID: 42363544 ↗

    L1SR_OBSCited in: Diagnosis & Workup: Serology, Imaging, Synovial Fluid & Classification Criteria
  335. [335]

    Smolen JS, Aletaha D, Bijlsma JW et al.. “Treating rheumatoid arthritis to target: recommendations of an international task force.” Annals of the rheumatic diseases (2010). PMID: 20215140 ↗

    L1GUIDELINECited in: Severity, Disease Activity & Risk Stratification
  336. [336]

    Singh JA, Saag KG, Bridges SL et al.. “2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2015). PMID: 26545940 ↗

    L1GUIDELINECited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prevention, Screening & Surveillance
  337. [337]

    Østergaard M, van Vollenhoven RF, Rudin A et al.. “Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial.” Annals of the rheumatic diseases (2023). PMID: 37423647 ↗

    L1RCTCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  338. [338]

    Fleischmann R, Pangan AL, Song IH et al.. “Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.” Arthritis & rheumatology (Hoboken, N.J.) (2019). PMID: 31287230 ↗

    L1RCTCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  339. [339]

    Baker MC, Kavanagh S, Cohen S et al.. “A Randomized, Double-Blind, Sham-Controlled, Clinical Trial of Auricular Vagus Nerve Stimulation for the Treatment of Active Rheumatoid Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 37390360 ↗

    L1RCTCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  340. [340]

    Santos Moreno P, García Salinas R, Caballero Uribe CV et al.. “Pan American League of Associations for Rheumatology recommendations for the management of rheumatoid arthritis.” The Lancet. Rheumatology (2025). PMID: 41240967 ↗

    L1GUIDELINECited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment
  341. [341]

    Kerschbaumer A, Sepriano A, Bergstra SA et al.. “Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.” Annals of the rheumatic diseases (2022). PMID: 36368906 ↗

    L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target
  342. [342]

    Morel J, Dernis E, Roux C et al.. “Effect of a 1-month methotrexate delay on pneumococcal vaccine immunogenicity and disease control in patients with early rheumatoid arthritis (VACIMRA): an open-label randomised trial.” The Lancet. Rheumatology (2025). PMID: 40749694 ↗

    L1RCTCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prevention, Screening & Surveillance
  343. [343]

    Tamai H, Ikeda K, Miyamoto T et al.. “Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trial.” The Lancet. Rheumatology (2023). PMID: 38251524 ↗

    L1RCTCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  344. [344]

    Genovese MC, Fleischmann R, Combe B et al.. “Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.” Lancet (London, England) (2018). PMID: 29908670 ↗

    L1RCTCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment
  345. [345]

    Lamb SE, Williamson EM, Heine PJ et al.. “Exercises to improve function of the rheumatoid hand (SARAH): a randomised controlled trial.” Lancet (London, England) (2014). PMID: 25308290 ↗

    L1RCTCited in: Severity, Disease Activity & Risk Stratification
  346. [346]

    Coates LC, Moverley AR, McParland L et al.. “Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.” Lancet (London, England) (2015). PMID: 26433318 ↗

    L1RCTCited in: Severity, Disease Activity & Risk Stratification
  347. [347]

    Rubbert-Roth A, Enejosa J, Pangan AL et al.. “Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis.” The New England journal of medicine (2020). PMID: 33053283 ↗

    L1RCTCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  348. [348]

    Emery P, Hammoudeh M, FitzGerald O et al.. “Sustained remission with etanercept tapering in early rheumatoid arthritis.” The New England journal of medicine (2014). PMID: 25372086 ↗

    L1RCTCited in: Severity, Disease Activity & Risk Stratification
  349. [349]

    Genovese MC, Kremer J, Zamani O et al.. “Baricitinib in Patients with Refractory Rheumatoid Arthritis.” The New England journal of medicine (2016). PMID: 27028914 ↗

    L1RCTCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  350. [350]

    Katchamart W, Johnson S, Lin HJ et al.. “Predictors for remission in rheumatoid arthritis patients: A systematic review.” Arthritis care & research (2010). PMID: 20235210 ↗

    L2SR_OBSCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target
  351. [351]

    Han L, Hazlewood GS, Barnabe C et al.. “Systematic Review of Outcomes and Patient Experience With Virtual Care in Rheumatoid Arthritis.” Arthritis care & research (2022). PMID: 33650316 ↗

    L2SR_OBSCited in: Severity, Disease Activity & Risk Stratification
  352. [352]

    Hamann P, Holland R, Hyrich K et al.. “Factors Associated With Sustained Remission in Rheumatoid Arthritis in Patients Treated With Anti-Tumor Necrosis Factor.” Arthritis care & research (2017). PMID: 27564526 ↗

    L2SR_OBSCited in: Severity, Disease Activity & Risk Stratification
  353. [353]

    Walrabenstein W, Wagenaar CA, van der Leeden M et al.. “A multidisciplinary lifestyle program for rheumatoid arthritis: the 'Plants for Joints' randomized controlled trial.” Rheumatology (Oxford, England) (2023). PMID: 36617162 ↗

    L1RCTCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  354. [354]

    Silvagni E, Zandonella Callegher S, Mauric E et al.. “Musculoskeletal ultrasound for treating rheumatoid arthritis to target-a systematic literature review.” Rheumatology (Oxford, England) (2022). PMID: 35512175 ↗

    L2SR_OBSCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target
  355. [355]

    Geenen R, Dures E. “A biopsychosocial network model of fatigue in rheumatoid arthritis: a systematic review.” Rheumatology (Oxford, England) (2019). PMID: 31682275 ↗

    L2SR_OBSCited in: Severity, Disease Activity & Risk Stratification
  356. [356]

    Gwinnutt JM, Wieczorek M, Rodríguez-Carrio J et al.. “Effects of diet on the outcomes of rheumatic and musculoskeletal diseases (RMDs): systematic review and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs.” RMD open (2022). PMID: 35654458 ↗

    L2SR_OBSCited in: Severity, Disease Activity & Risk Stratification
  357. [357]

    Smolen JS, Landewé RBM, Bergstra SA et al.. “EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.” Annals of the rheumatic diseases (2022). PMID: 36357155 ↗

    L1OTHERCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Immunosuppression Safety & Therapeutic Drug Monitoring
  358. [358]

    Smolen JS, Edwards CJ, Konzett V et al.. “EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update.” Annals of the rheumatic diseases (2026). PMID: 41826212 ↗

    L1OTHERCited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target
  359. [359]

    Smolen JS, Breedveld FC, Burmester GR et al.. “Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.” Annals of the rheumatic diseases (2015). PMID: 25969430 ↗

    L1REVIEW_NARRATIVECited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target
  360. [360]

    Franklyn K, Lau CS, Navarra SV et al.. “Definition and initial validation of a Lupus Low Disease Activity State (LLDAS).” Annals of the rheumatic diseases (2015). PMID: 26458737 ↗

    L2OTHERCited in: Severity, Disease Activity & Risk Stratification, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  361. [361]

    Meng X, Chen Z, Li T et al.. “Role and Therapeutic Potential for Targeting Fibroblast Growth Factor 10/FGFR1 in Relapsed Rheumatoid Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 37584284 ↗

    L4OTHERCited in: Severity, Disease Activity & Risk Stratification
  362. [362]

    Nel HJ, Malmström V, Wraith DC et al.. “Autoantigens in rheumatoid arthritis and the potential for antigen-specific tolerising immunotherapy.” The Lancet. Rheumatology (2020). PMID: 38279365 ↗

    L5REVIEW_NARRATIVECited in: Severity, Disease Activity & Risk Stratification, Complications: Disease-Driven & Treatment-Related
  363. [363]

    Maassen JM, van Ouwerkerk L, Allaart CF. “Tapering of disease-modifying antirheumatic drugs: an overview for daily practice.” The Lancet. Rheumatology (2021). PMID: 38287612 ↗

    L5REVIEW_NARRATIVECited in: Severity, Disease Activity & Risk Stratification
  364. [364]

    Alshammari MM, Abood NA, Kahwaji S et al.. “Effectiveness of metformin as an adjunctive therapy in rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials.” BMC rheumatology (2026). PMID: 42351297 ↗

    L1SR_MA_RCTCited in: Severity, Disease Activity & Risk Stratification
  365. [365]

    Singh JA, Noorbaloochi S, Singh G. “Golimumab for rheumatoid arthritis.” The Cochrane database of systematic reviews (2010). PMID: 20091667 ↗

    L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target
  366. [366]

    Singh JA, Beg S, Lopez-Olivo MA. “Tocilizumab for rheumatoid arthritis.” The Cochrane database of systematic reviews (2010). PMID: 20614469 ↗

    L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related
  367. [367]

    Wilsdon TD, Whittle SL, Thynne TR et al.. “Methotrexate for psoriatic arthritis.” The Cochrane database of systematic reviews (2019). PMID: 30656673 ↗

    L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target
  368. [368]

    Chen J, Veras MM, Liu C et al.. “Methotrexate for ankylosing spondylitis.” The Cochrane database of systematic reviews (2013). PMID: 23450553 ↗

    L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target
  369. [369]

    Kieffer C, Hebert V, Joly P et al.. “Efficacy and Safety of Rituximab in Pemphigus Foliaceus: A Systematic Review and Meta-analysis.” Dermatology and therapy (2026). PMID: 42390708 ↗

    L2SR_OBSCited in: Severity, Disease Activity & Risk Stratification
  370. [370]

    Konzett V, Kerschbaumer A, Willmann L et al.. “Detectable safety gestalt of rheumatoid arthritis treatments from pivotal clinical drug trials.” Rheumatology (Oxford, England) (2026). PMID: 42360790 ↗

    L1SR_OBSCited in: Severity, Disease Activity & Risk Stratification, History and Evolution of Treatment
  371. [371]

    Dag HH, Snoeck Henkemans SVJ, Looijen AEM et al.. “Eye-openers for advanced management of elderly-onset rheumatoid arthritis.” Rheumatology (Oxford, England) (2025). PMID: 40795771 ↗

    L2OTHERCited in: Severity, Disease Activity & Risk Stratification, Special Populations, Pregnancy & Fertility
  372. [372]

    Taylor PC. “Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis.” Rheumatology (Oxford, England) (2019). PMID: 30806707 ↗

    L5REVIEW_NARRATIVECited in: Severity, Disease Activity & Risk Stratification
  373. [373]

    Brock J, Basu N, Schlachetzki JCM et al.. “Immune mechanisms of depression in rheumatoid arthritis.” Nature reviews. Rheumatology (2023). PMID: 37923863 ↗

    L5REVIEW_NARRATIVECited in: Severity, Disease Activity & Risk Stratification
  374. [374]

    Szekanecz Z, Buch MH, Charles-Schoeman C et al.. “Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician.” Nature reviews. Rheumatology (2024). PMID: 38216757 ↗

    L5REVIEW_NARRATIVECited in: Severity, Disease Activity & Risk Stratification, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prevention, Screening & Surveillance
  375. [375]

    Kurowska-Stolarska M, Alivernini S. “Synovial tissue macrophages in joint homeostasis, rheumatoid arthritis and disease remission.” Nature reviews. Rheumatology (2022). PMID: 35672464 ↗

    L5REVIEW_NARRATIVECited in: Severity, Disease Activity & Risk Stratification
  376. [376]

    Briot K, Roux C. “Glucocorticoid-induced osteoporosis.” RMD open (2015). PMID: 26509049 ↗

    L5REVIEW_NARRATIVECited in: Severity, Disease Activity & Risk Stratification, Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  377. [377]

    Goodman SM, Miller AS, Turgunbaev M et al.. “Clinical Practice Guidelines: Incorporating Input From a Patient Panel.” Arthritis care & research (2017). PMID: 28620968 ↗

    L5GUIDELINECited in: Acute Management: Flares & Organ-Threatening Disease, Special Populations, Pregnancy & Fertility
  378. [378]

    Boers M, Hartman L, Opris-Belinski D et al.. “Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial.” Annals of the rheumatic diseases (2022). PMID: 35641125 ↗

    L1RCTCited in: Acute Management: Flares & Organ-Threatening Disease, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prevention, Screening & Surveillance
  379. [379]

    Fu Q, Wu C, Dai M et al.. “Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a prospective, multicentre, randomised trial and long-term follow-up.” Annals of the rheumatic diseases (2022). PMID: 35788493 ↗

    L1RCTCited in: Acute Management: Flares & Organ-Threatening Disease, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  380. [380]

    Ruyssen-Witrand A, Brusq C, Masson M et al.. “Comparison of two strategies of glucocorticoid withdrawal in patients with rheumatoid arthritis in low disease activity (STAR): a randomised, placebo- controlled, double-blind trial.” Annals of the rheumatic diseases (2025). PMID: 39874233 ↗

    L1RCTCited in: Acute Management: Flares & Organ-Threatening Disease
  381. [381]

    Kjørholt KE, Sundlisæter NP, Aga AB et al.. “Three-Year Results of Tapering Tumor Necrosis Factor Inhibitor to Withdrawal Compared to Stable Tumor Necrosis Factor Inhibitor Among Patients With Rheumatoid Arthritis in Sustained Remission: A Multicenter Randomized Trial.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40289847 ↗

    L1RCTCited in: Acute Management: Flares & Organ-Threatening Disease
  382. [382]

    Krause D, Mai A, Klaassen-Mielke R et al.. “The Efficacy of Short-Term Bridging Strategies With High- and Low-Dose Prednisolone on Radiographic and Clinical Outcomes in Active Early Rheumatoid Arthritis: A Double-Blind, Randomized, Placebo-Controlled Trial.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 35643951 ↗

    L1RCTCited in: Acute Management: Flares & Organ-Threatening Disease
  383. [383]

    Kedra J, Dieudé P, Giboin C et al.. “Towards the Lowest Efficacious Dose: Results From a Multicenter Noninferiority Randomized Open-Label Controlled Trial Assessing Tocilizumab or Abatacept Injection Spacing in Rheumatoid Arthritis in Remission.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 37942714 ↗

    L1RCTCited in: Acute Management: Flares & Organ-Threatening Disease
  384. [384]

    Kerschbaumer A, Sepriano A, Smolen JS et al.. “Efficacy of pharmacological treatment in rheumatoid arthritis: a systematic literature research informing the 2019 update of the EULAR recommendations for management of rheumatoid arthritis.” Annals of the rheumatic diseases (2020). PMID: 32033937 ↗

    L1SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target
  385. [385]

    van Ouwerkerk L, Verschueren P, Boers M et al.. “Initial glucocorticoid bridging in rheumatoid arthritis: does it affect glucocorticoid use over time?” Annals of the rheumatic diseases (2024). PMID: 37607810 ↗

    L1SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease
  386. [386]

    Dumoulin QA, Krijbolder DI, Visser K et al.. “Development of rheumatoid arthritis after methotrexate in anticitrullinated protein antibody-negative people with clinically suspect arthralgia at risk of rheumatoid arthritis: 4-year data from the TREAT EARLIER trial.” The Lancet. Rheumatology (2024). PMID: 39303731 ↗

    L1RCTCited in: Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Prevention, Screening & Surveillance
  387. [387]

    Kjørholt KE, Sundlisæter NP, Aga AB et al.. “Effects of tapering conventional synthetic disease-modifying antirheumatic drugs to drug-free remission versus stable treatment in rheumatoid arthritis (ARCTIC REWIND): 3-year results from an open-label, randomised controlled, non-inferiority trial.” The Lancet. Rheumatology (2024). PMID: 38583450 ↗

    L1RCTCited in: Acute Management: Flares & Organ-Threatening Disease
  388. [388]

    Conaghan PG, Nowak M, Du S et al.. “Evaluation of BMS-986142, a reversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study.” The Lancet. Rheumatology (2023). PMID: 38251590 ↗

    L1RCTCited in: Acute Management: Flares & Organ-Threatening Disease
  389. [389]

    Skaria TG, Sreeprakash A, Umesh R et al.. “Withholding methotrexate after vaccination with ChAdOx1 nCov19 in patients with rheumatoid or psoriatic arthritis in India (MIVAC I and II): results of two, parallel, assessor-masked, randomised controlled trials.” The Lancet. Rheumatology (2022). PMID: 36320825 ↗

    L1RCTCited in: Acute Management: Flares & Organ-Threatening Disease
  390. [390]

    Burmester GR, Buttgereit F, Bernasconi C et al.. “Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial.” Lancet (London, England) (2020). PMID: 32711802 ↗

    L1RCTCited in: Acute Management: Flares & Organ-Threatening Disease, Complications: Disease-Driven & Treatment-Related
  391. [391]

    Reid DM, Devogelaer JP, Saag K et al.. “Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.” Lancet (London, England) (2009). PMID: 19362675 ↗

    L1RCTCited in: Acute Management: Flares & Organ-Threatening Disease, Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  392. [392]

    Buttgereit F, Doering G, Schaeffler A et al.. “Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial.” Lancet (London, England) (2008). PMID: 18207016 ↗

    L1RCTCited in: Acute Management: Flares & Organ-Threatening Disease
  393. [393]

    Goodman SM, Springer B, Guyatt G et al.. “2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.” Arthritis care & research (2017). PMID: 28620917 ↗

    L1SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease, Special Populations, Pregnancy & Fertility
  394. [394]

    Buttgereit F, Boyadzhieva Z, Reisch M et al.. “Recommendations of the German, Austrian and Swiss rheumatology and other medical societies for the management of polymyalgia rheumatica.” Rheumatology (Oxford, England) (2026). PMID: 41346249 ↗

    L1GUIDELINECited in: Acute Management: Flares & Organ-Threatening Disease, History and Evolution of Treatment
  395. [395]

    Stanmore EK, Oldham J, Skelton DA et al.. “Fall incidence and outcomes of falls in a prospective study of adults with rheumatoid arthritis.” Arthritis care & research (2013). PMID: 23139011 ↗

    L2COHORTCited in: Acute Management: Flares & Organ-Threatening Disease
  396. [396]

    Lane JCE, Weaver J, Kostka K et al.. “Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study.” The Lancet. Rheumatology (2020). PMID: 32864627 ↗

    L3COHORTCited in: Acute Management: Flares & Organ-Threatening Disease
  397. [397]

    Bertrand D, Joly J, Neerinckx B et al.. “Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 trial.” RMD open (2024). PMID: 39117445 ↗

    L1RCTCited in: Acute Management: Flares & Organ-Threatening Disease, History and Evolution of Treatment
  398. [398]

    Lend K, Twisk JW, Kumar N et al.. “Glucocorticoid treatment in early rheumatoid arthritis is independently associated with increased PCSK9 levels: data from a randomised controlled trial.” RMD open (2025). PMID: 40480650 ↗

    L1RCTCited in: Acute Management: Flares & Organ-Threatening Disease
  399. [399]

    Rayens E, Sy LS, Qian L et al.. “Effectiveness and safety of the recombinant zoster vaccine in individuals ≥50 years of age with rheumatoid arthritis: a matched cohort and self-controlled case series study.” Annals of the rheumatic diseases (2025). PMID: 39979209 ↗

    L3CASE_REPORTCited in: Acute Management: Flares & Organ-Threatening Disease, Prevention, Screening & Surveillance
  400. [400]

    Bijlsma JW. “Disease control with glucocorticoid therapy in rheumatoid arthritis.” Rheumatology (Oxford, England) (2012). PMID: 22685274 ↗

    L1SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease
  401. [401]

    Ravindran V, Rachapalli S, Choy EH. “Safety of medium- to long-term glucocorticoid therapy in rheumatoid arthritis: a meta-analysis.” Rheumatology (Oxford, England) (2009). PMID: 19447767 ↗

    L1SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease
  402. [402]

    Hayashi S, Tachibana S, Maeda T et al.. “Real-world comparative study of the efficacy of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.” Rheumatology (Oxford, England) (2024). PMID: 37924201 ↗

    L2COHORTCited in: Acute Management: Flares & Organ-Threatening Disease
  403. [403]

    Rodríguez-Carrio J, Burska A, Conaghan PG et al.. “Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider.” RMD open (2023). PMID: 36882218 ↗

    L2SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease
  404. [404]

    Coburn BW, Baker JF, Hsu JY et al.. “Association of Cardiovascular Outcomes With Low-Dose Glucocorticoid Prescription in Patients With Rheumatoid Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 38923870 ↗

    L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
  405. [405]

    Prisco L, Moll M, Wang J et al.. “Relationship Between Rheumatoid Arthritis and Pulmonary Function Measures on Spirometry in the UK Biobank.” Arthritis & rheumatology (Hoboken, N.J.) (2021). PMID: 33982900 ↗

    L4OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
  406. [406]

    Manzo A, Bozzalla Cassione E, Montecucco C et al.. “Prediction of long-term drug-free outcomes in ACPA-positive and ACPA-negative rheumatoid arthritis by combined clinical and ultrasound assessment of residual disease: a 5-year prospective study.” RMD open (2025). PMID: 39880410 ↗

    L2COHORTCited in: Acute Management: Flares & Organ-Threatening Disease
  407. [407]

    Schmajuk G, Trupin L, Yelin E et al.. “Prevalence of Arthritis and Rheumatoid Arthritis in Coal Mining Counties of the United States.” Arthritis care & research (2019). PMID: 30875457 ↗

    L4OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
  408. [408]

    Yazdany J, Tonner C, Schmajuk G et al.. “Receipt of glucocorticoid monotherapy among Medicare beneficiaries with rheumatoid arthritis.” Arthritis care & research (2014). PMID: 25244314 ↗

    L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
  409. [409]

    Goodman SM, Mirza SZ, DiCarlo EF et al.. “Rheumatoid Arthritis Flares After Total Hip and Total Knee Arthroplasty: Outcomes at One Year.” Arthritis care & research (2020). PMID: 31609524 ↗

    L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
  410. [410]

    Wilson JC, Sarsour K, Gale S et al.. “Incidence and Risk of Glucocorticoid-Associated Adverse Effects in Patients With Rheumatoid Arthritis.” Arthritis care & research (2019). PMID: 29856128 ↗

    L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
  411. [411]

    George MD, Baker JF, Wallace B et al.. “Variability in Glucocorticoid Prescribing for Rheumatoid Arthritis and the Influence of Provider Preference on Long-Term Use of Glucocorticoids.” Arthritis care & research (2021). PMID: 32702188 ↗

    L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
  412. [412]

    Buttgereit F, Tam LS. “Glucocorticoid treatment in patients with inflammatory rheumatic diseases: current practice and open questions.” The Lancet. Rheumatology (2026). PMID: 41936369 ↗

    L5REVIEW_NARRATIVECited in: Acute Management: Flares & Organ-Threatening Disease
  413. [413]

    Barnes PJ, Adcock IM. “Glucocorticoid resistance in inflammatory diseases.” Lancet (London, England) (2009). PMID: 19482216 ↗

    L5REVIEW_NARRATIVECited in: Acute Management: Flares & Organ-Threatening Disease
  414. [414]

    Nevins IS, van der Pol JA, Van Ouwerkerk L et al.. “Induction of Cure in Early Arthritis (I CEA): results of a randomised clinical trial to compare three treatment strategies in recent onset undifferentiated arthritis.” RMD open (2026). PMID: 42209019 ↗

    L1RCTCited in: Acute Management: Flares & Organ-Threatening Disease
  415. [415]

    Pamuk ON, Harmandar F. “A case of cervical spine meningioma following etanercept use in a patient with RA.” Nature reviews. Rheumatology (2009). PMID: 19648944 ↗

    L4CASE_REPORTCited in: Acute Management: Flares & Organ-Threatening Disease
  416. [416]

    Wechalekar MD, Vinik O, Schlesinger N et al.. “Intra-articular glucocorticoids for acute gout.” The Cochrane database of systematic reviews (2013). PMID: 23633379 ↗

    L1SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease
  417. [417]

    Gonçalves-Bradley DC, J Maria AR, Ricci-Cabello I et al.. “Mobile technologies to support healthcare provider to healthcare provider communication and management of care.” The Cochrane database of systematic reviews (2020). PMID: 32813281 ↗

    L2SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease, Prevention, Screening & Surveillance
  418. [418]

    Verhoef LM, van den Bemt BJ, van der Maas A et al.. “Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.” The Cochrane database of systematic reviews (2019). PMID: 31125448 ↗

    L1SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease
  419. [419]

    van Herwaarden N, den Broeder AA, Jacobs W et al.. “Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.” The Cochrane database of systematic reviews (2014). PMID: 25264908 ↗

    L1SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease, History and Evolution of Treatment
  420. [420]

    Ponkilainen V, Karjalainen TV, Kuitunen I et al.. “Perioperative use of disease-modifying anti-rheumatic drugs (DMARDs) in people with inflammatory arthritis.” The Cochrane database of systematic reviews (2026). PMID: 42159164 ↗

    L1SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease, Special Populations, Pregnancy & Fertility
  421. [421]

    Lee YH, Song GG. “Risk of disease flare and clinical reversibility following discontinuation versus dose reduction of biological DMARDs in Rheumatoid arthritis: A systematic review and meta-analysis.” Seminars in arthritis and rheumatism (2026). PMID: 42269230 ↗

    L1SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease
  422. [422]

    Palmowski A, Haugegaard T, Hafström I et al.. “Changes in bone mineral density and fractures during 2 years of low-dose glucocorticoid treatment for rheumatoid arthritis: a systematic literature review and individual participant data meta-analysis.” RMD open (2026). PMID: 42097691 ↗

    L1SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease
  423. [423]

    Wallace BI, Moore MN, Heisler AC et al.. “Fibromyalgianess and glucocorticoid persistence among patients with rheumatoid arthritis.” Rheumatology (Oxford, England) (2022). PMID: 34293092 ↗

    L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
  424. [424]

    Keystone EC, Smolen J, van Riel P. “Developing an effective treatment algorithm for rheumatoid arthritis.” Rheumatology (Oxford, England) (2012). PMID: 22718927 ↗

    L5REVIEW_NARRATIVECited in: Acute Management: Flares & Organ-Threatening Disease
  425. [425]

    Kirwan JR, Buttgereit F. “Symptom control with low-dose glucocorticoid therapy for rheumatoid arthritis.” Rheumatology (Oxford, England) (2012). PMID: 22685271 ↗

    L5REVIEW_NARRATIVECited in: Acute Management: Flares & Organ-Threatening Disease
  426. [426]

    Buttgereit F, Smolen JS, Coogan AN et al.. “Clocking in: chronobiology in rheumatoid arthritis.” Nature reviews. Rheumatology (2015). PMID: 25800214 ↗

    L5REVIEW_NARRATIVECited in: Acute Management: Flares & Organ-Threatening Disease
  427. [427]

    Smolen JS, Aletaha D. “Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges.” Nature reviews. Rheumatology (2015). PMID: 25687177 ↗

    L5REVIEW_NARRATIVECited in: Acute Management: Flares & Organ-Threatening Disease, Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  428. [428]

    Buttgereit F, Palmowski A, Bond M et al.. “Osteoporosis and fracture risk are multifactorial in patients with inflammatory rheumatic diseases.” Nature reviews. Rheumatology (2024). PMID: 38831028 ↗

    L5REVIEW_NARRATIVECited in: Acute Management: Flares & Organ-Threatening Disease
  429. [429]

    Baschant U, Lane NE, Tuckermann J. “The multiple facets of glucocorticoid action in rheumatoid arthritis.” Nature reviews. Rheumatology (2012). PMID: 23045254 ↗

    L5REVIEW_NARRATIVECited in: Acute Management: Flares & Organ-Threatening Disease
  430. [430]

    Buttgereit F. “Views on glucocorticoid therapy in rheumatology: the age of convergence.” Nature reviews. Rheumatology (2020). PMID: 32076129 ↗

    L5REVIEW_NARRATIVECited in: Acute Management: Flares & Organ-Threatening Disease
  431. [431]

    Hoes JN, Jacobs JW, Buttgereit F et al.. “Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis.” Nature reviews. Rheumatology (2010). PMID: 21119718 ↗

    L5REVIEW_NARRATIVECited in: Acute Management: Flares & Organ-Threatening Disease
  432. [432]

    Förger F, Villiger PM. “Immunological adaptations in pregnancy that modulate rheumatoid arthritis disease activity.” Nature reviews. Rheumatology (2020). PMID: 31932747 ↗

    L5REVIEW_NARRATIVECited in: Acute Management: Flares & Organ-Threatening Disease, Special Populations, Pregnancy & Fertility
  433. [433]

    Chen AY, Wolchok JD, Bass AR. “TNF in the era of immune checkpoint inhibitors: friend or foe?” Nature reviews. Rheumatology (2021). PMID: 33686279 ↗

    L5REVIEW_NARRATIVECited in: Acute Management: Flares & Organ-Threatening Disease
  434. [434]

    Pan J, Zhu YY, Zou YW et al.. “Long-term dynamic of muscle mass and its effectors in female patients with rheumatoid arthritis: a 5-year prospective cohort study.” Therapeutic advances in musculoskeletal disease (2026). PMID: 42130900 ↗

    L2COHORTCited in: Acute Management: Flares & Organ-Threatening Disease
  435. [435]

    Zhang Q, Qi Y, Wang X et al.. “Hospitalization risk in patients with rheumatoid arthritis-associated interstitial lung disease or bronchiectasis: A matched cohort study.” Seminars in arthritis and rheumatism (2026). PMID: 42127546 ↗

    L2COHORTCited in: Acute Management: Flares & Organ-Threatening Disease
  436. [436]

    Gumber L, Rayner F, Bigirumurame T et al.. “Patient-reported outcomes as early warning signs of flare following drug cessation in rheumatoid arthritis.” RMD open (2025). PMID: 40169281 ↗

    L2OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
  437. [437]

    Adami G, Fassio A, Rossini M et al.. “Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs).” RMD open (2023). PMID: 36599630 ↗

    L3OTHERCited in: Acute Management: Flares & Organ-Threatening Disease
  438. [438]

    Zhao L, Ma S, Chen S et al.. “The Role of Therapeutic Apheresis in the Management of Rheumatoid Arthritis A Systematic Review and Meta-Analysis.” Journal of clinical apheresis (2026). PMID: 42389975 ↗

    L1SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease
  439. [439]

    Gao Y, Ye G, Gao L et al.. “Meta-Analysis of the Incidence and Influencing Factors of Malignant Tumors in Patients with Rheumatoid Arthritis.” Journal of epidemiology and global health (2026). PMID: 42185654 ↗

    L2SR_OBSCited in: Acute Management: Flares & Organ-Threatening Disease
  440. [440]

    Duch KS, Alkattan M, Holm TÁM et al.. “Glucocorticoid use among patients with rheumatoid arthritis during the first year of treatment-a cohort study.” Rheumatology international (2026). PMID: 42283855 ↗

    L2COHORTCited in: Acute Management: Flares & Organ-Threatening Disease
  441. [441]

    England BR, Smith BJ, Baker NA et al.. “2022 American College of Rheumatology Guideline for Exercise, Rehabilitation, Diet, and Additional Integrative Interventions for Rheumatoid Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 37227071 ↗

    L1GUIDELINECited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  442. [442]

    England BR, Smith BJ, Baker NA et al.. “2022 American College of Rheumatology Guideline for Exercise, Rehabilitation, Diet, and Additional Integrative Interventions for Rheumatoid Arthritis.” Arthritis care & research (2023). PMID: 37227116 ↗

    L1GUIDELINECited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  443. [443]

    Mysler E, Sidiropoulos PI, Balanescu A et al.. “Upadacitinib vs adalimumab in patients with rheumatoid arthritis and a prior inadequate response or intolerance to a tumour necrosis factor inhibitor: 12-week results from the randomised, double-blind, SELECT-SWITCH study.” Annals of the rheumatic diseases (2026). PMID: 41991443 ↗

    L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  444. [444]

    Imai Y, Kono M, Ishii T et al.. “Spacing of a TNF inhibitor or dose reduction of methotrexate vs continued treatment in patients with rheumatoid arthritis in remission or low disease activity: a randomised, controlled trial (SORAIRO trial).” Annals of the rheumatic diseases (2026). PMID: 41763966 ↗

    L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  445. [445]

    Giles JT, Sattar N, Gabriel S et al.. “Cardiovascular Safety of Tocilizumab Versus Etanercept in Rheumatoid Arthritis: A Randomized Controlled Trial.” Arthritis & rheumatology (Hoboken, N.J.) (2020). PMID: 31469238 ↗

    L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment
  446. [446]

    Winkler A, Sun W, De S et al.. “The Interleukin-1 Receptor-Associated Kinase 4 Inhibitor PF-06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial.” Arthritis & rheumatology (Hoboken, N.J.) (2021). PMID: 34423919 ↗

    L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  447. [447]

    Choi MY, Barnabe C, Barber CE et al.. “Pragmaticism of Randomized Controlled Trials of Biologic Treatment With Methotrexate in Rheumatoid Arthritis: A Systematic Review.” Arthritis care & research (2019). PMID: 29908014 ↗

    L1SR_MA_RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  448. [448]

    Desai SP, Leatherwood C, Forman M et al.. “Treat-to-Target Approach in Rheumatoid Arthritis: A Quality Improvement Trial.” Arthritis care & research (2021). PMID: 31758663 ↗

    L2RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  449. [449]

    Lopez-Olivo MA, Lin H, Rizvi T et al.. “Randomized Controlled Trial of Patient Education Tools for Patients With Rheumatoid Arthritis.” Arthritis care & research (2021). PMID: 32583971 ↗

    L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  450. [450]

    Blalock SJ, Solow EB, Reyna VF et al.. “Enhancing Patient Understanding of Medication Risks and Benefits.” Arthritis care & research (2021). PMID: 32799397 ↗

    L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  451. [451]

    Sepriano A, Kerschbaumer A, Bergstra SA et al.. “Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis.” Annals of the rheumatic diseases (2022). PMID: 36376026 ↗

    L2SR_OBSCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  452. [452]

    Ytterberg SR, Bhatt DL, Mikuls TR et al.. “Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis.” The New England journal of medicine (2022). PMID: 35081280 ↗

    L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prevention, Screening & Surveillance
  453. [453]

    Nissen SE, Yeomans ND, Solomon DH et al.. “Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis.” The New England journal of medicine (2016). PMID: 27959716 ↗

    L1RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment, Prevention, Screening & Surveillance
  454. [454]

    Lovell DJ, Ruperto N, Goodman S et al.. “Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.” The New England journal of medicine (2008). PMID: 18716298 ↗

    L2RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment, Special Populations, Pregnancy & Fertility
  455. [455]

    Amaral JK, Sutaria R, Schoen RT. “Treatment of Chronic Chikungunya Arthritis With Methotrexate: A Systematic Review.” Arthritis care & research (2018). PMID: 29361202 ↗

    L2SR_OBSCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related
  456. [456]

    Lopez-Olivo MA, Kakpovbia-Eshareturi V, des Bordes JK et al.. “Treating Early Undifferentiated Arthritis: A Systematic Review and Meta-Analysis of Direct and Indirect Trial Evidence.” Arthritis care & research (2018). PMID: 29161466 ↗

    L1SR_OBSCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  457. [457]

    Gossec L, Bessette L, Xavier RM et al.. “Barriers to, Facilitators of, and Interventions to Support Treat-to-Target Implementation in Rheumatoid Arthritis: A Systematic Review.” Arthritis care & research (2024). PMID: 39090845 ↗

    L2SR_OBSCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  458. [458]

    Smolen JS, Taylor PC, Tanaka Y et al.. “Impact of high rheumatoid factor levels on treatment outcomes with certolizumab pegol and adalimumab in patients with rheumatoid arthritis.” Rheumatology (Oxford, England) (2024). PMID: 39222436 ↗

    L2RCTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  459. [459]

    Ruiz JI, Lei X, Giordano SH et al.. “Survival in patients with rheumatoid arthritis and recently diagnosed early-stage colorectal, lung, or prostate cancer receiving tumour necrosis factor inhibitors: a retrospective cohort study.” The Lancet. Rheumatology (2025). PMID: 39914441 ↗

    L2COHORTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  460. [460]

    Burmester GR, Cohen SB, Winthrop KL et al.. “Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis.” RMD open (2023). PMID: 36754548 ↗

    L1TRIAL_NONRANDOMCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  461. [461]

    Chen Y, Zhang Q, Liu S et al.. “Bidirectional association of rheumatoid arthritis and inflammatory bowel diseases: a large-scale prospective cohort study.” Rheumatology (Oxford, England) (2025). PMID: 40511997 ↗

    L2COHORTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  462. [462]

    Smolen JS, Landewé R, Bijlsma J et al.. “EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.” Annals of the rheumatic diseases (2017). PMID: 28264816 ↗

    L1REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  463. [463]

    Zack SR, Alzoubi O, Satoeya N et al.. “Another Notch in the Belt of Rheumatoid Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 38961731 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  464. [464]

    Chin A, Terrett A, Kwon M et al.. “Recommendations for the Use of Disease-Modifying Antirheumatic Drugs in Pregnancy and Reproductive Health for Patients With Rheumatic Disease: A Scoping Review.” Arthritis care & research (2025). PMID: 40256995 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Special Populations, Pregnancy & Fertility
  465. [465]

    Sparks JA, Lesperance T, Accortt NA et al.. “Subsequent Cardiovascular Events Among Patients With Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis: Patterns of Disease-Modifying Antirheumatic Drug Treatment.” Arthritis care & research (2019). PMID: 29799667 ↗

    L2OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  466. [466]

    Tan JM, Reeve E, Fraser L et al.. “Barriers and Enablers in the Use of Parenteral Methotrexate in Rheumatoid Arthritis Patients: A Scoping Review.” Arthritis care & research (2023). PMID: 37128818 ↗

    L2REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  467. [467]

    Fang H, Chen L, Knight JC. “From genome-wide association studies to rational drug target prioritisation in inflammatory arthritis.” The Lancet. Rheumatology (2019). PMID: 38258277 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  468. [468]

    Heutz JW, de Jong PHP, Verstappen M et al.. “Sustained DMARD-free remission in subgroups of patients with rheumatoid arthritis: an analysis of two prospective cohorts with early arthritis.” The Lancet. Rheumatology (2024). PMID: 39718182 ↗

    L2OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  469. [469]

    Ciancio A, Amati A, Gandolfo S et al.. “Aligning approaches to rheumatoid arthritis drug development: a comparison of FDA and EMA guidance.” The Lancet. Rheumatology (2026). PMID: 42331475 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target, History and Evolution of Treatment
  470. [470]

    Scott DL, Wolfe F, Huizinga TW. “Rheumatoid arthritis.” Lancet (London, England) (2010). PMID: 20870100 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Special Populations, Pregnancy & Fertility
  471. [471]

    Burmester GR, Pope JE. “Novel treatment strategies in rheumatoid arthritis.” Lancet (London, England) (2017). PMID: 28612748 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  472. [472]

    Chen J, Liu C, Lin J. “Methotrexate for ankylosing spondylitis.” The Cochrane database of systematic reviews (2006). PMID: 17054209 ↗

    L1SR_OBSCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  473. [473]

    Lopez-Olivo MA, Amezaga Urruela M, McGahan L et al.. “Rituximab for rheumatoid arthritis.” The Cochrane database of systematic reviews (2015). PMID: 25603545 ↗

    L1SR_OBSCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  474. [474]

    Ruiz Garcia V, Burls A, Cabello JB et al.. “Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.” The Cochrane database of systematic reviews (2017). PMID: 28884785 ↗

    L1SR_OBSCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  475. [475]

    Katchamart W, Trudeau J, Phumethum V et al.. “Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis.” The Cochrane database of systematic reviews (2010). PMID: 20393970 ↗

    L1SR_OBSCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  476. [476]

    Ruiz Garcia V, Jobanputra P, Burls A et al.. “Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.” The Cochrane database of systematic reviews (2011). PMID: 21328299 ↗

    L1SR_OBSCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  477. [477]

    Hazlewood GS, Barnabe C, Tomlinson G et al.. “Methotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis: A network meta-analysis.” The Cochrane database of systematic reviews (2016). PMID: 27571502 ↗

    L1SR_OBSCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  478. [478]

    Lethaby A, Lopez-Olivo MA, Maxwell L et al.. “Etanercept for the treatment of rheumatoid arthritis.” The Cochrane database of systematic reviews (2013). PMID: 23728649 ↗

    L1SR_OBSCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  479. [479]

    Ruiz Garcia V, Jobanputra P, Burls A et al.. “Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.” The Cochrane database of systematic reviews (2014). PMID: 25231904 ↗

    L1SR_OBSCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  480. [480]

    Clarke B, Yates M, Adas M et al.. “The safety of JAK-1 inhibitors.” Rheumatology (Oxford, England) (2021). PMID: 33950230 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  481. [481]

    Nash P. “Clinical use of Jak 1 inhibitors for rheumatoid arthritis.” Rheumatology (Oxford, England) (2021). PMID: 33950231 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  482. [482]

    Nouri B, Nair N, Barton A. “Predicting treatment response to IL6R blockers in rheumatoid arthritis.” Rheumatology (Oxford, England) (2020). PMID: 32864695 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  483. [483]

    Tanaka Y. “Stopping tumour necrosis factor-targeted biological DMARDs in rheumatoid arthritis.” Rheumatology (Oxford, England) (2016). PMID: 27856656 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  484. [484]

    Fragoulis GE, Conway R, Nikiphorou E. “Methotrexate and interstitial lung disease: controversies and questions. A narrative review of the literature.” Rheumatology (Oxford, England) (2019). PMID: 31504978 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  485. [485]

    Cronstein BN, Aune TM. “Methotrexate and its mechanisms of action in inflammatory arthritis.” Nature reviews. Rheumatology (2020). PMID: 32066940 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  486. [486]

    Winthrop KL. “The emerging safety profile of JAK inhibitors in rheumatic disease.” Nature reviews. Rheumatology (2017). PMID: 28250461 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Immunosuppression Safety & Therapeutic Drug Monitoring, Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  487. [487]

    Taylor PC, Feldmann M. “Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis.” Nature reviews. Rheumatology (2009). PMID: 19798034 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  488. [488]

    Wicks IP, Roberts AW. “Targeting GM-CSF in inflammatory diseases.” Nature reviews. Rheumatology (2015). PMID: 26633290 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  489. [489]

    van Vollenhoven R. “Treat-to-target in rheumatoid arthritis - are we there yet?” Nature reviews. Rheumatology (2019). PMID: 30700865 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  490. [490]

    Parra Sánchez AR, Voskuyl AE, van Vollenhoven RF. “Treat-to-target in systemic lupus erythematosus: advancing towards its implementation.” Nature reviews. Rheumatology (2022). PMID: 35039665 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  491. [491]

    Bertolino GM, Maumus M, Jorgensen C et al.. “Therapeutic potential in rheumatic diseases of extracellular vesicles derived from mesenchymal stromal cells.” Nature reviews. Rheumatology (2023). PMID: 37666995 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  492. [492]

    Chan ES, Cronstein BN. “Methotrexate--how does it really work?” Nature reviews. Rheumatology (2010). PMID: 20197777 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  493. [493]

    Winthrop KL, Cohen SB. “Oral surveillance and JAK inhibitor safety: the theory of relativity.” Nature reviews. Rheumatology (2022). PMID: 35318462 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  494. [494]

    Gunkl-Tóth L, McInnes IB, Nagy G. “Bridging the gap: combining treat-to-target and difficult-to-treat strategies in the management of rheumatoid arthritis.” Nature reviews. Rheumatology (2026). PMID: 41772290 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  495. [495]

    Cho IY, Jung JH, Kang S et al.. “Rheumatoid arthritis and risk of myocardial infarction: A nationwide cohort study.” European journal of preventive cardiology (2026). PMID: 42429686 ↗

    L2COHORTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  496. [496]

    Pope JE. “Management of Fatigue in Rheumatoid Arthritis.” RMD open (2020). PMID: 32385141 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  497. [497]

    Manara M, Sinigaglia L. “Bone and TNF in rheumatoid arthritis: clinical implications.” RMD open (2015). PMID: 26557382 ↗

    L5REVIEW_NARRATIVECited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  498. [498]

    Teng Y, Yin H, Feng R et al.. “Methotrexate inhibits glucocorticoids-induced osteoclastogenesis via activating IFN-γR/STAT1 pathway in the treatment of rheumatoid arthritis.” RMD open (2024). PMID: 39510764 ↗

    L5OTHERCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related
  499. [499]

    Hooker RS, Reinhart GM. “Trends in DMARD prescribing by rheumatologists, NPs, and PAs among medicare beneficiaries, 2013-2023: an observational retrospective cohort study.” Rheumatology international (2026). PMID: 42334644 ↗

    L2COHORTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  500. [500]

    Murata K, Fujii T, Ebina K et al.. “Real-world clinical outcomes of patients with disproportionate articular pain in rheumatoid arthritis: ANSWER cohort study.” Scandinavian journal of rheumatology (2026). PMID: 42318602 ↗

    L2COHORTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  501. [501]

    Pan X, Tian J, Chen J et al.. “Correction: Clinical characteristics and risk factors of severe myelosuppression in rheumatoid arthritis patients with csDMARD non-adherence: a case series.” Frontiers in pharmacology (2026). PMID: 42318336 ↗

    L4CASE_REPORTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  502. [502]

    Lini D, Colina M, Andracco R et al.. “Real-World Effectiveness of Baricitinib in Rheumatoid Arthritis: Significant Reduction of Disease Activity Independent of Age in a Multicentre Retrospective Cohort Study.” Mediterranean journal of rheumatology (2026). PMID: 42368989 ↗

    L3COHORTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target
  503. [503]

    Yamashita Y, Maeda K, Okabe H et al.. “Long-term longitudinal changes in bone matrix and turnover markers in rheumatoid arthritis: A retrospective cohort study.” Medicine (2026). PMID: 42332458 ↗

    L3COHORTCited in: Long-term Management: The DMARD Ladder & Treat-to-Target, Complications: Disease-Driven & Treatment-Related
  504. [504]

    Tamai H, Ikeda K, Miyamoto T et al.. “Association of methotrexate polyglutamates concentration with methotrexate efficacy and safety in patients with rheumatoid arthritis treated with predefined dose: results from the MIRACLE trial.” Annals of the rheumatic diseases (2025). PMID: 39874232 ↗

    L1RCTCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  505. [505]

    Taylor PC, Weinblatt ME, McInnes IB et al.. “Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: a phase III randomised trial (contRAst 3).” Annals of the rheumatic diseases (2023). PMID: 37696589 ↗

    L1RCTCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  506. [506]

    Fleischmann RM, van der Heijde D, Strand V et al.. “Anti-GM-CSF otilimab versus tofacitinib or placebo in patients with active rheumatoid arthritis and an inadequate response to conventional or biologic DMARDs: two phase 3 randomised trials (contRAst 1 and contRAst 2).” Annals of the rheumatic diseases (2023). PMID: 37699654 ↗

    L1TRIAL_NONRANDOMCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  507. [507]

    Taylor PC, Takeuchi T, Burmester GR et al.. “Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database.” Annals of the rheumatic diseases (2021). PMID: 34706874 ↗

    L2SR_OBSCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  508. [508]

    Nam JL, Winthrop KL, van Vollenhoven RF et al.. “Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA.” Annals of the rheumatic diseases (2010). PMID: 20447957 ↗

    L1SR_OBSCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  509. [509]

    Konzett V, Laskou F, Smolen JS et al.. “Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2025 update of the EULAR recommendations for the management of rheumatoid arthritis.” Annals of the rheumatic diseases (2026). PMID: 41997804 ↗

    L1SR_OBSCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  510. [510]

    Buch MH, Smolen JS, Betteridge N et al.. “Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis.” Annals of the rheumatic diseases (2011). PMID: 21378402 ↗

    L1SR_OBSCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  511. [511]

    Akiyama S, Hamdeh S, Micic D et al.. “Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis.” Annals of the rheumatic diseases (2020). PMID: 33051220 ↗

    L2SR_OBSCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  512. [512]

    Ye BD, Pesegova M, Alexeeva O et al.. “Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study.” Lancet (London, England) (2019). PMID: 30929895 ↗

    L1RCTCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  513. [513]

    Agueusop I, Margerie D, Remaury A et al.. “Deciphering differential biomarkers for anti-interleukin-6 receptor and anti-tumour necrosis factor-α treatment response in rheumatoid arthritis by multiomics analysis.” RMD open (2025). PMID: 40759562 ↗

    L3RCTCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  514. [514]

    Zubrzycka-Sienkiewicz A, Klama K, Ullmann M et al.. “Comparison of the efficacy and safety of a proposed biosimilar MSB11456 with tocilizumab reference product in subjects with moderate-to-severe rheumatoid arthritis: results of a randomised double-blind study.” RMD open (2024). PMID: 38316489 ↗

    L1RCTCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  515. [515]

    Farisogullari B, Santos EJF, Dures E et al.. “Efficacy of pharmacological interventions: a systematic review informing the 2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases.” RMD open (2023). PMID: 38056919 ↗

    L1SR_OBSCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  516. [516]

    Triboulet F, Juge PA, Truchetet ME et al.. “Evaluation of rheumatoid arthritis-associated interstitial lung disease in patients treated with JAK inhibitors: a MAJIK-SFR cohort study.” RMD open (2025). PMID: 39762124 ↗

    L2COHORTCited in: Immunosuppression Safety & Therapeutic Drug Monitoring, Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  517. [517]

    Tanaka Y, Hanami K, Miyazaki Y et al.. “Real-world effectiveness, safety and patient-reported outcomes of sarilumab in patients with rheumatoid arthritis: a 52-week, prospective, open-label, non-interventional, observational, nationwide, large-cohort study in Japan (PROFILE-J).” RMD open (2026). PMID: 42120177 ↗

    L2COHORTCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  518. [518]

    Bower H, Frisell T, di Giuseppe D et al.. “Comparative cardiovascular safety with janus kinase inhibitors and biological disease-modifying antirheumatic drugs as used in clinical practice: an observational cohort study from Sweden in patients with rheumatoid arthritis.” RMD open (2023). PMID: 37996125 ↗

    L2COHORTCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  519. [519]

    Beauvais C, Fayet F, Rousseau A et al.. “Efficacy of a nurse-led patient education intervention in promoting safety skills of patients with inflammatory arthritis treated with biologics: a multicentre randomised clinical trial.” RMD open (2022). PMID: 35296528 ↗

    L1RCTCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  520. [520]

    Syversen SW, Jørgensen KK, Goll GL et al.. “Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.” JAMA (2021). PMID: 34932077 ↗

    L1RCTCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  521. [521]

    Rigby W, Buckner JH, Louis Bridges S et al.. “HLA-DRB1 risk alleles for RA are associated with differential clinical responsiveness to abatacept and adalimumab: data from a head-to-head, randomized, single-blind study in autoantibody-positive early RA.” Arthritis research & therapy (2021). PMID: 34537057 ↗

    L1RCTCited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  522. [522]

    Rubbert-Roth A. “Assessing the safety of biologic agents in patients with rheumatoid arthritis.” Rheumatology (Oxford, England) (2012). PMID: 22718926 ↗

    L5REVIEW_NARRATIVECited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  523. [523]

    Jorge A, Ung C, Young LH et al.. “Hydroxychloroquine retinopathy - implications of research advances for rheumatology care.” Nature reviews. Rheumatology (2018). PMID: 30401979 ↗

    L5REVIEW_NARRATIVECited in: Immunosuppression Safety & Therapeutic Drug Monitoring
  524. [524]

    Riley TR, George MD. “Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis.” RMD open (2021). PMID: 33597206 ↗

    L5REVIEW_NARRATIVECited in: Immunosuppression Safety & Therapeutic Drug Monitoring, Complications: Disease-Driven & Treatment-Related
  525. [525]

    Antoniou KM, Distler O, Gheorghiu AM et al.. “ERS/EULAR clinical practice guidelines for connective tissue disease-associated interstitial lung disease developed by the task force for connective tissue disease-associated interstitial lung disease of the European Respiratory Society (ERS) and the European Alliance of Associations for Rheumatology (EULAR) Endorsed by the European Reference Network on rare respiratory diseases (ERN-LUNG).” Annals of the rheumatic diseases (2025). PMID: 40912974 ↗

    L1GUIDELINECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment, Prevention, Screening & Surveillance
  526. [526]

    Johnson SR, Bernstein EJ, Bolster MB et al.. “2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Screening and Monitoring of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases.” Arthritis care & research (2024). PMID: 38973729 ↗

    L1GUIDELINECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment, Prevention, Screening & Surveillance
  527. [527]

    Shirai Y, Honda S, Ikari K et al.. “Association of the RPA3-UMAD1 locus with interstitial lung diseases complicated with rheumatoid arthritis in Japanese.” Annals of the rheumatic diseases (2020). PMID: 32737115 ↗

    L3SR_OBSCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  528. [528]

    Hyldgaard C, Hilberg O, Pedersen AB et al.. “A population-based cohort study of rheumatoid arthritis-associated interstitial lung disease: comorbidity and mortality.” Annals of the rheumatic diseases (2017). PMID: 28611082 ↗

    L2COHORTCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  529. [529]

    Kimbrough BA, Crowson CS, Davis JM et al.. “Decline in Incidence of Extra-Articular Manifestations of Rheumatoid Arthritis: A Population-Based Cohort Study.” Arthritis care & research (2023). PMID: 37691141 ↗

    L2COHORTCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  530. [530]

    Russell MD, Schaffer A, Yang Z et al.. “Trends in autoimmune rheumatic disease diagnoses before and after the COVID-19 pandemic in England: a population-based cohort study using OpenSAFELY.” The Lancet. Rheumatology (2026). PMID: 42379213 ↗

    L2COHORTCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  531. [531]

    England BR, Baker JF, George MD et al.. “Advanced therapies in US veterans with rheumatoid arthritis-associated interstitial lung disease: a retrospective, active-comparator, new-user, cohort study.” The Lancet. Rheumatology (2025). PMID: 39793598 ↗

    L2COHORTCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  532. [532]

    Figueroa-Parra G, Gilbert EL, Valenzuela-Almada MO et al.. “Risk of severe COVID-19 outcomes associated with rheumatoid arthritis and phenotypic subgroups: a retrospective, comparative, multicentre cohort study.” The Lancet. Rheumatology (2022). PMID: 36118532 ↗

    L2COHORTCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  533. [533]

    Avouac J, Drumez E, Hachulla E et al.. “COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study.” The Lancet. Rheumatology (2021). PMID: 33786454 ↗

    L2COHORTCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  534. [534]

    Md Yusof MY, Arnold J, Saleem B et al.. “Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study.” The Lancet. Rheumatology (2023). PMID: 36712951 ↗

    L2COHORTCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related
  535. [535]

    Matteson EL, Matucci-Cerinic M, Kreuter M et al.. “Patient-level factors predictive of interstitial lung disease in rheumatoid arthritis: a systematic review.” RMD open (2023). PMID: 37507209 ↗

    L2SR_OBSCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  536. [536]

    Rosa-Baez C, Rangel-Pelaez C, Rodriguez-Martin I et al.. “Assessing the MUC5B promoter variant in a large cohort of systemic sclerosis-associated interstitial lung disease.” RMD open (2025). PMID: 40803819 ↗

    L3SR_OBSCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  537. [537]

    Yuan H, Cui S, Yang L et al.. “Efficacy of non-conventional synthetic DMARDs for patients with rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis.” RMD open (2023). PMID: 37899093 ↗

    L2SR_OBSCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  538. [538]

    Joo YB, Ahn SM, Bang SY et al.. “MUC5B promoter variant rs35705950, rare but significant susceptibility locus in rheumatoid arthritis-interstitial lung disease with usual interstitial pneumonia in Asian populations.” RMD open (2022). PMID: 36581384 ↗

    L3SR_OBSCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  539. [539]

    Kronzer VL, Williamson KA, Hayashi K et al.. “Uncovering specific genetic-respiratory disease endotypes for rheumatoid arthritis risk.” Annals of the rheumatic diseases (2025). PMID: 39919896 ↗

    L3OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  540. [540]

    Tanaka H, Okada Y, Nakayamada S et al.. “Extracting immunological and clinical heterogeneity across autoimmune rheumatic diseases by cohort-wide immunophenotyping.” Annals of the rheumatic diseases (2024). PMID: 37903543 ↗

    L4OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  541. [541]

    Winthrop KL, Mease P, Kerschbaumer A et al.. “Unmet need in rheumatology: reports from the Advances in Targeted Therapies meeting, 2023.” Annals of the rheumatic diseases (2024). PMID: 38123338 ↗

    L5OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  542. [542]

    Winthrop KL, Weinblatt ME, Bathon J et al.. “Unmet need in rheumatology: reports from the Targeted Therapies meeting 2019.” Annals of the rheumatic diseases (2019). PMID: 31662322 ↗

    L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  543. [543]

    van Mourik AG, Keijser JBD, van Delft MAM et al.. “Dimerization as a key feature of autoreactive IgA antibody responses.” Annals of the rheumatic diseases (2025). PMID: 41318346 ↗

    L3OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  544. [544]

    Winthrop KL, Weinblatt ME, Crow MK et al.. “Unmet need in rheumatology: reports from the Targeted Therapies meeting 2018.” Annals of the rheumatic diseases (2019). PMID: 30712015 ↗

    L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  545. [545]

    Palomäki A, Palotie A, Koskela J et al.. “Lifetime risk of rheumatoid arthritis-associated interstitial lung disease in MUC5B mutation carriers.” Annals of the rheumatic diseases (2021). PMID: 34344703 ↗

    L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  546. [546]

    Tang X, Peng Y, Jiang Z et al.. “Efferocytosis and Its Role in Rheumatic Diseases.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40452369 ↗

    L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  547. [547]

    Shih PC, Wang SI, Wei JCC. “Association of Abatacept With Lower Mortality Risk Compared to Rituximab in Rheumatoid Arthritis-Associated Interstitial Lung Disease: An Emulated Target Trial.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40693411 ↗

    L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related
  548. [548]

    Brooks RT, Luedders B, Wheeler A et al.. “The Risk of Lung Cancer in Rheumatoid Arthritis and Rheumatoid Arthritis-Associated Interstitial Lung Disease.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 39073264 ↗

    L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  549. [549]

    Spagnolo P, Lee JS, Sverzellati N et al.. “The Lung in Rheumatoid Arthritis: Focus on Interstitial Lung Disease.” Arthritis & rheumatology (Hoboken, N.J.) (2018). PMID: 29806092 ↗

    L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  550. [550]

    Suga K, Seng A, Yao C et al.. “Single-Cell Analysis Reveals Peripheral Helper T Cells in Rheumatoid Arthritis-Related Interstitial Lung Disease.” Arthritis & rheumatology (Hoboken, N.J.) (2026). PMID: 41629202 ↗

    L4OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  551. [551]

    Kronzer VL, Yang Y, Roul P et al.. “Associations of Fire Smoke and Other Pollutants With Incident Rheumatoid Arthritis and Rheumatoid Arthritis-Associated Interstitial Lung Disease.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 39800945 ↗

    L3OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  552. [552]

    Chen J, Doyle TJ, Liu Y et al.. “Biomarkers of rheumatoid arthritis-associated interstitial lung disease.” Arthritis & rheumatology (Hoboken, N.J.) (2015). PMID: 25302945 ↗

    L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  553. [553]

    Fava A, Wagner CA, Guthridge CJ et al.. “Serum Soluble Mediator Signatures of Lupus Nephritis: Histologic Features and Response to Treatment.” Arthritis care & research (2025). PMID: 41048053 ↗

    L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  554. [554]

    Coziahr K, Wheeler AM, Luedders BA et al.. “Combining Three Peripheral Blood Biomarkers to Stratify Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk.” Arthritis care & research (2025). PMID: 41392523 ↗

    L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  555. [555]

    England BR, Roul P, Mahajan TD et al.. “Performance of Administrative Algorithms to Identify Interstitial Lung Disease in Rheumatoid Arthritis.” Arthritis care & research (2020). PMID: 31421018 ↗

    L3OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  556. [556]

    Eder L, Croxford R, Drucker AM et al.. “Understanding COVID-19 Risk in Patients With Immune-Mediated Inflammatory Diseases: A Population-Based Analysis of SARS-CoV-2 Testing.” Arthritis care & research (2022). PMID: 34486829 ↗

    L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  557. [557]

    Samhouri BF, Vassallo R, Achenbach SJ et al.. “Incidence, Risk Factors, and Mortality of Clinical and Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Population-Based Cohort.” Arthritis care & research (2022). PMID: 34995017 ↗

    L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  558. [558]

    Dharia T, Venkatachalam S, Baker JF et al.. “Medication Interruptions and Subsequent Disease Flares During the COVID-19 Pandemic: A Longitudinal Online Study of Patients With Rheumatic Disease.” Arthritis care & research (2022). PMID: 34890121 ↗

    L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  559. [559]

    Droz N, Gilardin L, Cacoub P et al.. “Kinetic profiles and management of hepatitis B virus reactivation in patients with immune-mediated inflammatory diseases.” Arthritis care & research (2013). PMID: 23436730 ↗

    L4REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  560. [560]

    Nannini C, Medina-Velasquez YF, Achenbach SJ et al.. “Incidence and mortality of obstructive lung disease in rheumatoid arthritis: a population-based study.” Arthritis care & research (2013). PMID: 23436637 ↗

    L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  561. [561]

    Cooles FAH, Isaacs JD. “The interferon gene signature as a clinically relevant biomarker in autoimmune rheumatic disease.” The Lancet. Rheumatology (2021). PMID: 38288732 ↗

    L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  562. [562]

    Juge PA, Lee JS, Ebstein E et al.. “MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease.” The New England journal of medicine (2018). PMID: 30345907 ↗

    L3OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  563. [563]

    Li M, Wang Q, He J et al.. “A machine learning-based classification model for interstitial lung disease in rheumatoid arthritis.” Frontiers in medicine (2026). PMID: 42221109 ↗

    L3TRIAL_NONRANDOMCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), History and Evolution of Treatment
  564. [564]

    Gustafsson AL, Heckemann RA, Erlandsson MC et al.. “Handgrip weakness is associated with motor cortex atrophy in rheumatoid arthritis: a cross-sectional study with a hand exercise intervention.” BMC medicine (2026). PMID: 42192374 ↗

    L4TRIAL_NONRANDOMCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  565. [565]

    Barnes H, Holland AE, Westall GP et al.. “Cyclophosphamide for connective tissue disease-associated interstitial lung disease.” The Cochrane database of systematic reviews (2018). PMID: 29297205 ↗

    L1SR_OBSCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  566. [566]

    Chioni A, Campochiaro C, Keret S et al.. “Nintedanib combined with dual immunosuppression for interstitial lung disease in systemic sclerosis and rheumatoid arthritis: A systematic review and pooled multicentre real-world cohort study.” Autoimmunity reviews (2026). PMID: 42162630 ↗

    L2SR_OBSCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  567. [567]

    Serrano-Combarro A, Atienza-Mateo B, Martín-Gutiérrez A et al.. “Baricitinib in rheumatoid arthritis-interstitial lung disease: a literature review and national multicentre study of 72 patients.” Rheumatology (Oxford, England) (2025). PMID: 40493905 ↗

    L4REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  568. [568]

    Zhang Q, Qi Y, Wang X et al.. “Risk of total and cause-specific mortality in patients with rheumatoid arthritis-associated interstitial lung disease or bronchiectasis.” Rheumatology (Oxford, England) (2025). PMID: 40644608 ↗

    L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  569. [569]

    Catrina AI, Deane KD, Scher JU. “Gene, environment, microbiome and mucosal immune tolerance in rheumatoid arthritis.” Rheumatology (Oxford, England) (2014). PMID: 25539828 ↗

    L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  570. [570]

    Chang SH, Lee JS, Ha YJ et al.. “Lung function trajectory of rheumatoid arthritis-associated interstitial lung disease.” Rheumatology (Oxford, England) (2023). PMID: 36702465 ↗

    L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  571. [571]

    Black RJ, Lester S, Tieu J et al.. “Mortality estimates and excess mortality in rheumatoid arthritis.” Rheumatology (Oxford, England) (2023). PMID: 36919770 ↗

    L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  572. [572]

    Esposito AJ, Sparks JA, Gill RR et al.. “Screening for preclinical parenchymal lung disease in rheumatoid arthritis.” Rheumatology (Oxford, England) (2022). PMID: 34875040 ↗

    L2OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prevention, Screening & Surveillance
  573. [573]

    Perry E, Kelly C, Eggleton P et al.. “The lung in ACPA-positive rheumatoid arthritis: an initiating site of injury?” Rheumatology (Oxford, England) (2014). PMID: 24831057 ↗

    L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  574. [574]

    Segelmark M. “Serological testing in small vessel vasculitis.” Rheumatology (Oxford, England) (2020). PMID: 32348521 ↗

    L5OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  575. [575]

    Wang D, Zhang J, Lau J et al.. “Mechanisms of lung disease development in rheumatoid arthritis.” Nature reviews. Rheumatology (2019). PMID: 31455869 ↗

    L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  576. [576]

    Buch MH, Mallat Z, Dweck MR et al.. “Current understanding and management of cardiovascular involvement in rheumatic immune-mediated inflammatory diseases.” Nature reviews. Rheumatology (2024). PMID: 39232242 ↗

    L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  577. [577]

    Wells AU, Denton CP. “Interstitial lung disease in connective tissue disease--mechanisms and management.” Nature reviews. Rheumatology (2014). PMID: 25266451 ↗

    L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  578. [578]

    Szekanecz Z, Gunkl-Tóth L, Szamosi S et al.. “Diagnostic, prognostic and therapeutic biomarkers in rheumatoid arthritis.” Nature reviews. Rheumatology (2026). PMID: 42298194 ↗

    L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  579. [579]

    Stanford SM, Bottini N. “PTPN22: the archetypal non-HLA autoimmunity gene.” Nature reviews. Rheumatology (2014). PMID: 25003765 ↗

    L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  580. [580]

    Artifoni M, Rothschild PR, Brézin A et al.. “Ocular inflammatory diseases associated with rheumatoid arthritis.” Nature reviews. Rheumatology (2013). PMID: 24323074 ↗

    L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  581. [581]

    Brooks RT, England BR, Kronzer VL et al.. “The evolving comorbidity landscape of rheumatoid arthritis.” Nature reviews. Rheumatology (2026). PMID: 42215625 ↗

    L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  582. [582]

    Jani M, Hirani N, Matteson EL et al.. “The safety of biologic therapies in RA-associated interstitial lung disease.” Nature reviews. Rheumatology (2013). PMID: 24366321 ↗

    L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  583. [583]

    Miyabe Y, Lian J, Miyabe C et al.. “Chemokines in rheumatic diseases: pathogenic role and therapeutic implications.” Nature reviews. Rheumatology (2019). PMID: 31705045 ↗

    L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  584. [584]

    Aringer M, Distler O, Hoffmann-Vold AM et al.. “Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases.” RMD open (2024). PMID: 39719300 ↗

    L5REVIEW_NARRATIVECited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  585. [585]

    Vermant M, Kalkanis A, Jacob J et al.. “Lung ultrasound outperforms symptom-based screening to detect interstitial lung disease associated with rheumatoid arthritis.” RMD open (2025). PMID: 40010942 ↗

    L1OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  586. [586]

    Kim SH, Kim SY, Yoon HY et al.. “PM10 increases mortality risk in rheumatoid arthritis-associated interstitial lung disease.” RMD open (2024). PMID: 38331470 ↗

    L3OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  587. [587]

    Higuchi T, Oka S, Furukawa H et al.. “Association of a FAM13A variant with interstitial lung disease in Japanese rheumatoid arthritis.” RMD open (2023). PMID: 36717188 ↗

    L3OTHERCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  588. [588]

    Zhenyan B, Huang L, Lu J et al.. “The pharmacokinetics and its covariates of rituximab in different clinical populations: a systematic review and narrative synthesis.” European journal of clinical pharmacology (2026). PMID: 42426484 ↗

    L2SR_OBSCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  589. [589]

    Du D, Qin J, Zhang G et al.. “Diagnostic accuracy of lung ultrasound in identifying connective tissue disease related interstitial lung disease: a systematic review and meta-analysis.” Clinical and experimental rheumatology (2026). PMID: 42370501 ↗

    L1SR_OBSCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  590. [590]

    Qiaoqian Z, Qing W, Bowen L et al.. “Tumor markers in rheumatoid arthritis -associated interstitial lung disease: a systematic review and meta-analysis.” BMC rheumatology (2026). PMID: 42337778 ↗

    L3SR_OBSCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  591. [591]

    Qi S, Jiang Y, Li H et al.. “Detection of rheumatoid arthritis-associated interstitial lung disease: a systematic review and meta-analysis.” BMC pulmonary medicine (2026). PMID: 42324528 ↗

    L1SR_OBSCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map), Prevention, Screening & Surveillance
  592. [592]

    Yamane T, Inoue A, Yasuda N et al.. “Real-world retention of nintedanib and factors associated with treatment discontinuation in connective tissue disease-associated interstitial lung disease: a retrospective cohort study of 92 patients.” Clinical rheumatology (2026). PMID: 42402543 ↗

    L4COHORTCited in: Multisystem & Extra-Articular Involvement (Organ-by-Organ Map)
  593. [593]

    Liu J, Jiang Y, Zhang S et al.. “Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial.” Annals of the rheumatic diseases (2025). PMID: 39919893 ↗

    L1RCTCited in: Complications: Disease-Driven & Treatment-Related
  594. [594]

    Sebbag E, Molina-Collada J, Ndoye R et al.. “Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer.” Annals of the rheumatic diseases (2025). PMID: 39739386 ↗

    L2SR_OBSCited in: Complications: Disease-Driven & Treatment-Related
  595. [595]

    Vanags D, Williams B, Johnson B et al.. “Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial.” Lancet (London, England) (2006). PMID: 16950363 ↗

    L1RCTCited in: Complications: Disease-Driven & Treatment-Related
  596. [596]

    Smolen JS, Burmester GR, Combe B et al.. “Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.” Lancet (London, England) (2016). PMID: 27863807 ↗

    L1RCTCited in: Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  597. [597]

    Zhang Q, Qi Y, Wang X et al.. “Risk of Serious Infection in Patients With Rheumatoid Arthritis-Associated Interstitial Lung Disease or Bronchiectasis: A Comparative Cohort Study.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40708472 ↗

    L3COHORTCited in: Complications: Disease-Driven & Treatment-Related
  598. [598]

    Beltai A, Barnetche T, Daien C et al.. “Cardiovascular Morbidity and Mortality in Primary Sjögren's Syndrome: A Systematic Review and Meta-Analysis.” Arthritis care & research (2020). PMID: 30570824 ↗

    L2SR_OBSCited in: Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  599. [599]

    Mathieu S, Gossec L, Dougados M et al.. “Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis.” Arthritis care & research (2011). PMID: 20890982 ↗

    L2SR_OBSCited in: Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  600. [600]

    Wetzman A, Lukas C, Gaujoux-Viala C et al.. “Risk of Cancer After Initiation of Targeted Therapies in Patients With Rheumatoid Arthritis and a Prior Cancer: Systematic Review With Meta-Analysis.” Arthritis care & research (2022). PMID: 34549898 ↗

    L2SR_OBSCited in: Complications: Disease-Driven & Treatment-Related, History and Evolution of Treatment
  601. [601]

    Lin TC, Yoshida K, Tedeschi SK et al.. “Risk of Hepatitis B Virus Reactivation in Patients With Inflammatory Arthritis Receiving Disease-Modifying Antirheumatic Drugs: A Systematic Review and Meta-Analysis.” Arthritis care & research (2018). PMID: 28834412 ↗

    L2SR_OBSCited in: Complications: Disease-Driven & Treatment-Related
  602. [602]

    Singh S, Fumery M, Singh AG et al.. “Comparative Risk of Cardiovascular Events With Biologic and Synthetic Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.” Arthritis care & research (2020). PMID: 30875456 ↗

    L2SR_OBSCited in: Complications: Disease-Driven & Treatment-Related
  603. [603]

    Hanberg JS, Fu X, Wang X et al.. “Effectiveness of a fourth dose of COVID-19 mRNA vaccine in patients with systemic autoimmune rheumatic diseases using disease-modifying antirheumatic drugs: an emulated target trial.” The Lancet. Rheumatology (2023). PMID: 38258675 ↗

    L2TRIAL_NONRANDOMCited in: Complications: Disease-Driven & Treatment-Related
  604. [604]

    Singh JA, Cameron C, Noorbaloochi S et al.. “Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis.” Lancet (London, England) (2015). PMID: 25975452 ↗

    L1SR_OBSCited in: Complications: Disease-Driven & Treatment-Related
  605. [605]

    Gentry CA, Humphrey MB, Thind SK et al.. “Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study.” The Lancet. Rheumatology (2020). PMID: 32984847 ↗

    L2COHORTCited in: Complications: Disease-Driven & Treatment-Related
  606. [606]

    Kameda H, Takeuchi T, Yamaoka K et al.. “Long-term safety and efficacy of upadacitinib in Japanese patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: 5-year results from the SELECT-SUNRISE randomised controlled trial.” RMD open (2025). PMID: 41193232 ↗

    L1RCTCited in: Complications: Disease-Driven & Treatment-Related
  607. [607]

    Cao S, Li Y, Song R et al.. “L-arginine metabolism inhibits arthritis and inflammatory bone loss.” Annals of the rheumatic diseases (2024). PMID: 37775153 ↗

    L5OTHERCited in: Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  608. [608]

    Hoshida Y, Tsujii A, Ohshima S et al.. “Effect of Recent Antirheumatic Drug on Features of Rheumatoid Arthritis-Associated Lymphoproliferative Disorders.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 38272827 ↗

    L4OTHERCited in: Complications: Disease-Driven & Treatment-Related
  609. [609]

    Frank KM, Hogarth DK, Miller JL et al.. “Investigation of the cause of death in a gene-therapy trial.” The New England journal of medicine (2009). PMID: 19587341 ↗

    L4CASE_REPORTCited in: Complications: Disease-Driven & Treatment-Related
  610. [610]

    Yun H, Chen L, Roy JA et al.. “Rheumatoid Arthritis Disease Activity and Hospitalized Infection in a Large US Registry.” Arthritis care & research (2023). PMID: 35866713 ↗

    L2OTHERCited in: Complications: Disease-Driven & Treatment-Related
  611. [611]

    Curtis JR, Yang S, Singh JA et al.. “Is Rheumatoid Arthritis a Cardiovascular Risk-Equivalent to Diabetes Mellitus?” Arthritis care & research (2018). PMID: 29409152 ↗

    L2OTHERCited in: Complications: Disease-Driven & Treatment-Related
  612. [612]

    Garcia-Montoya L, Villota-Eraso C, Yusof MYM et al.. “Lessons for rituximab therapy in patients with rheumatoid arthritis.” The Lancet. Rheumatology (2020). PMID: 38273611 ↗

    L5REVIEW_NARRATIVECited in: Complications: Disease-Driven & Treatment-Related
  613. [613]

    Widdifield J, Kwong JC, Chen S et al.. “Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis.” The Lancet. Rheumatology (2022). PMID: 35441151 ↗

    L3OTHERCited in: Complications: Disease-Driven & Treatment-Related
  614. [614]

    Frisoni GB, Aho E, Brayne C et al.. “Alzheimer's disease outlook: controversies and future directions.” Lancet (London, England) (2025). PMID: 40997840 ↗

    L5REVIEW_NARRATIVECited in: Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  615. [615]

    Singh JA, Wells GA, Christensen R et al.. “Adverse effects of biologics: a network meta-analysis and Cochrane overview.” The Cochrane database of systematic reviews (2011). PMID: 21328309 ↗

    L1SR_OBSCited in: Complications: Disease-Driven & Treatment-Related
  616. [616]

    Hagen KB, Byfuglien MG, Falzon L et al.. “Dietary interventions for rheumatoid arthritis.” The Cochrane database of systematic reviews (2009). PMID: 19160281 ↗

    L1SR_OBSCited in: Complications: Disease-Driven & Treatment-Related
  617. [617]

    Tuntland H, Kjeken I, Nordheim LV et al.. “Assistive technology for rheumatoid arthritis.” The Cochrane database of systematic reviews (2009). PMID: 19821383 ↗

    L1SR_OBSCited in: Complications: Disease-Driven & Treatment-Related
  618. [618]

    Whittle SL, Richards BL, Husni E et al.. “Opioid therapy for treating rheumatoid arthritis pain.” The Cochrane database of systematic reviews (2011). PMID: 22071805 ↗

    L1SR_OBSCited in: Complications: Disease-Driven & Treatment-Related
  619. [619]

    Richards BL, Whittle SL, Buchbinder R. “Antidepressants for pain management in rheumatoid arthritis.” The Cochrane database of systematic reviews (2011). PMID: 22071859 ↗

    L1SR_OBSCited in: Complications: Disease-Driven & Treatment-Related
  620. [620]

    Baker JF, England BR, George MD et al.. “Elevations in adipocytokines and mortality in rheumatoid arthritis.” Rheumatology (Oxford, England) (2022). PMID: 35325041 ↗

    L2OTHERCited in: Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  621. [621]

    McDonnell T, Ioannou Y, Rahman A. “PEGylated drugs in rheumatology--why develop them and do they work?” Rheumatology (Oxford, England) (2013). PMID: 23962623 ↗

    L5REVIEW_NARRATIVECited in: Complications: Disease-Driven & Treatment-Related
  622. [622]

    Liao KP, Solomon DH. “Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis.” Rheumatology (Oxford, England) (2012). PMID: 22986289 ↗

    L5REVIEW_NARRATIVECited in: Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  623. [623]

    Listing J, Gerhold K, Zink A. “The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment.” Rheumatology (Oxford, England) (2012). PMID: 23192911 ↗

    L5REVIEW_NARRATIVECited in: Complications: Disease-Driven & Treatment-Related
  624. [624]

    Kiely PDW, Lloyd ME. “Ankle arthritis - an important signpost in rheumatologic practice.” Rheumatology (Oxford, England) (2021). PMID: 33097958 ↗

    L5REVIEW_NARRATIVECited in: Complications: Disease-Driven & Treatment-Related
  625. [625]

    Robinson WH, Younis S, Love ZZ et al.. “Epstein-Barr virus as a potentiator of autoimmune diseases.” Nature reviews. Rheumatology (2024). PMID: 39390260 ↗

    L5REVIEW_NARRATIVECited in: Complications: Disease-Driven & Treatment-Related
  626. [626]

    Komatsu N, Takayanagi H. “Mechanisms of joint destruction in rheumatoid arthritis - immune cell-fibroblast-bone interactions.” Nature reviews. Rheumatology (2022). PMID: 35705856 ↗

    L5REVIEW_NARRATIVECited in: Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  627. [627]

    Tuckermann J, Adams RH. “The endothelium-bone axis in development, homeostasis and bone and joint disease.” Nature reviews. Rheumatology (2021). PMID: 34480164 ↗

    L5REVIEW_NARRATIVECited in: Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  628. [628]

    Lochhead RB, Strle K, Arvikar SL et al.. “Lyme arthritis: linking infection, inflammation and autoimmunity.” Nature reviews. Rheumatology (2021). PMID: 34226730 ↗

    L5REVIEW_NARRATIVECited in: Complications: Disease-Driven & Treatment-Related
  629. [629]

    Rákóczi É, Szekanecz Z. “Pneumococcal vaccination in autoimmune rheumatic diseases.” RMD open (2017). PMID: 28955497 ↗

    L5REVIEW_NARRATIVECited in: Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  630. [630]

    Beretta M, Martin E, Fogel O et al.. “Adaptive immune responses to SARS-CoV-2 in DMARD-treated patients with chronic inflammatory rheumatisms.” RMD open (2025). PMID: 40617588 ↗

    L4OTHERCited in: Complications: Disease-Driven & Treatment-Related
  631. [631]

    Kachhadia MP, Puri P, Patel K et al.. “Sodium-Glucose Co-Transporter 2 Inhibitor Use and Risk of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis and Type 2 Diabetes: A Retrospective Observational Cohort Study Using Real-World Data.” Journal of clinical medicine research (2026). PMID: 42327973 ↗

    L2COHORTCited in: Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  632. [632]

    Taylor-Williams O, Wall CJ, Nossent J et al.. “Revision Risk Following Total Hip Arthroplasty in Patients With Rheumatoid Arthritis: A Cohort Study From the Australian Orthopaedic Association National Joint Replacement Registry.” ANZ journal of surgery (2026). PMID: 42316895 ↗

    L2COHORTCited in: Complications: Disease-Driven & Treatment-Related, Special Populations, Pregnancy & Fertility
  633. [633]

    Paparozzi J, Barroca C, Gogerdchian H et al.. “Nutraceutical enhancement of paraoxonase 1 activity in chronic inflammation: A systematic review of animal-based and plant-based nutraceuticals.” Nutrition and health (2026). PMID: 42393907 ↗

    L5SR_OBSCited in: Complications: Disease-Driven & Treatment-Related, Prevention, Screening & Surveillance
  634. [634]

    Cook JA, Wilson N, Wilkins K et al.. “Clinical and cost-effectiveness of oral versus intramuscular glucocorticoids in rheumatoid arthritis: protocol for a multicentre randomised controlled trial with economic evaluation and qualitative sub-study (LEADER trial).” BMJ open (2026). PMID: 42431665 ↗

    L5OTHERCited in: Complications: Disease-Driven & Treatment-Related
  635. [635]

    Rausch Osthoff AK, Niedermann K, Braun J et al.. “2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis.” Annals of the rheumatic diseases (2018). PMID: 29997112 ↗

    L1GUIDELINECited in: History and Evolution of Treatment
  636. [636]

    Combe B, Landewe R, Daien CI et al.. “2016 update of the EULAR recommendations for the management of early arthritis.” Annals of the rheumatic diseases (2016). PMID: 27979873 ↗

    L1GUIDELINECited in: History and Evolution of Treatment
  637. [637]

    Fraenkel L, Bathon JM, England BR et al.. “2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2021). PMID: 34101376 ↗

    L1GUIDELINECited in: History and Evolution of Treatment
  638. [638]

    Goodman SM, Springer BD, Chen AF et al.. “2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.” Arthritis care & research (2022). PMID: 35718887 ↗

    L1GUIDELINECited in: History and Evolution of Treatment, Special Populations, Pregnancy & Fertility
  639. [639]

    Singh JA, Saag KG, Bridges SL et al.. “2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.” Arthritis care & research (2015). PMID: 26545825 ↗

    L1GUIDELINECited in: History and Evolution of Treatment
  640. [640]

    Teuwen MMH, van Weely SFE, Vliet Vlieland TPM et al.. “Effectiveness of longstanding exercise therapy compared with usual care for people with rheumatoid arthritis and severe functional limitations: a randomised controlled trial.” Annals of the rheumatic diseases (2024). PMID: 38171602 ↗

    L1RCTCited in: History and Evolution of Treatment
  641. [641]

    Atchia I, Brown AK, Chitale S et al.. “Recommendations for rheumatology ultrasound training and practice in the UK.” Rheumatology (Oxford, England) (2021). PMID: 33167033 ↗

    L5GUIDELINECited in: History and Evolution of Treatment
  642. [642]

    Hanauer SB, Feagan BG, Lichtenstein GR et al.. “Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.” Lancet (London, England) (2002). PMID: 12047962 ↗

    L1RCTCited in: History and Evolution of Treatment
  643. [643]

    Simkin PA. “Oral zinc sulphate in rheumatoid arthritis.” Lancet (London, England) (1976). PMID: 60622 ↗

    L1RCTCited in: History and Evolution of Treatment
  644. [644]

    Bombardier C, Laine L, Reicin A et al.. “Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.” The New England journal of medicine (2000). PMID: 11087881 ↗

    L1RCTCited in: History and Evolution of Treatment
  645. [645]

    Silverman E, Mouy R, Spiegel L et al.. “Leflunomide or methotrexate for juvenile rheumatoid arthritis.” The New England journal of medicine (2005). PMID: 15843668 ↗

    L1RCTCited in: History and Evolution of Treatment
  646. [646]

    Fleischmann R, Mysler E, Bessette L et al.. “Long-term safety and efficacy of upadacitinib or adalimumab in patients with rheumatoid arthritis: results through 3 years from the SELECT-COMPARE study.” RMD open (2022). PMID: 35121639 ↗

    L1RCTCited in: History and Evolution of Treatment
  647. [647]

    Smolen JS, Trefler J, Racewicz A et al.. “Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47.” RMD open (2024). PMID: 39424404 ↗

    L1RCTCited in: History and Evolution of Treatment
  648. [648]

    Buch MH, Aletaha D, Combe BG et al.. “Efficacy and safety of filgotinib in patients with rheumatoid arthritis: week 156 interim results from a long-term extension study.” RMD open (2024). PMID: 39455065 ↗

    L2RCTCited in: History and Evolution of Treatment
  649. [649]

    Kim HJ, Swan H, Kazmi SZ et al.. “Familial risk of seropositive rheumatoid arthritis and interaction with smoking: a population-based cohort study.” Rheumatology (Oxford, England) (2023). PMID: 36692153 ↗

    L2COHORTCited in: History and Evolution of Treatment, Prevention, Screening & Surveillance
  650. [650]

    Van den Ende CH, Vliet Vlieland TP, Munneke M et al.. “WITHDRAWN: Dynamic exercise therapy for treating rheumatoid arthritis.” The Cochrane database of systematic reviews (2008). PMID: 18253972 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  651. [651]

    Garner SE, Fidan DD, Frankish RR et al.. “Rofecoxib for rheumatoid arthritis.” The Cochrane database of systematic reviews (2005). PMID: 15674912 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  652. [652]

    Radner H, Ramiro S, Buchbinder R et al.. “Pain management for inflammatory arthritis (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and other spondylarthritis) and gastrointestinal or liver comorbidity.” The Cochrane database of systematic reviews (2012). PMID: 22258995 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  653. [653]

    Alfadhli AA, McDonald JW, Feagan BG. “Methotrexate for induction of remission in refractory Crohn's disease.” The Cochrane database of systematic reviews (2005). PMID: 15674908 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  654. [654]

    Alfadhli AA, McDonald JW, Feagan BG. “Methotrexate for induction of remission in refractory Crohn's disease.” The Cochrane database of systematic reviews (2003). PMID: 12535475 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  655. [655]

    McDonald JW, Wang Y, Tsoulis DJ et al.. “Methotrexate for induction of remission in refractory Crohn's disease.” The Cochrane database of systematic reviews (2014). PMID: 25099640 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  656. [656]

    Eccleston C, Cooper TE, Fisher E et al.. “Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents.” The Cochrane database of systematic reviews (2017). PMID: 28770976 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  657. [657]

    McDonald JW, Tsoulis DJ, Macdonald JK et al.. “Methotrexate for induction of remission in refractory Crohn's disease.” The Cochrane database of systematic reviews (2012). PMID: 23235598 ↗

    L1SR_OBSCited in: History and Evolution of Treatment
  658. [658]

    Whittle SL, Hughes RA. “Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review.” Rheumatology (Oxford, England) (2004). PMID: 14963199 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  659. [659]

    Huber LC, Distler O, Tarner I et al.. “Synovial fibroblasts: key players in rheumatoid arthritis.” Rheumatology (Oxford, England) (2006). PMID: 16567358 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  660. [660]

    Choy E, Aletaha D, Behrens F et al.. “Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis.” Rheumatology (Oxford, England) (2017). PMID: 27550301 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  661. [661]

    Walker JG, Littlejohn GO, McMurray NE et al.. “Stress system response and rheumatoid arthritis: a multilevel approach.” Rheumatology (Oxford, England) (1999). PMID: 10556255 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  662. [662]

    Dayer JM. “The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis.” Rheumatology (Oxford, England) (2003). PMID: 12817089 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  663. [663]

    Choy EH, De Benedetti F, Takeuchi T et al.. “Translating IL-6 biology into effective treatments.” Nature reviews. Rheumatology (2020). PMID: 32327746 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  664. [664]

    Scher JU, Abramson SB. “The microbiome and rheumatoid arthritis.” Nature reviews. Rheumatology (2011). PMID: 21862983 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  665. [665]

    Chang MH, Fuhlbrigge RC, Nigrovic PA. “Joint-specific memory, resident memory T cells and the rolling window of opportunity in arthritis.” Nature reviews. Rheumatology (2024). PMID: 38600215 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  666. [666]

    Semb AG, Ikdahl E, Wibetoe G et al.. “Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis.” Nature reviews. Rheumatology (2020). PMID: 32494054 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  667. [667]

    Frisell T, Saevarsdottir S, Askling J. “Family history of rheumatoid arthritis: an old concept with new developments.” Nature reviews. Rheumatology (2016). PMID: 27098907 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  668. [668]

    Atzeni F, Rodríguez-Carrio J, Popa CD et al.. “Cardiovascular effects of approved drugs for rheumatoid arthritis.” Nature reviews. Rheumatology (2021). PMID: 33833437 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  669. [669]

    Dutt S, Roul P, Yang Y et al.. “Multimorbidity Patterns and Rheumatoid Arthritis Disease Outcomes: Findings From a Multicenter, Prospective Cohort.” Arthritis care & research (2023). PMID: 37394710 ↗

    L2OTHERCited in: History and Evolution of Treatment
  670. [670]

    Wang H, Chen H, Li Y et al.. “Mechanistic study on the reduction of TNF-α and β-CTX levels in RA patients by moxibustion combined with western medication through regulation of the Wnt/β-catenin pathway.” Frontiers in immunology (2026). PMID: 42254021 ↗

    L1RCTCited in: History and Evolution of Treatment
  671. [671]

    Portal PHG, Peixoto GN, de Matos MR et al.. “Add-on tocilizumab versus placebo for resistant major depression in psychiatric outpatients with low-grade inflammation in a tertiary public hospital in Southern Brazil: randomised triple-blind clinical trial protocol.” BMJ open (2026). PMID: 42285573 ↗

    L5TRIAL_NONRANDOMCited in: History and Evolution of Treatment
  672. [672]

    Yoshida Y, Hosokawa Y, Taogoshi T et al.. “Effect of different folic acid doses on methotrexate-related toxicity and its association with erythrocyte methotrexate-polyglutamates in patients with rheumatic diseases: a single-center exploratory randomized controlled trial.” Clinical rheumatology (2026). PMID: 42249242 ↗

    L1RCTCited in: History and Evolution of Treatment
  673. [673]

    Masoud I, Al Shaer NSH, Masoud A et al.. “Antibody-Drug Conjugates in Solid Tumor Oncology and the Frontier of Precision Immunosuppression: A Mechanistic, Translational, and Clinical Review.” International journal of molecular sciences (2026). PMID: 42352921 ↗

    L5REVIEW_NARRATIVECited in: History and Evolution of Treatment
  674. [674]

    Goodman SM, Springer BD, Chen AF et al.. “2022 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.” Arthritis & rheumatology (Hoboken, N.J.) (2022). PMID: 35722708 ↗

    L1GUIDELINECited in: Special Populations, Pregnancy & Fertility
  675. [675]

    Goodman SM, Springer B, Guyatt G et al.. “2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty.” Arthritis & rheumatology (Hoboken, N.J.) (2017). PMID: 28620948 ↗

    L1GUIDELINECited in: Special Populations, Pregnancy & Fertility
  676. [676]

    Schanberg LE, Mulugeta LY, Akinlade B et al.. “Therapeutic Development in Polyarticular Course Juvenile Idiopathic Arthritis: Extrapolation, Dose Selection, and Clinical Trial Design.” Arthritis & rheumatology (Hoboken, N.J.) (2023). PMID: 37067688 ↗

    L5TRIAL_NONRANDOMCited in: Special Populations, Pregnancy & Fertility
  677. [677]

    Fleischmann R, Baumgartner SW, Weisman MH et al.. “Long term safety of etanercept in elderly subjects with rheumatic diseases.” Annals of the rheumatic diseases (2005). PMID: 16150792 ↗

    L2SR_OBSCited in: Special Populations, Pregnancy & Fertility
  678. [678]

    Vinet É, De Moura C, Pineau CA et al.. “Serious Infections in Rheumatoid Arthritis Offspring Exposed to Tumor Necrosis Factor Inhibitors: A Cohort Study.” Arthritis & rheumatology (Hoboken, N.J.) (2018). PMID: 29771477 ↗

    L2COHORTCited in: Special Populations, Pregnancy & Fertility
  679. [679]

    Rom AL, Wu CS, Olsen J et al.. “Fetal growth and preterm birth in children exposed to maternal or paternal rheumatoid arthritis: a nationwide cohort study.” Arthritis & rheumatology (Hoboken, N.J.) (2014). PMID: 25393524 ↗

    L2COHORTCited in: Special Populations, Pregnancy & Fertility
  680. [680]

    Tsao NW, Lynd LD, Sadatsafavi M et al.. “Patterns of Biologics Utilization and Discontinuation Before and During Pregnancy in Women With Autoimmune Diseases: A Population-Based Cohort Study.” Arthritis care & research (2018). PMID: 28973840 ↗

    L2COHORTCited in: Special Populations, Pregnancy & Fertility
  681. [681]

    Köller MD, Aletaha D, Funovits J et al.. “Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients.” Rheumatology (Oxford, England) (2009). PMID: 19812228 ↗

    L2SR_OBSCited in: Special Populations, Pregnancy & Fertility
  682. [682]

    Goodman SM, Menon I, Christos PJ et al.. “Management of perioperative tumour necrosis factor α inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and meta-analysis.” Rheumatology (Oxford, England) (2015). PMID: 26447162 ↗

    L1SR_OBSCited in: Special Populations, Pregnancy & Fertility
  683. [683]

    Nguyen NV, Svenungsson E, Dominicus A et al.. “Hydroxychloroquine in lupus or rheumatoid arthritis pregnancy and risk of major congenital malformations: a population-based cohort study.” Rheumatology (Oxford, England) (2025). PMID: 38479815 ↗

    L2COHORTCited in: Special Populations, Pregnancy & Fertility
  684. [684]

    Jinno S, Onishi A, Hattori S et al.. “Comparison of retention of biologics in Japanese patients with elderly-onset rheumatoid arthritis-the ANSWER cohort study.” Rheumatology (Oxford, England) (2025). PMID: 38317442 ↗

    L2COHORTCited in: Special Populations, Pregnancy & Fertility
  685. [685]

    Nathan NO, Mørch LS, Wu CS et al.. “Rheumatoid arthritis and risk of spontaneous abortion: a Danish nationwide cohort study.” Rheumatology (Oxford, England) (2020). PMID: 31776579 ↗

    L2COHORTCited in: Special Populations, Pregnancy & Fertility
  686. [686]

    Hiramatsu Y, Kotani T, Nakamura E et al.. “Effect of treat-to-target strategies on maternal and neonatal outcomes of rheumatoid arthritis: a multicentre real-world ANSWER cohort study.” Rheumatology (Oxford, England) (2026). PMID: 41134194 ↗

    L2COHORTCited in: Special Populations, Pregnancy & Fertility
  687. [687]

    Salliot C, Nguyen Y, Gusto G et al.. “Female hormonal exposures and risk of rheumatoid arthritis in the French E3N-EPIC cohort study.” Rheumatology (Oxford, England) (2021). PMID: 33547777 ↗

    L2COHORTCited in: Special Populations, Pregnancy & Fertility
  688. [688]

    Roodenrijs NMT, Hamar A, Kedves M et al.. “Pharmacological and non-pharmacological therapeutic strategies in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis.” RMD open (2021). PMID: 33419871 ↗

    L1SR_OBSCited in: Special Populations, Pregnancy & Fertility
  689. [689]

    Lien HJT, Pedersen TT, Jakobsen B et al.. “Single-cell resolution of longitudinal blood transcriptome profiles in rheumatoid arthritis, systemic lupus erythematosus and healthy control pregnancies.” Annals of the rheumatic diseases (2024). PMID: 38049980 ↗

    L2OTHERCited in: Special Populations, Pregnancy & Fertility
  690. [690]

    Meissner Y, Fischer-Betz R, Andreoli L et al.. “EULAR recommendations for a core data set for pregnancy registries in rheumatology.” Annals of the rheumatic diseases (2020). PMID: 33055080 ↗

    L5OTHERCited in: Special Populations, Pregnancy & Fertility
  691. [691]

    Brouwer J, Hazes JM, Laven JS et al.. “Fertility in women with rheumatoid arthritis: influence of disease activity and medication.” Annals of the rheumatic diseases (2014). PMID: 24833784 ↗

    L2OTHERCited in: Special Populations, Pregnancy & Fertility
  692. [692]

    Visser K, Katchamart W, Loza E et al.. “Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative.” Annals of the rheumatic diseases (2008). PMID: 19033291 ↗

    L1OTHERCited in: Special Populations, Pregnancy & Fertility
  693. [693]

    Camacho EM, Verstappen SM, Lunt M et al.. “Multiple adverse pregnancy outcomes before symptom onset are associated with a worse disease outcome in women with recent-onset inflammatory polyarthritis.” Annals of the rheumatic diseases (2011). PMID: 21998113 ↗

    L2REVIEW_NARRATIVECited in: Special Populations, Pregnancy & Fertility
  694. [694]

    Ince-Askan H, Mandaviya PR, Felix JF et al.. “Altered DNA methylation in children born to mothers with rheumatoid arthritis during pregnancy.” Annals of the rheumatic diseases (2019). PMID: 31142478 ↗

    L2OTHERCited in: Special Populations, Pregnancy & Fertility
  695. [695]

    Burmester GR, Landewé R, Genovese MC et al.. “Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis.” Annals of the rheumatic diseases (2016). PMID: 27338778 ↗

    L2OTHERCited in: Special Populations, Pregnancy & Fertility
  696. [696]

    Ma KK, Nelson JL, Guthrie KA et al.. “Adverse pregnancy outcomes and risk of subsequent rheumatoid arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2014). PMID: 24574209 ↗

    L3OTHERCited in: Special Populations, Pregnancy & Fertility
  697. [697]

    de Steenwinkel FD, Hokken-Koelega AC, de Ridder MA et al.. “Rheumatoid arthritis during pregnancy and postnatal catch-up growth in the offspring.” Arthritis & rheumatology (Hoboken, N.J.) (2014). PMID: 24578030 ↗

    L2OTHERCited in: Special Populations, Pregnancy & Fertility
  698. [698]

    Chen JS, Roberts CL, Simpson JM et al.. “Pregnancy Outcomes in Women With Rare Autoimmune Diseases.” Arthritis & rheumatology (Hoboken, N.J.) (2015). PMID: 26434922 ↗

    L2OTHERCited in: Special Populations, Pregnancy & Fertility
  699. [699]

    Zanetti A, Zambon A, Scirè CA et al.. “Impact of rheumatoid arthritis and methotrexate on pregnancy outcomes: retrospective cohort study of the Italian Society for Rheumatology.” RMD open (2022). PMID: 36597979 ↗

    L2COHORTCited in: Special Populations, Pregnancy & Fertility
  700. [700]

    Secher AEP, Granath F, Glintborg B et al.. “Risk of pre-eclampsia and impact of disease activity and antirheumatic treatment in women with rheumatoid arthritis, axial spondylarthritis and psoriatic arthritis: a collaborative matched cohort study from Sweden and Denmark.” RMD open (2022). PMID: 36328400 ↗

    L2COHORTCited in: Special Populations, Pregnancy & Fertility
  701. [701]

    Brouwer J, Fleurbaaij R, Hazes JMW et al.. “Subfertility in Women With Rheumatoid Arthritis and the Outcome of Fertility Assessments.” Arthritis care & research (2017). PMID: 27723275 ↗

    L4OTHERCited in: Special Populations, Pregnancy & Fertility
  702. [702]

    Bortoluzzi A, Andreoli L, Carrara G et al.. “Improved Pregnancy Outcome in Patients With Rheumatoid Arthritis Who Followed an Ideal Clinical Pathway.” Arthritis care & research (2021). PMID: 31912644 ↗

    L2OTHERCited in: Special Populations, Pregnancy & Fertility
  703. [703]

    Kuriya B, Hernández-Díaz S, Liu J et al.. “Patterns of medication use during pregnancy in rheumatoid arthritis.” Arthritis care & research (2011). PMID: 21557526 ↗

    L2OTHERCited in: Special Populations, Pregnancy & Fertility
  704. [704]

    Quaak CH, Röder E, Wintjes HM et al.. “Time to pregnancy in women with rheumatoid arthritis who want to conceive treated according to a treat-to-target approach: a comparison of an observational cohort with a historical reference cohort.” The Lancet. Rheumatology (2026). PMID: 41905370 ↗

    L2OTHERCited in: Special Populations, Pregnancy & Fertility
  705. [705]

    Boots AM, Maier AB, Stinissen P et al.. “The influence of ageing on the development and management of rheumatoid arthritis.” Nature reviews. Rheumatology (2013). PMID: 23774902 ↗

    L5REVIEW_NARRATIVECited in: Special Populations, Pregnancy & Fertility
  706. [706]

    Østensen M, Förger F. “Management of RA medications in pregnant patients.” Nature reviews. Rheumatology (2009). PMID: 19506586 ↗

    L5REVIEW_NARRATIVECited in: Special Populations, Pregnancy & Fertility
  707. [707]

    Takeuchi T, Kameda H. “The Japanese experience with biologic therapies for rheumatoid arthritis.” Nature reviews. Rheumatology (2010). PMID: 20877307 ↗

    L5REVIEW_NARRATIVECited in: Special Populations, Pregnancy & Fertility
  708. [708]

    Akkara Veetil BM, Bongartz T. “Perioperative care for patients with rheumatic diseases.” Nature reviews. Rheumatology (2011). PMID: 22083219 ↗

    L5REVIEW_NARRATIVECited in: Special Populations, Pregnancy & Fertility
  709. [709]

    Camellino D, Matteson EL, Buttgereit F et al.. “Monitoring and long-term management of giant cell arteritis and polymyalgia rheumatica.” Nature reviews. Rheumatology (2020). PMID: 32759996 ↗

    L5REVIEW_NARRATIVECited in: Special Populations, Pregnancy & Fertility
  710. [710]

    Park J, Lim H, Choi S et al.. “Incidence and risk factors of postoperative infection after wrist arthroscopy: an 11-year nationwide population-based cohort study in South Korea.” Orthopaedics & traumatology, surgery & research : OTSR (2026). PMID: 42235885 ↗

    L2COHORTCited in: Special Populations, Pregnancy & Fertility
  711. [711]

    Kajita Y, Harada Y, Takahashi R et al.. “Short- to mid-term clinical outcomes and survivorship of the Nexel total elbow arthroplasty in Japanese patients: a single-center retrospective study.” Journal of shoulder and elbow arthroplasty (2026). PMID: 42040741 ↗

    L4COHORTCited in: Special Populations, Pregnancy & Fertility
  712. [712]

    Guan H, Zhou H, Yuan F et al.. “A retrospective cohort study in China: association between Tripterygium glycosides and reduced serum albumin levels in elderly rheumatoid arthritis patients.” Frontiers in medicine (2026). PMID: 41930137 ↗

    L2COHORTCited in: Special Populations, Pregnancy & Fertility
  713. [713]

    Tanaka Y, Taylor PC, Ritsema JAS et al.. “Efficacy/Effectiveness, Safety and Treatment Persistence of Filgotinib in Rheumatoid Arthritis: A Narrative Review of Clinical Trials and Real-World Evidence.” Rheumatology and therapy (2026). PMID: 41903081 ↗

    L5TRIAL_NONRANDOMCited in: Special Populations, Pregnancy & Fertility
  714. [714]

    Pina Vegas L, Drouin J, Weill A et al.. “Pregnancy outcomes in women with rheumatoid arthritis: an 11-year French nationwide study.” RMD open (2024). PMID: 38242551 ↗

    L2OTHERCited in: Special Populations, Pregnancy & Fertility
  715. [715]

    Sigmo GD, Hauge S, Hetland HB et al.. “Men with psoriatic arthritis, rheumatoid arthritis and axial spondylarthritis have more children and at an earlier age than matched controls: results from a nationwide cohort.” RMD open (2025). PMID: 40789721 ↗

    L2OTHERCited in: Special Populations, Pregnancy & Fertility
  716. [716]

    Alsing CL, Igland J, Nystad TW et al.. “Data-driven identification of subgroups in early rheumatoid arthritis: mortality and cardiovascular disease in a cohort from western Norway.” RMD open (2025). PMID: 41005975 ↗

    L2OTHERCited in: Special Populations, Pregnancy & Fertility
  717. [717]

    Kumar C, Kuhn M, Herrmann K et al.. “Severe methotrexate toxicity in elderly patients under diuretics.” RMD open (2024). PMID: 38176739 ↗

    L3OTHERCited in: Special Populations, Pregnancy & Fertility
  718. [718]

    Hamroun S, Martin de Frémont G, Costedoat-Chalumeau N et al.. “Evaluation of pregnancy outcomes in patients with rheumatoid arthritis compared with the general population: results from a French national prospective and matched study.” RMD open (2026). PMID: 42419787 ↗

    L2OTHERCited in: Special Populations, Pregnancy & Fertility
  719. [719]

    Esperón P, Vital M, Giletti A. “The impact of gene polymorphisms on the response of methotrexate-based treatments.” European journal of clinical pharmacology (2026). PMID: 42104114 ↗

    L5SR_OBSCited in: Special Populations, Pregnancy & Fertility
  720. [720]

    Yang M, Xu F, Zhang B et al.. “Age-stratified treatment response in rheumatoid arthritis: a systematic review, meta-analysis, and integrated genetic and single-cell evidence implicating IL6R/TYK2 signaling.” Clinical rheumatology (2026). PMID: 41845003 ↗

    L1SR_OBSCited in: Special Populations, Pregnancy & Fertility
  721. [721]

    Schieir O, Tosevski C, Glazier RH et al.. “Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis.” Annals of the rheumatic diseases (2017). PMID: 28219882 ↗

    L2SR_OBSCited in: Prevention, Screening & Surveillance
  722. [722]

    Jiang Y, Rudin RS, Solomon DH. “Clinical Visit Frequencies in Rheumatology: A Systematic Literature Review.” Arthritis care & research (2023). PMID: 36807719 ↗

    L2SR_OBSCited in: Prevention, Screening & Surveillance
  723. [723]

    Björk M, Dragioti E, Alexandersson H et al.. “Inflammatory Arthritis and the Effect of Physical Activity on Quality of Life and Self-Reported Function: A Systematic Review and Meta-Analysis.” Arthritis care & research (2022). PMID: 34632707 ↗

    L1SR_OBSCited in: Prevention, Screening & Surveillance
  724. [724]

    Rentsch CT, DeVito NJ, MacKenna B et al.. “Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform.” The Lancet. Rheumatology (2020). PMID: 33349815 ↗

    L2COHORTCited in: Prevention, Screening & Surveillance
  725. [725]

    Feng J, Pan C, Gou Y et al.. “EAT-Lancet Diet Modifies the Risk of Rheumatoid Arthritis Through Metabolomic Signature.” Arthritis & rheumatology (Hoboken, N.J.) (2025). PMID: 40546003 ↗

    L2OTHERCited in: Prevention, Screening & Surveillance
  726. [726]

    Takada H, Demoruelle MK, Deane KD et al.. “Expansion of HLA-DR Positive Peripheral Helper T and Naive B Cells in Anticitrullinated Protein Antibody-Positive Individuals At Risk for Rheumatoid Arthritis.” Arthritis & rheumatology (Hoboken, N.J.) (2024). PMID: 38412870 ↗

    L3OTHERCited in: Prevention, Screening & Surveillance
  727. [727]

    Katz P, Pedro S, Michaud K. “Sleep Disorders Among Individuals With Rheumatoid Arthritis.” Arthritis care & research (2023). PMID: 35997482 ↗

    L4OTHERCited in: Prevention, Screening & Surveillance
  728. [728]

    Klareskog L, Catrina AI, Paget S. “Rheumatoid arthritis.” Lancet (London, England) (2009). PMID: 19157532 ↗

    L5OTHERCited in: Prevention, Screening & Surveillance
  729. [729]

    Hoving JL, Lacaille D, Urquhart DM et al.. “Non-pharmacological interventions for preventing job loss in workers with inflammatory arthritis.” The Cochrane database of systematic reviews (2014). PMID: 25375291 ↗

    L1SR_OBSCited in: Prevention, Screening & Surveillance
  730. [730]

    Hu Y, Wen M, Wen L et al.. “Comorbid autoimmune disease in stiff-person syndrome spectrum disorder: a systematic review and meta-analysis.” Journal of neurology (2026). PMID: 42390536 ↗

    L2SR_OBSCited in: Prevention, Screening & Surveillance
  731. [731]

    Panoulas VF, Metsios GS, Pace AV et al.. “Hypertension in rheumatoid arthritis.” Rheumatology (Oxford, England) (2008). PMID: 18467370 ↗

    L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
  732. [732]

    Finckh A, Courvoisier D, Lamacchia C. “Measuring ACPA in the general population or primary care: is it useful?” RMD open (2020). PMID: 32079664 ↗

    L5REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance
  733. [733]

    Montes D, Hulshizer CA, Myasoedova E et al.. “Utilisation of cardiovascular preventive services in a rheumatoid arthritis population-based cohort.” RMD open (2023). PMID: 37945289 ↗

    L2OTHERCited in: Prevention, Screening & Surveillance

Revision History

All updates applied to this page

Loading revisions…